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Before you is what can be viewed as the culmination of four years of dedicated 
work. Four years ago I learned about a vacancy at the Erasmus Medical Center and 
met my current co-promotors. Not much later I decided to make the unorthodox 
transition from abstract financial predictions to public health research. This meant 
also a transition from business to academia, from clear targets and deadlines to a 
greater sense of independency, from national to international collaborations, from 
Amsterdam to Rotterdam. There has not been a single day that I have regretted the 
decision.
For the few who will actually read through some of the remainder of this thesis, 
I hope that you will find some interesting new ideas and methods to inform your 
research or practice. The thesis opens with a general introduction into the field of 
public health and the subject of colorectal cancer screening in particular, followed 
by three parts in which the main research findings are presented, and is concluded 
by a general discussion of the most important findings and implications. All chapters 
in the three middle parts can be read independently in combination with Chapter 2. 
I have tried to be consistent throughout in the use of terminology and abbreviations, 
and have tried to remove repetitious text on methods and background. In some 
instances, however, this was not possible without reformulating the original study 
reports as published in the literature, in which case I favored to preserve the original 
text. I hope and expect that this will not cause any serious confusion.
I am humbled to have been able to collaborate with many excellent researchers 
over the years both within our department as well as abroad. I have learned a lot 
from these collaborations, and owe a great deal to my co-authors. Although I will 
make acknowledgements at the end of this thesis, I would like to briefly mention 
two names here who were particularly important for this thesis, Dr. Marjolein van 
Ballegooijen and Dr. Iris Lansdorp-Vogelaar. Thank you for the trust and opportuni-
ties that you have given me from the start. I could not have hoped for a better first 
step into this field of research.
To the question whether the thesis will really add significantly to the knowledge 
that the Universe contains, I would echo Dr. Francis Collins, director of the US 
National Institutes of Health in Nature: “Well, it would be a rather small contribution, 
to be sure. I think the greatest beneficiary of my PhD was not the Universe, it was 
probably me.”
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General introduction
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Colorectal cancer is a fi rst-order global public health problem. It is the fourth lead-
ing cause of cancer-related deaths among men and women,1 despite an increasing 
awareness among researchers, policymakers and public. The disease is associated 
with Western diet, and primarily affects Western countries (Figure 1.1), where it is 
even the second leading cause of cancer deaths. In general, the causes of the disease 
are poorly understood, and treatment of advanced stages is often ineffective. 
The natural history or development of colorectal cancer has been well-documented 
to be a relatively slow process starting from easily treatable abnormalities.2 Popula-
tion screening is therefore widely believed to provide an important opportunity for 
disease prevention and aversion of disease-related mortality. Consequently, in the 
last two decades, many programs have been implemented worldwide.3,4 However, 
although benefi ts of screening are well-established, the performance of screening 
programs is often suboptimal and even cause for concern.5
Figure 1.1 Global colorectal cancer incidence.173
The purpose of this thesis is to further advance the knowledge on population-level 
effects of screening, the best screening tests, the importance of program performance 
indicators for key screening outcomes, and specifi c questions related to personalized 
screening. Before addressing the central questions of this thesis in Part II-IV, in 
Part I, we will fi rst provide more background information on the history of public 
health until present, and on colorectal cancer screening in particular. More details 
on methods, microsimulation modeling, are provided in Chapter 2. Finally, in Part 
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V, we will conclude this thesis by discussing the most important findings, strengths, 
short-comings, and suggestions for future practice and research. 
This research is part of the public health discipline, the overarching aim of which is 
the “organized promotion of health and the prevention and treatment of diseases”.6
Historical context
In the early 20th century, medical screening has emerged as a relatively young branch 
on the history of public health. The origens of public health go back at least 4000 
years.6 Already in 2000 before the common era (BCE), African and Asian communi-
ties started to make use of facilities such as fresh water supplies and sewerage 
systems. Ancient Jewish scriptures from around 500 BCE promoted disease control 
measures such as isolation (quarantine) for certain infectious diseases. Also around 
500 BCE, Hippocrates first inspired Greeks and Romans to adopt healthy lifestyles 
(diet, exercise), to strategically allocate cities near fresh water and clean soil, to build 
aquaducts, bathing houses, underground sewerage, and public hospitals.7 However, 
despite such early milestones for public health, a true understanding of disease 
causes allowing for effective public health interventions, like primary prevention and 
screening, was lacking.
European middle ages have been characterized to a large extent by little structural 
advancements in public health.6 Many of the Roman hygienic establishments were 
destroyed or lost to decay. Cities no longer employed active sewerage systems, 
sanitary workers, public health care facilities, or public health administrations. No 
wonder in hindsight, medieval cities were often plagued by outbreaks of infamous 
infectious diseases such as black death, small pox, dysentery, leprosy, and influ-
enza.8 Epidemics could only be controlled on a local ad hoc basis, but prevention 
was impossible at this stage in history.
It was during the 17th century that groundbreaking developments took place which 
would ultimately lead to the defeat of prevailing infectious diseases. The city of Lon-
don started in 1603 to record the numbers and causes of deaths in weekly mortality 
bills. These allowed early epidemiologists to discover patterns in the occurrence of 
disease,9 and served for instance as evidence for the benefits of small pox inoculation 
(18th century) and the importance of clean living conditions and water (19th century). 
Also in the 17th century, Anthony van Leeuwenhoek would discover microscopy and 
the existence of micro-organisms, a technology which would later be applied by 
other pioneers to discover the bacterial origins of infectious disease (19th century). 
Infectious diseases had lost their mystery, and could now be prevented through 
vaccination and improvements in public hygiene.
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The developments described above substantially improved the life expectancy in 
Western society, and ushered in the “epidemiological transition” in leading causes 
of death from infectious- to the current prevailing chronic diseases, such as cardio-
vascular disease, diabetes, and cancer (Figure 1.2). At this stage, early 20th century, 
medical screening first became a favorable method for disease control. Chronic 
diseases were often poorly treatable at the stage of presentation. Also, there was a 
general lack in understanding of the complex mix of genetic, environmental and life-
style factors causing chronic diseases, which prohibited true prevention of disease. 
The relatively slow progression of chronic diseases provided a good opportunity to 
intervene during early stages of development.
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Figure 1.2 The transition in leading causes of death in the United States during the 20th century.174
The rise of screening, or secondary disease prevention, was spurred by the develop-
ment of valid and acceptable forms of testing, and effective treatments for early 
stages of disease.10 Access to health care also became more widespread during this 
age. 
Early forms of screening included screening for syphilis at around 1950 (after 
already in 1906 a test had been developed to detect the presence of the causal bac-
teria, and treatment through penicillin became available on large-scale immediately 
after World War II;11 diabetes in 1946-47 (after around 1900 insurance companies in 
New York already performed large-scale urine glucose testing, and treatment with 
insulin injections was discovered in 1923;12-14 and cervical cancer in the 1950s (after 
Papanicolaou reported on the usefulness of “Pap” smear testing for detecting cervical 
cancers in 1928, and surgically treatable “in situ” lesions by 1949).15,16 One of the first 
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cancer screening centers in the United States was the Memorial Hospital in New 
York, currently Memorial Sloan Kettering Cancer Center.
The wide application of screening for colorectal cancer is a more recent develop-
ment even still. Although Lockhart-Mummery and Dukes discovered the precancer-
ous stage of colorectal cancer already in 1927,17 and the first major screening studies 
with a rigid endoscopy (“proctoscopy”) were initiated in the United States during the 
1940s, screening with proctoscopy never became popular because of an unfavorable 
balance in harms versus benefits.18,19 Proctoscopy screening improved disease inci-
dence and survival rates, but was labor-intensive, very unpleasant, and inadequate 
for complete colorectal examination. Operative follow-up for more proximal lesions 
detected on follow-up barium enema screening often required complicated surgery 
with a high complication rate. 
Critical breakthroughs for colorectal cancer screening were the development of 
alternative screening methods in the 1960s (fecal testing, colonoscopy),20,21 and the 
subsequent publication of evidence from several studies showing that screening 
could reduce colorectal cancer mortality by approximately 15%.22 Soon professional 
societies followed up on this evidence by recommending population-wide screen-
ing,23 and screening has rapidly popularized ever since.3
Screening is still the preferred method of prevention for many diseases and 
development disorders. Cancer screening is currently recommended for cervical, 
breast, and colorectal cancer,24 and in the United States, also for lung cancer in 
heavy smokers.25,26 Its popularity can be attributed in part to a persistent lack in 
understanding of chronic disease causation,27 the ongoing development of improved 
screening methods, and high costs of treatment.28 Also, the alternative method of 
disease prevention, primary prevention through lifestyle changes, is often difficult 
to achieve, even though potentially much more effective.29 In contrast to the early 
days of screening, formal criteria are now used to rigorously assess the merits of 
screening, and to assure that the overall benefits outweigh the inevitable harms.
screeninG tHeory
screening definition
An often-cited definition of medical screening was published in 1951 by the Commis-
sion on Chronic Illness. It understands screening as “the presumptive identification 
of unrecognized disease or defect by the application of tests, examinations, or other 
procedures which can be applied rapidly. Screening tests sort out apparently well 
persons who probably have a disease from those who probably do not. A screen-
ing test is not meant to be diagnostic. Persons with positive or suspicious findings 
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must be referred to their physicians for diagnosis and necessary treatment.”30 This 
definition also applies to the case of colorectal cancer and this thesis, on the note 
that some forms of colorectal cancer testing do allow for immediate diagnosis and 
treatment.
world Health organization criteria for screening
A comprehensive list of principles for screening evaluation was published in 1968 by 
Wilson and Jungner on behalf of the World Health Organization (WHO).31 Principles 
included that the condition should be an important health problem, there should 
be acceptable treatments and suitable tests, and that the cost should be in reason-
able balance with overall health care spending. Although the Wilson-Jungner criteria 
have become the standard criteria for screening implementation, they have some 
important limitations. For example, no direct screening effectiveness evidence is 
required by Wilson and Jungner to assess the appropriateness. Further, they used 
imprecise notions like ‘important’ (public health problem), ‘suitable’ (screening test) 
and ‘adequately’ (understood natural history). In actual practice, countries often use 
additional or more specific criteria in the spirit of Wilson and Jungner.32,33
In 2008, the WHO itself has updated its criteria for screening (Box 1.1).34 New 
criteria include the requirement of a scientific basis for the effectiveness of screening, 
quality monitoring and assurance, and institutionalized attention for the autonomy 
and well-being of participants. Despite the addition of these important elements, 
the updated criteria leave substantial room for interpretation and require further 
specification in order to become practicable. Also, the cost factor of screening is no 
longer included, while in practice, the cost-to-benefit ratio is becoming increasingly 
important for screening program evaluation due to rising health care costs and aging 
populations.
operational summary of criteria for screening evaluation
Our own work to inform health policy focusses primarily on three of the above 
mentioned criteria for screening, namely the established effectiveness of screening, 
the balance of benefits and harms, and the cost-effectiveness (Box 1.2),35 similar 
to criteria proposed by Harris et al.36 In our decision analyses, we aim to provide 
the evidence needed to compare available strategies for screening in terms of each 
of these criteria. Relevant outcome measures include: cancer deaths averted and 
life-years gained for effectiveness; the number of screening examinations, associated 
adverse effects, and over-diagnosis for harms; and cost per (quality-adjusted) life-
year gained as a measure of cost-effectiveness. Effectiveness should preferably be 
established in randomized controlled trials. Costs are estimable from insurer data.
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Although ethical considerations are important in decision making, it is not a core 
focus of our work to inform screening practice. Within the Erasmus MC University 
Medical Center, a separate department is devoted to research on ethics of screening 
and health care in general. Our primary aim is to inform policy makers on pivotal 
health outcomes and cost. Implicitly, however, there may be ethically laden as-
sumptions in cost-effectiveness research about the importance of health benefits, 
harms and costs across different time periods (e.g. current versus future) and differ-
ent population subgroups (e.g. young versus old, low versus high social economic 
status). This is explained in some more detail in the next section.
Box 1.1 Updated World Health Organization criteria for screening
(1) The screening program should respond to a recognized need.
(2)	 The	objectives	of	screening	should	be	defined	at	the	outset.
(3)	 There	should	be	a	defined	target	population.
(4)	 There	should	be	scientific	evidence	of	screening	program	effectiveness.
(5)  The program should integrate education, testing, clinical services and program 
management.
(6)  There should be quality assurance, with mechanisms to minimize potential risks 
of screening.
(7)	 	The	program	should	ensure	informed	choice,	confidentiality	and	respect	for	au-
tonomy.
(8)  The program should promote equity and screening access for the entire target 
population.
(9) Program evaluation should be planned from the outset.
(10)	 The	overall	benefits	of	screening	should	outweigh	the	harm.
Box 1.2 Erasmus criteria for screening evaluation35
(1)	 	Substantial	positive	health	benefits.	Effects	established	preferably	in	randomized	
controlled trials
(2)	 Limited	adverse	side-effects.	Anticipated	balance	clarified	prior	to	participation.
(3)	 	Reasonable	ratio	between	cost	and	benefits.	Ratio	stable	to	potential	short-term	
developments.
cost-effectiveness analysis
Cost-effectiveness analysis is an established method to relate cost of care to esti-
mated harms and benefits. It serves to inform policy makers on efficient allocation 
of limited health care budgets. Outcomes often take the form of a ratio of the level 
of expenditure per unit of health benefit, where the incorporated health benefits may 
be adjusted for potential harms from the evaluated health service. Cost-effectiveness 
ratios can be used to benchmark cost-pro-benefit across different health care services 
and sectors.
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Cost-effectiveness can be assessed either incrementally from less to more effective 
strategies in case of mutually exclusive choices (incremental cost-effectiveness ratio, 
ICER), or compared to the current intervention or “null” for all evaluated strategies 
(average cost-effectiveness ratio, ACER).37 The cost per (quality-adjusted) life-year 
gained is one of the most common cost-effectiveness metrics in the literature. This 
ratio divides the estimated (incremental) cost of a health service by the estimated 
(incremental) benefits in terms of life-years gained. Cost is usually assessed either 
from a third party payer perspective, primarily including direct costs of health ser-
vices, or from a societal perspective, also including (to the extent possible) costs for 
lost productivity, travel expenses, and other indirect costs. Fixed costs are generally 
not considered. Life-years gained are typically assessed by first estimating the effect 
of a health service on disease-related mortality, as preferably established in clinical 
trials, and then comparing the age of cancer deaths with the average age of other 
cause deaths (i.e. life expectancy in the general population). Optional quality-of-life 
adjustments quantify the lack in quality of life for each life-year gained; downward 
adjustments can be used to incorporate the harmful side-effects of services, e.g. risk 
of disability or pain.
It is common in practice to discount future cost and benefits as included in cost-
effectiveness ratios. The principle of discounting originates from finance, where 
there are opportunity costs and potential risks for receiving cash flows in the future 
rather than today. Effectively, discounting means that immediate costs and benefits 
are valued higher than future costs and benefits. As a consequence, benefits at 
younger ages are often valued higher than benefits at older ages. The convention in 
medical literature is to use annual discount rates of 3%,38 however, in some countries 
it is customary to use different or even differential rates for cost and benefits.39
Some institutions have defined acceptance thresholds for cost-effectiveness. In 
theory, these can be used to assess whether health care expenditure per unit of 
benefit is in an acceptable or cost-effective range. Acceptability thresholds vary 
notably by country. Within the WHO-CHOICE framework, the WHO has proposed 
thresholds of <1x GDP per capita for very cost-effective policy, 1-3 x GDP per capita 
for cost-effective policy, and >3 x GDP per capita for not cost-effective, which boils 
down to a cost-effectiveness threshold of approximately US$100,000 for the United 
States and North-West Europe. For many countries, lower acceptability thresholds 
have been proposed, such as the United Kingdom (£20,000),40 the United States (US$ 
50,000),38 and the Netherlands (€80,000 for curative care, €20,000 for preventive 
care).41 In practice, however, effective drugs or therapies are rarely dismissed for 
cost-effectiveness ratios below the WHO threshold.
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colorectal cancer
Disease epidemiology
Colorectal cancer ranks among the most common and deadly forms of non-commu-
nicable disease. According to the WHO,42 approximately 724,000 (1.3%) out of all 
55.9 million deaths in 2012 were attributable to the disease (Figure 1.3). For refer-
ence, this is more than cervical cancer and prostate cancer combined. In Northern/
Southern America and Europe, the disease is more common than in other parts of 
the world, causing 1.9% and 2.7% of all deaths, respectively. The only cancer that 
is more deadly in Western countries, is lung cancer. However, unlike colorectal 
cancer, lung cancer is mainly caused by a known modifiable risk factor, smoking.43 
In developing countries, infectious diseases such as HIV and malaria remain the 
dominant causes of mortality. This explains, together with limited healthcare budgets 
and accessibility, why population-wide screening for colorectal cancer is no priority 
for most developing countries.
In 2012, 1.4 million new colorectal cancer cases were diagnosed worldwide.44 
In the past decades, the incidence has been increasing in most parts of the world 
along with increasing standards of living and more Western lifestyle.1 Although some 
countries, such as the United States, have managed to bend these curves,45 generally 
colorectal cancer is a public health problem of increasing severity.42
The main risk factors for colorectal cancer include age, gender and family his-
tory of disease. Incidence increases steeply with respect to age, and men have 
approximately 40% higher risk of getting cancer than women (Figure 1.4). Persons 
with one first-degree relative diagnosed with colorectal cancer have, on average, 
2-fold higher risk compared to average-risk, while people with 2 or more diagnosed 
relatives may have even 4-fold increased risk.46 Familial risk is sometimes conferred 
though hereditary syndromes such as familial adenomatous polyposis and Lynch 
syndrome.47 Human microbiota and their DNA have also been identified as potential 
risk factors for colorectal cancer,48 however, the relationship is largely still to be 
revealed. Finally, during the 1990s many lifestyle factors have been associated with 
increased colorectal cancer risk, including tobacco, alcohol, and red meat consump-
tion (relative risks 1.4-1.5).49 Conversely, multi-vitamin use, aspirin use, and active 
lifestyle may decrease risk (relative risk 0.5-0.7).
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natural history
Colorectal cancer is detectable at an early stage of development. It has a latent pre-
clinical phase of on average 2-4 years,50 that can be detected by all existing screening 
methods (see screening). Most cancers develop from benign precursor lesions or 
polyps visible by endoscopy and imaging. The majority of cancers (65-95%) are be-
lieved to develop through the adenoma-carcinoma sequence,51,52 from adenomatous 
polyps (adenomas). A minority develops through alternative pathways, the most 
important one starting from sessile serrated polyps.51
Conventional adenomas usually have a pedunculated shape (stalked) and tubular 
or tubulovillous histology.53 Some adenomas may have alternative optical features 
(elevated, flat, depressed) or histology (villous). Adenomas may grow in size to 
become more than 50mm in diameter. Generally, adenomas do not penetrate the 
lining of the colorectum, but when high-grade dysplasia occur they may at some 
point turn malignant. Approximately 30-50% of people will develop one or more 
adenomas throughout their life. The risk of each individual lesion progressing to 
cancer is much lower, with only about 4-5% of people in the United States and 
Europe developing the disease. It has been estimated that the average time from 
adenoma onset to cancer incidence, in cancer patients, is approximately 20 years,50 
leaving a substantial window for early detection and removal of adenomas before 
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cancer progression. High risk adenoma characteristics include size (diameter >1cm), 
number, histology (villous) and the presence of severe dysplasia.54,55
The sessile serrated pathway to colorectal cancer is believed to cause 5-33% of 
all colorectal cancers.56 Serrated lesions include hyperplastic polyps without any 
malignant potential, sessile serrated polyps, and traditional serrated polyps. The 
latter two types of lesions are microscopically distinguishable from conventional 
adenomas by their saw-tooth configuration. Also, serrated polyps generally have 
different molecular features, such as more increased tumor suppressor methylation 
(CpG island, MLH1), BRAF gene mutations, and micro-satellite instability. The ap-
proximate average duration from onset to cancer in serrated adenomas is believed 
to be somewhat shorter, at approximately 15 years.57,58
Cancer stages differentiated in this thesis are stage I through IV according to the 
5th edition of the American Joint Committee on Cancer Staging Manual (table 1.1). 
Stage I cancers are local, invading but not penetrating the submucosal layer and 
muscles of the colorectum. Stage II cancers invade and potentially penetrate the 
outer layer of the colorectum, and may invade other adjacent organs or structures. 
In stage III, cancer is metastasized in one or more lymph nodes. Finally, stage IV 
cancers are tumors with distant metastasis. Although more recent stage classifications 
exist, these were not used in our studies due to unavailability of corresponding 
registry data (chapter 2). Other types of cancer than adenocarcinoma are more 
rare, less well studied, and not in the scope of this thesis (carcinoids, lymphomas, 
sarcomas, melanomas and squamous cell carcinoma).
Table 1.1 Colorectal cancer stages according to the American Joint Committee on Cancer a
Stage TNMa Description
0 Tis, N0, M0 Tumor remains ‘in situ’, i.e. intraepithelial or invading the lamina propria
I T1-2, N0, M0 Tumor invades the submucosa (a) or muscularis propria (b)
II T3-4, N0, M0 Tumor invades the subserosa or pericolorectal tissues (a), or other organs and 
structures (b)
III T1-4, N1, M0 Tumor affects 1-3 regional lymph nodes (a) or 4 or more (b)
IV T1-4, N0-2, M1 Tumor affects distant organs
a	For	 staging,	we	 follow	 the	common	classification	of	 stages	as	proposed	by	 the	American	Joint	
Committee on Cancer in their 5th edition Manual for Cancer Staging,149 which for colorectal cancer is 
closely	related	to	alternative	classifications	such	as	TMN150 and Dukes’ staging.151
b	 In	TNM	classification,	T	 reflects	 the	 invasiveness	of	 the	primary	 tumor,	N	 the	number	of	 lymph	
nodes affected, and M the metastasis to distant organs.
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Patients
There are accepted clinical guidelines on treatment of colorectal cancer patients (see 
treatment).
Patients with adenomas detected in screening are not monitored as intensively as 
cancer patients, but they are examined more often than average-risk persons without 
detected adenomas. Surveillance guidelines in Europe and United States are largely 
similar, with the distinction that European guidelines indicate annual colonoscopy 
surveillance for some very high-risk patients (large adenoma number/size), while US 
guidelines generally recommend three-year intervals for such patients.59,60 Although 
there is agreement among experts regarding the use of surveillance colonoscopy 
in patients with removed adenomas, in actual practice guidelines may often not be 
complied with: multiple surveys have exposed that many physicians are not familiar 
with or abiding by guidelines.61-64
In this thesis, screening participants are not considered patients unless they are 
diagnosed with a disease requiring close monitoring, medication, or treatment. In the 
Introduction and Discussion of the thesis we avoided using the term “patients” for 
average-risk screening participants. In the intermediate parts, we did use the term 
patients for screening participants according to American journal standards
treatment
There are three dominant methods for cancer treatment. Surgery was first applied 
effectively for cancer treatment around 1870 by Joseph Lister. Radiotherapy was 
introduced soon after Wilhelm Röntgen discovered x-ray in 1895.65 Finally, around 
1950 chemotherapy was discovered as another method for treatment of leukemia by 
Sidney Farber and others.66 Most colorectal cancers are still treated with one or more 
of these options.
The intensity, cost, and effects of treatment are related to the stage of disease. Ac-
cording to the National Comprehensive Cancer Network guidelines,67 stage I cancers 
should generally be treated using surgery. For stage II cancer adjuvant chemotherapy 
and radio treatment may be recommended. More advanced cancers are treated using 
increasingly intensive combinations of surgery, chemotherapy, and radiotherapy. 
Precursor lesions, including adenomas with high-grade dysplasia, can usually be re-
moved using “polypectomy”, or the targeted resection of cell tissue using endoscopy 
with snare.
Population-wide screening programs can be effective only when treatment fa-
cilities are available and accessible for a large majority of the population. In most 
Western countries today, the availability of facilities for diagnosis and treatment of 
colorectal cancer is not a limiting factor. This is underscored by the expenditure 
levels for cancer treatment: in the United States alone, the treatment expenses for 
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colorectal cancer in patients aged 65 or older were estimated at US $14 billion for 
2008,68 and overall cancer treatment expenditures in 2012 were US $ 88 billion.69 For 
certain population subgroups in Western countries, healthcare accessibility is still 
an important problem, mainly because of financial barriers.70 In Europe healthcare 
accessibility generally is higher than in the United States. However, even in Europe, 
a significant proportion of the population cannot afford health care.
In developing or third-world countries the resources and facilities available for 
diagnosis and treatment of any kind of disease are more limited, and devoted to 
more urgent healthcare problems.71,72 The Asia Pacific Working Group on Colorectal 
Cancer, identified healthcare access as one of the potential hurdles for implementa-
tion for screening in Asian countries in 2005: “Health-care systems and health insur-
ance cover only a minority of people. Furthermore, access to health-care facilities is 
limited in many rural areas and communities of low socioeconomic status.”73 Since 
2008, however, screening has been recommended for high incidence countries in 
the region.74
Treatment accessibility is closely linked to cost. Good estimates of the costs of 
treatment are often unavailable, and quickly become outdated when new treatments 
enter the market. In this thesis, we used 1998-2003 reimbursement data from the 
Medicare and Medicaid Services in the United States to approximate cost of screen-
ing and treatment. We adjusted payments for general inflation as measured by the 
Consumer Price Index. In our analyses, we also include patient time costs. The data 
suggest that treatment costs approach $75,000 per annum in advanced-stage cancer 
cases (table 1.2). This may be an underestimate given approval by the United States 
Federal Drug Agency of several novel drugs after 2003, such as bevacizumab and 
cetuximab (2004), and more recently, aflibercept (2012), ramucirumab (2015) and 
trifluridine / tripiracil (2015).
Inverse to the increasing intensity and cost of treatment for more advanced disease 
stages, 5-year survival rates deteriorate with each disease stage, from 89.9% in stage 
I, to 70.5% in stage II-III, to 12.9% for stage IV.75 For many of the approved expensive 
chemotherapeutic agents in the United States available for treatment of advanced-
stage colorectal cancer patients, the additional median survival benefits compared 
to established treatment regimens are in the order of on average 1-2 months.76-79 
Average survival benefit is often not reported.
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Table 1.2 Treatment and screening cost estimates.152 a
Disease stage Third party payer Societal perspective Patient time (hr)
Cancer care
Initial care I 29,943 34,180 243.5
II 41,322 45,559 243.5
III 50,383 54,620 243.5
IV 65,791 70,028 243.5
Continuing care I 2,383 2,723 19.56
II 2,220 2,561 19.56
III 3,174 3,515 19.56
IV 9,839 10,180 19.56
Terminal care CRC I 53,677 58,598 282.8
II 53,525 58,446 282.8
III 56,399 61,320 282.8
IV 75,692 80,613 282.8
Terminal care OC I 13,225 18,146 282.8
II 11,567 16,488 282.8
III 15,303 20,224 282.8
IV 41,090 46,011 282.8
Screening
gFOBT - 5 0
FIT - 26 0
COL w/o polypectomy - 585 917 8
COL w/ polypectomy - 762 1133 8
Complication of COL - 5966 6245 16
Abbreviations: hr = hour; CRC = colorectal cancer; OC = other causes; gFOBT = guaiac-based fecal 
occult blood test; FIT = fecal Immunochemical test; COL = colonoscopy.
a Care was divided in four phases. The terminal phase takes precedence over the initial and con-
tinuing	phase.	The	terminal	phase	reflects	the	last	12	months	of	life.	The	initial	phase	reflects	the	
12	months	following	diagnosis	for	persons	who	survival	for	more	than	12	months	(if	survive	for	≤12	
months, person only experiences the terminal phase). The continuing phase is the time between the 
initial phase and the terminal phase for persons who survive for more than 24 months. All costs in 
Table 1.2 have been annualized. Persons who survive only a fraction of a given phase of care should 
be assigned only a fraction of the costs of that phase.
screening
Compared to screening for cancer in other organs, there is a relative wealth of 
screening options for colorectal cancer. Already in the 19th century, rigid endoscopes 
were developed to inspect rectum and part of the sigmoid colon.80 X-ray (barium 
enema) imaging was used to examine the whole colon in patients with detected 
lesions. In the early 1960s, Overholt developed the flexible sigmoidoscope (FSIG),81 
which was used to endoscopically examine the rectum and entire sigmoid colon. In 
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1967, an internist from the United States recognized that colorectal cancer patients 
often suffer from major rectal bleeding and developed an alternative, non- invasive 
test for occult blood in stool.20 In the early 1970s, full colon examination with colo-
noscopy was introduced, which also allowed for the immediate removal of detected 
lesions.21 Over time each of the tests have been further improved or replaced by 
more advanced techniques.
Currently, four types of colorectal cancer tests can be distinguished: blood-based 
biomarker tests, stool-based tests, endoscopic examination techniques, and radio-
imaging techniques (table 1.3). There is one approved blood-based test in the United 
States, Sept9, which qualitatively detects the methylated Septin 9 gene (approved by 
the Federal Drug Agency, April 2016). Common stool-based tests include guaiac-based 
fecal occult blood testing (FOBT) specific for the heme component in blood, fecal 
immunochemical testing (FIT) specific for the globin molecule in human blood, and 
multi-target stool DNA testing (sDNA) adding molecular assays for KRAS mutations, 
NDRG4 and BMP3 gene methylation, and Beta-actin hemoglobin. Endoscopic tests 
include FSIG and colonoscopy, and also capsule endoscopy or capsule endoscopies. 
Finally, radiography-based tests include CT colonography and the more dated double-
contrast barium enema (DCBE).
Table 1.3 Performance of common colorectal cancer screening tests
Type Subtypes Evidence Test 
Sensitivity a
Incidence 
Reduction
Mortality 
Reduction
Reference
Blood Septin 9 Indirect .48 - - 153
Stool gFOBT (Hemoccult II) RCT (4) .25-.52 c .00-.20 c .09-.32 118,154-159
sFOBT	(Hemoccult	SENSA) Indirect .64-.80 - - 160
FIT Observational .73-.88 - .10-.22 104-106
mt-sDNA (Cologuard) Indirect .92 - - 161
Endoscopy FSIG RCT (4) .95 .18-.26 .21-.31 117,119,120,162,163
Colonoscopy Observational .95 .48-.91 .68-.88 163-169
Capsule endoscopy Indirect .88 - - 170
Imaging DCBE Indirect .48 - - 171
CTC Indirect .67-.94 b - - 104
Abbreviations: gFOBT = guaiac-based fecal occult blood testing; sFOBT = high-sensitivity gFOBT; 
FIT = fecal immunochemical test; mt-sDNA	=	multi-target	stool	DNA	test;	FSIG	=	flexible	sigmoidos-
copy;	DCBE	=	Double-contrast	barium	enema;	CTC	=	computed	tomographic	colonography.
a Sensitivity for cancer is reported. Most stool-based tests have low sensitivity for adenomas, imaging 
has low sensitivity for diminutive lesions but high sensitivity for large adenomas, and endoscopy has 
high sensitivity for all adenomas (>75%).163
b Sensitivity for adenomas over 10 mm in diameter
c The incidence reduction achieved in the Minnesota Colon Cancer Control Study of 20% was 
achieved with rehydrated guaiac fecal occult blood test slides, which are associated with higher 
sensitivity of approximately 90%.172
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All of the above-mentioned screening methods have their particular advantages and 
disadvantages, that each individual patient may weigh differently. Stool-based tests 
are the most simple, least intrusive and cheapest of all colorectal cancer tests; blood-
based tests may be more acceptable to some people, and can be completed during 
routine patient examinations by primary care physicians; CT imaging is a more sensi-
tive and protective non-invasive test than the above tests; finally, endoscopy is the 
most sensitive for detecting both colorectal adenomas and cancer, and allows for im-
mediate treatment of adenoma patients. All tests except primary colonoscopy require 
follow-up of positive results with colonoscopy. Disadvantages of the stool-based and 
blood-based tests are that they have to be repeated frequently; CT colonography 
requires inconvenient cathartic preparation and may impose risks associated with 
low-dose radiation; colonoscopy disadvantages include price, risk of perforation, 
and inconvenience.
Not surprisingly given the different test features, the actual observed acceptability 
of tests has been suggested to differ across settings and cultures.82 However, the 
general pattern across randomized clinical studies comparing non-invasive tests 
with endoscopy is that non-invasive methods are preferred by most people.83-88 
Paradoxically, survey data from the U.S. suggest that, in practice, Americans tend 
to use colonoscopy more often than FOBT.89 Part of this apparent paradox for the 
United States may stem from the differences in short- and long-term preferences. 
It is uncertain from existing evidence whether people would have been willing to 
comply with high-frequency screening methods for longer periods. Some programs 
have suggested reasonable compliance rates with FIT across up to 4 rounds of 
testing.90-92 Although high adherence for innovative testing methods such as sDNA 
and Sept9 is less well-established, these tests may  have the potential to be more 
acceptable to some people.93
In the United States, approximately 60% of the population reported being up-to-
date with screening recommendations for any type of test.94 Regionally, programs 
with mailed outreach have reported screening rates of over 80%.95,96 In most other 
countries, uptake rates are lower. For example, colonoscopy-based screening pro-
grams in Germany and Poland have population uptake rates of only approximately 
15%.97 FOBT programs also do not necessarily have high adherence rates. For ex-
ample, in Belgium reported uptake rates are less than 10%.5 On the other end of 
the spectrum are Netherlands, Finland, and the Basque country in Spain, where 
uptake rates are higher than 60%.5,98 Overall, data suggest that the acceptability of 
the existing screening methods for colorectal cancer may be lower than that for 
breast and cervical cancer, which may be attributable in part to gender differences in 
preferences and, for some settings, to high costs of colorectal examinations.99
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Costs differ substantially across screening tests. In the United States, a single low-
sensitivity guaiac-based FOBT (gFOBT) is reimbursed at approximately US $5, a 
single FIT is reimbursed at approximately US $26, colonoscopy without polypectomy 
is reimbursed at on average US $585, and colonoscopy with polypectomy at US $762 
(table 1.2). Similar to treatment, we used Medicare reimbursement and co-payment 
rates to approximate costs. Indirect (societal) costs of colonoscopy are relatively 
higher for invasive screening modalities due to the cathartic preparation, traveling, 
and more substantial procedure time. It is not clear to what extent fixed costs are 
incorporated in per-test reimbursements. Overhead costs for screening programs 
may be substantial, although less so for opportunistic than for organized programs 
(see Programs).100
Evidence for the effectiveness of screening tests is of variable quality, and often 
indirect. To our knowledge, Sept9 is the only used blood test for colorectal cancer. 
The approval by the United States Federal Drug Agency was based on evidence sug-
gesting it may detect around 70% of cancers, with a specificity of greater than 80%.101 
More recent evidence suggests a lower sensitivity of only 50% for Sept9 (table 1.3). 
For stool-based tests, randomized controlled trials have been conducted only for 
gFOBT with Hemoccult II (Beckman Coulter Inc.), suggesting that this may reduce 
colorectal cancer-related mortality by approximately 9-33% (intention-to-screen) 
(table 1.3). The effects of current stool-based tests are generally deemed higher 
than those of gFOBT,102,103 because these tests have better diagnostic performance 
characteristics than classical guaiac-based tests.104 For FIT, recent population-based 
studies have suggested that the mortality reduction for screening may be as high 
as 62%, although the observed corresponding population-level effects of programs 
were still modest due to low population participation (table 1.3).105,106 For endo-
scopic tests, sigmoidoscopy is the only test with effectiveness estimates from trials. 
The estimated mortality reduction across 5 trials was 21-31% (table 1.3), with higher 
per-protocol effects and effects for the distal end of the colorectum (45%).107 For 
colonoscopy, direct estimates of the effectiveness are available only from obser-
vational studies with inherent weaknesses (primarily selection bias). These studies 
suggest that screening colonoscopy may reduce cancer-related mortality by even 
higher percentages >50% (table 1.3). The effectiveness of capsule endoscopy has 
not been assessed directly, however, the estimated diagnostic performance is for 
large adenomas and cancer of 88% is close to that of colonoscopy. Likewise, no 
direct evidence for the effectiveness of radio-imaging exists, but sensitivity for large 
adenomas is comparable to colonoscopy (table 1.3).
Given the high present level of treatment costs, multiple independent modeling 
studies have indicated that colorectal cancer screening is very cost-effective.108,109 
For the Dutch screening program, Wilschut and colleagues evaluated a number of 
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different screening strategies varying in terms of test, interval, and age range. All 
of the evaluated strategies had ACERs of less than €20,000 per life-year gained.110 
Studies for the United States Centers for Medicare and Medicaid Services from 2010 
also indicated that colorectal screening, independent of screening modality, is highly 
cost-effective, with ACERs ranging from less than US $0 up to $14,000.111
Screening for colorectal is recommended in most Western countries. Expert panels 
across and within countries differ in the types of tests included in the recommenda-
tions for screening. The Council of the European Union endorsed only annual or 
biennial screening with sensitive guaiac-based fecal occult blood testing (sFOBT) be-
tween ages 50-74 years,112 which was reconfirmed more recently by a pan-European 
expert panel.113 In the United States, the American Cancer Society, the United States 
Multi-Society Task Force on Colorectal Cancer, and American College of Radiology 
recommended screening from age 50 with either colonoscopy at 10 year intervals, 
FSIG, DCBE and CTC at 5 year intervals, sFOBT or FIT with 1 year intervals, and 
sDNA with unspecified interval;103,114 the United States Preventive Services Task Force 
recommended no screening after age 75, and recommended the same tests except 
for DCBE, which they replaced with Sept9; the American College of Gastroenterolo-
gists favors colonoscopy for screening.115 For South-East Asia and Australia, the Asian 
Pacific Working Group on Colorectal Cancer restrict recommended strategies for 
screening to FIT.74
recent DeVeloPments
Programs
Many screening programs have been initiated over the last two decades.4 Although 
available information on screening programs is incomplete, fully implemented or-
ganized programs are known to exist at least in Croatia, France, Slovenia, parts of 
the UK (England, Wales, and N. Ireland), several Canadian provinces, Israel and 
Japan. Organized programs are being rolled out in many other countries, including 
Australia, Belgium (since 2013), Denmark (since 2014), Finland (since 2009), Poland 
(since 2000), and the Netherlands (since 2014). Many other countries, including 
Russia, are running pilot programs. Some countries have opted for opportunistic 
screening programs, where screening may be promoted but is not offered by the 
government. Countries with opportunistic programs include Austria, Germany, 
Czech Republic and Greece in Europe, and Uruguay and the United States in the 
Americas. In Europe, no screening activity is currently known to exist in Bulgaria, 
Estonia, Hungary, and Romania.
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The Dutch screening program as initiated in 2014 will roll out screening over a 
period of five years. By 2019, biennial FIT screening will be offered to all men and 
women aged 55 through 75 years. Screening is performed with a new kind of FIT, 
the FOB Gold (Sentinel Technologies Inc.), which will be sent and collected via mail. 
Periodical monitoring and modeling is used to control positivity and colonoscopy 
referral rates for the test.116 The estimate is that the program will eventually prevent 
2400 deaths from colorectal cancer per year. For the Netherlands, initial program 
performance looks promising, with first year adherence exceeding 70%.98
current topics in research
Recent research related to colorectal cancer screening has focused on several areas 
for improvement of screening programs.
First, as already addressed to some extent, studies have looked at the question of 
the effectiveness of stool-based versus endoscopic testing for colorectal cancer. In 
the past five years, four studies have been published which evaluated the benefits 
of FSIG screening.117-120 In 2015, the first data regarding population-level effects of 
FIT were published.105,106 More definite answers on the question of effectiveness in 
colonoscopy versus stool-based testing will come from randomized clinical trials. 
Trials have been initiated to evaluate 10-15 year benefits of colonoscopy and FIT 
screening, but results are not expected before 2025.86,121,122 In advance of trial results, 
in this thesis, we used modeling to compare the effectiveness of fecal colorectal 
cancer testing with colonoscopy screening (see research questions).
A second major development, non-exclusive to colorectal cancer screening, is the 
utilization and evaluation of performance indicators. In the United States, physician 
reimbursement will be made dependent on quality indicator scores, some of which 
still are to be validated. An obvious and critically important determinant of outcomes 
for screening programs is screening adherence. Already in 2000, cost-effectiveness 
studies have suggested that the outcomes of FOBT screening may be highly sensitive 
to adherence rates.123 As we mentioned in the previous section (see screening), 
multiple trials from the past 10 years have found that initial test adherence may be 
higher for stool-based testing than for colonoscopy.83-88 Only very recently, the first 
population-based studies and trials have reported overall FIT or sFOBT compliance 
rates over up to 4 rounds of testing, with cumulative adherence rates of around 
50%.90-92 Translation to primary cancer-related outcomes has not been performed. In 
this thesis, we present novel randomized clinical trial data from the U.S. with adher-
ence and outcome data for up to 7 rounds of sFOBT screening versus colonoscopy. 
Modeling was used to assess and compare the long-term corresponding benefits.
Colonoscopy quality is another important outcome determinant that has received 
a lot of attention in recent years. In the past six years several high-impact studies 
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have suggested that there is a strong association between the main colonoscopy 
quality indicator, adenoma detection rate (ADR), and patient outcomes.124,125 Other 
studies have looked at alternative quality indicators such as adequacy of bowel 
preparation,126,127 colonoscopy withdrawal time,128,129 and colonoscopy completion 
(or cecal intubation) rates.127,130 The American College of Gastroenterology Task 
Forces on Quality in Endoscopy has reviewed currently available data and published 
an update on what quality indicators to use for colonoscopy to assure satisfactory 
screening outcomes.131,132 Primary recommended quality indicators include, both the 
ADR (target value <25%), cecal intubation rate (>95%), and adequate follow-up 
recommendation rate (>95%). This thesis includes a report on the estimated relation-
ship between observed ADR adenoma variation and colorectal cancer screening 
benefits, risks, and cost.
A third development, again broader for general health care, is a shifted focus 
toward more personalized health services. It is recognized increasingly that every 
person is different, and may not benefit equally from a certain form of therapy or 
screening. Current colorectal cancer screening guidelines only take into consideration 
persons’ age, their history of adenomas, and family history of disease and polyposis 
syndromes, but no other known risk factors for colorectal cancer. In the past 5 years, 
several studies have been published focusing on prediction of risk of neoplasia 
from personal characteristics including age, gender, BMI or waist circumference, 
family history, and smoking.133-135 Hemoglobin levels from quantitative stool tests 
have also been proposed for risk estimation.136,137 Most risk prediction tools have not 
been externally validated. Implications of risk scores for optimal screening strate-
gies are unknown, the assessment of which may require modeling.138 In this thesis, 
we investigated the relevance of general health status and screening status for the 
question whether to screen elderly patients, as well as more intensive examination 
of adenoma patients (discussed below).
Finally, there is an increasing amount of attention for management of patients 
with colorectal adenomas. It is well-known that adenoma patients are at higher 
risk for colorectal cancer,139 however, scant data are available to compare cancer 
outcomes for different surveillance strategies. Current recommendations lean heavily 
on evidence from the 1990s and early 2000s with few cancer outcome points.54,140 
There are concerns that with improved colonoscopy quality, the guidelines may no 
longer be appropriate.141 In recent years, new pooled data have been published from 
older studies on adenoma recurrence risks with different surveillance intervals and 
types of baseline adenomas.54,55,142 A Dutch study has compared adenoma findings 
for two intervals in patients with a family history,143 and an American study looked 
specifically at surveillance benefits for elderly patients.144 Finally, a Norwegian study 
has used population-based registries to compare colorectal cancer mortality risk 
General introduction 33
of patients with low- or high-risk adenoma to the general population (in a non-
screening setting), finding differences of maximum 40% between high- and low-risk 
patients.145 Despite these new data, evidence is still too fragmented to adequately 
inform clinical guidelines. In Europe, several countries are accruing patients for a 
large-scale, long-term randomized clinical trial, named the European Polyp Surveil-
lance (EPoS) study.146 In this thesis, we used modeling to estimate the effectiveness 
and cost-effectiveness of surveillance strategies to be evaluated in EPoS.
researcH questions
The remainder of this thesis has three main parts (Part II-IV), which focus on the 
estimation of population-level impact of screening (Chapter 3-5), the importance 
of various effect determinants in actual screening practice (Chapter 6-9), and the 
potential for more personalized test strategies in specific high-risk patients (Chapter 
10-11). Personalized screening is interpreted here broadly as taking into account for 
screening regimens, any other factors than age. Adenoma surveillance is presented 
under the umbrella of personalized screening on the basis that adenoma findings are 
taken into account for recommended strategies of examination.
For each of the above chapters, the corresponding research question is formulated 
below. All questions were addressed using microsimulation modeling. The micro-
simulation model will be presented in detail in Chapter 2. Some modeling studies 
were partly informed by novel empirical data. Where applicable, these data are 
presented in the chapters listed below.
(1) What is the expected impact of achieving 80% screening rates by 2018 on CRC 
incidence and mortality in the United States? (Chapter 3)
(2) How does currently available colonoscopy capacity in the United States compare 
to estimated need under a national screening program? (Chapter 4)
(3) Which fraction of CRC mortality in the United States is attributable to nonuse of 
screening? (Chapter 5)
(4) What are the estimated benefits of colonoscopy versus sFOBT screening with 
observed adherence rates from the National Colonoscopy Study? (Chapter 6)
(5) How does observed ADR variation influence screening benefits, harms and costs? 
(Chapter 7)
(6) How do FIT and colonoscopy screening benefits compare at different levels of 
ADR? (Chapter 8)
(7) What is the outcome effect of increasing time to diagnostic colonoscopy follow-
ing a positive fecal colorectal cancer test result? (Chapter 9)
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(8) Up to what age should screening for colorectal cancer be considered in elderly 
unscreened patients? (Chapter 10)
(9) How effective and cost-effective is currently recommended surveillance of ad-
enoma patients compared to less intensive surveillance or screening? (Chapter 
11)
suPPort
The present work was conducted as part of the research consortium Population-based 
research optimizing screening through personalized regimens (PROSPR) funded by 
the National Cancer Institute (NCI) within the United States National Institutes of 
Health.147 PROSPR is a program with the scientific goal of supporting research to 
better understand how to improve the screening process (recruitment, screening, 
diagnosis, referral for treatment) for breast, colorectal, and cervical cancer. NCI has 
funded seven research centers and one statistical coordinating center. The specific 
aims of our collaboration with Kaiser Permanente Northern and Southern California 
were to compare the effectiveness of a FIT program and colonoscopy screening 
for colorectal cancer, to study the balance of benefits and harms, and to conduct 
exploratory studies to inform future research to optimize screening programs.
Another important source of financial support was the Cancer Intervention and 
Surveillance Modeling Network (CISNET) funded by NCI.148 CISNET is a consortium 
of NCI-sponsored investigators who use statistical modeling to improve the under-
standing of cancer control interventions in prevention, screening, and treatment and 
their effects on population trends in incidence and mortality. These models can be 
used to guide public health research and priorities, and they can aid in the develop-
ment of optimal cancer control strategies.
This thesis was supervised by Dr. Marjolein van Ballegooijen, Dr. Iris Lansdorp-
Vogelaar, and Prof. Harry de Koning from the Erasmus MC Department of Public 
Health. The sub-department involved in screening evaluation has an esteemed repu-
tation in informing both national and international screening recommendations for 
various cancer types, including breast, lung, colorectal, prostate cancer, esophageal, 
and cervical cancer.
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Microsimulation Screening Analysis
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The ruling paradigm of evidenced-based health care dictates that decision makers 
should seek for a solid empirical evidence basis to support their decision making. 
In actual practice, for many decisions there are no data to directly inform decisions. 
As we showed in the last chapter, the most rigorous study design to assess the effect 
of health care interventions, experimental study, is applied only selectively in actual 
practice. There are far more screening options and possible screening strategies 
then ever could be evaluated in trials. Moreover, in colorectal cancer screening, the 
most important disease outcomes (e.g. death from disease) occur only rarely, which 
means that practitioners are often forced to look at intermediate outcomes that are 
more difficult to interpret (e.g. adenomas). Finally, empirical studies may span many 
years, which means that there is inherently a lag in informed-decision making if 
decisions are based entirely on empirical basis. These kinds of limitations combined 
with advances in computer science have stimulated researchers since the 1980s to 
look for inventive new ways to study diseases and health care interventions.
Microsimulation modeling is an established method to inform policy decisions. 
Microsimulation models integrate existing knowledge on population demographics, 
the natural history of disease, risk factors, potential screening test characteristics and 
effects, and costs of care. The information is used to simulate screening in virtual 
populations similar to existing populations in terms of life expectancy and disease 
risk. Quality of models can be assessed by periodic validation to newly published 
outcome data. Validated models are invaluable tools for finding optimal strategies 
and policies for screening for diverse settings. 
Applications of microsimulation modeling include extrapolation of empirical study 
findings for long-term effects, optimization of screening strategies in terms of inter-
vals and starting and stopping ages, and evaluation of individualized strategies. The 
MISCAN model has been used many times to inform decision makers in screening 
evaluation and planning. In this thesis, we present a number of applications for mi-
crosimulation modeling. Studies were all conducted using the MISCAN-colon model. 
A more detailed description of the model is provided in subsequent paragraphs.
moDel structure
MISCAN-colon is a stochastic, semi-Markov, microsimulation model for colorectal 
cancer (CRC) programmed in Delphi (Borland Software Inc.). It can be used to 
explain and predict trends in CRC incidence and mortality and to quantify the ef-
fects and costs of primary prevention of CRC, screening for CRC, surveillance after 
polypectomy, and treatment.
40 Chapter 2
The term ‘microsimulation’ implies that the individuals are moved through the 
model one at a time, rather than as proportions of a cohort. The term ‘semi-Markov’ 
implies that MISCAN-colon, unlike traditional Markov models, does not assume an-
nual state transitions; instead it generates durations in states, allowing for various 
time distributions and dependency of consecutive state transitions, and thereby 
increases model flexibility and computational performance. The term ‘stochastic’ 
implies that the model determines the states and corresponding durations by draw-
ing from probability distributions, rather than using fixed values. Hence, the results 
of the model are subject to random variation.
MISCAN-colon consists of three modules: a demography module, natural history 
module, and screening module.
DemoGraPHy moDule
Using birth- and life-tables representative for the population under consideration, 
MISCAN-colon draws a date of birth and a date of non-CRC death for each individual 
simulated.176 The maximum age an individual can achieve is assumed to be 100 
years.
natural History moDule
transitions
As each simulated person ages, one or more adenomas may develop (Figure 2.1). 
These adenomas can be either progressive or non-progressive. Both progressive and 
non-progressive adenomas can grow in size from small (≤5mm), to medium (6-9mm), 
to large (≥10mm); however, only progressive adenomas can develop into preclinical 
cancer. A preclinical cancer may progress through stages I to IV without symptoms, 
or be diagnosed during each stage CRC because of symptoms. After clinical diag-
nosis, CRC survival is simulated using age-, stage-, and localization-specific survival 
estimates for clinically diagnosed CRC as obtained by Rutter and colleagues.177 For 
individuals with synchronous CRCs at time of diagnosis, the survival of the most 
advanced cancer is used. The date of death for individuals with CRC is set to the 
earliest simulated death due either to CRC or another cause (‘Demography module’).
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independent of age and localization
dependent on age; independent of localization
dependent on age and localization
No Lesion Adenoma 
≤ 5 mm 
Adenoma 
6-9 mm 
Adenoma  
≥ 10 mm 
 progressive  
Adenoma 
≥ 10 mm 
Adenoma 
6-9 mm 
non-progressive  
Preclinical 
stage I 
Preclinical 
stage II 
Preclinical 
stage III 
Preclinical 
stage IV 
 screen-detectable 
adenoma phase 
 screen-detectable 
cancer phase a 
Clinical 
stage I 
Clinical 
stage II 
Clinical 
stage III 
Clinical 
stage IV 
 clinical 
cancer phase a 
Cancer 
death 
Figure 2.1 The stages of disease in the semi-Markov model.
a Cancer stages were based on the 5th edition Cancer Staging Manual from the American Joint Com-
mittee on Cancer149
transition rates and durations
An individual’s risk of developing adenomas depends on the individual’s age and 
a personal Gamma-distributed risk index (non-homogeneous Poisson process). As 
a result of the latter most individuals develop no adenomas, whilst some develop 
many. We assumed that the distribution of adenomas over the colon and rectum 
equals the distribution of cancers as observed in SEER before the introduction of 
screening.75 The age-specific onset of adenomas and the dispersion of the personal 
risk index were calibrated to data on the prevalence and multiplicity distribution 
of adenomas as observed in autopsy studies (Figure 2.2).178-187 The age-specific 
probability of adenoma-progressivity and the age- and localization-specific transition 
probabilities between preclinical cancer stages and between preclinical and clinical 
cancer stages were simultaneously calibrated to SEER data on the age-, stage-, and 
localization-specific incidence of CRC as observed before the introduction of screen-
ing (Figure 2.3).75
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Figure 2.2 Simulated versus observed adenoma prevalence in selected autopsy studies (with 95% 
confidence	intervals).a
a Observed results are only shown for the two largest studies on which the model has been cali-
brated. MISCAN-colon has additionally been calibrated to 8 other autopsy studies.
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The average durations between the preclinical cancer stages were calibrated to the 
rates of screen-detected and interval cancers observed in randomized controlled 
trials evaluating screening using guaiac fecal occult blood tests.157,188,189 This exercise 
has been described extensively elsewhere.190 The average duration from the emer-
gence of an adenoma until progression into preclinical cancer (i.e. the adenoma 
dwell-time) was calibrated to the rates of interval cancers (including surveillance 
detected cancers) observed in a randomized controlled trial evaluating once-only 
sigmoidoscopy screening (Figure 2.4).190 We assumed an equal overall dwell-time 
for adenomas developing into CRC from a medium size (30% of all CRCs) and from 
a large size (70% of all CRCs). All durations in the adenoma and preclinical cancer 
phase were drawn from Exponential distributions. Durations of the disease stages 
within the adenoma and preclinical cancer phase, respectively, were assumed to 
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Figure 2.3a-e Simulated versus observed colorectal cancer incidence in 1975-1979 Surveillance 
Epidemiology	and	End	Results	program	data.
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be perfectly correlated (i.e. if a small adenoma grows into a medium-sized ad-
enoma rapidly, it will also grow into a large adenoma or develop into CRC rapidly). 
However, durations in the adenoma phase were assumed to be uncorrelated with 
durations in the preclinical cancer phase (i.e. a rapidly growing adenoma does not 
necessarily develop into a rapidly progressing cancer). The proportion of medium 
sized, non-progressive adenomas growing large and the average duration in the me-
dium size, non-progressive adenoma state were calibrated to size-specific adenoma 
detection rates observed in a Dutch randomized controlled trial on colonoscopy 
screening (not shown). All calibrations were performed using the Nelder-Mead search 
algorithm to minimize deviances from observed values based on log-likelihood func-
tions (Poisson likelihood for incidence, Binomial likelihood for adenoma prevalence, 
and Multinomial likelihood for cancer stages).
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Figure 2.4a-b Simulated versus observed distal colorectal cancer incidence in the intervention 
group of the UK Flexible Sigmoidoscopy Trial.
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screeninG moDule
Screening will alter some of the simulated life histories: some cancers will be pre-
vented by the detection and removal of adenomas, while other cancers will be 
detected in an earlier stage with a more favorable survival. The effectiveness of 
screening depends on a test’s assumed ability to detect adenomas and CRC. As the 
stage-specific survival of screen-detected CRC as observed in randomized controlled 
trials on guaiac fecal occult blood testing was substantially more favorable than that 
of clinically detected CRC, even after correcting for lead-time bias,190 we assigned 
those screen-detected cancers that would have been clinically detected in the same 
stage the survival corresponding to a one stage less progressive cancer. Hence, a 
cancer screen-detected in stage II, that would also have been clinically diagnosed 
in stage II, is assigned the survival of a clinically diagnosed stage I cancer. The 
only exceptions were screen-detected stage IV cancers. These cancers were always 
assigned the survival of a clinically diagnosed stage IV cancer.
Besides positive health effects of screening, the model also allows for the evalua-
tion of colonoscopy-related complications and over-diagnosis and over-treatment of 
CRC (i.e. the detection and treatment of cancers that would not have been diagnosed 
without screening).
inteGratinG moDules
The demography module generates a date of birth and a date of non-CRC death for 
each individual simulated, creating a life-history without adenomas or CRC. Then, 
in Patient A in Figure 2.5, the natural history module generates an adenoma. This 
adenoma progresses into preclinical cancer, which, in the absence of screening, is 
diagnosed because of symptoms in stage II and results in CRC death before non-CRC 
death would have occurred. In the screening module a screening examination is 
simulated, indicated by the black arrow. During this examination the adenoma is 
detected, and as a result both CRC and CRC death are prevented. Hence, integrating 
all 3 modules for Patient A, screening prolongs life by the amount indicated by the 
blue arrow. Patient B also develops an adenoma, and although this adenoma does 
progress into preclinical cancer, Patient B would never have been diagnosed with 
CRC in a scenario without screening (see Life history 2). However, during the screening 
examination simulated in the screening module, indicated by the red arrow, CRC is 
screen-detected in stage I. Hence, in this patient screening results in over-diagnosis 
of CRC: it detects a cancer that would never have been diagnosed in a scenario 
without screening. Hence, integrating all 3 modules in this patient, screening does 
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not prolong life but results in additional LYs with CRC care (over-treatment), as 
indicated by the red arrow.
PATIENT A: BENEFIT FROM SCREENING
Demography module
Life history 1 birth    non-CRC 
(without CRC)   death
Natural history module
adenoma adenoma preclinical preclinical clinical
Life history 2 birth  ≤ 5 mm ≥10 mm CRC stage I CRC stage II CRC stage II   CRC 
(developing CRC)   death
Screening module
adenoma
Life history 3 birth  ≤ 5 mm no lesion   non-CRC 
(with screening)   death
screening detects adenoma
adenoma
6-9 mm
adenoma
6-9 mm
life-years gained
PATIENT B: OVER-DIAGNOSIS FROM SCREENING
Demography module
Life history 1 birth    non-CRC 
(without CRC)   death
Natural history module
adenoma adenoma preclinical
Life history 2 birth  ≤ 5 mm ≥10 mm CRC stage I   non-CRC 
(developing CRC)   death
Screening module
adenoma adenoma preclinical screen detected
Life history 3 birth  ≤ 5 mm ≥10 mm CRC stage I CRC stage I   non-CRC 
(with screening)   death
   screening
 detects CRC life-years with overtreatment
adenoma preclinical
6-9 mm CRC stage II
adenoma
6-9 mm
Figure 2.5 Integrating MISCAN modules for two example patients.
ValiDation
MISCAN-colon has been validated to several randomized clinical trials. In 2004, it 
was validated to National Polyp Study data evaluating colonoscopy surveillance in 
adenoma patients.191 In 2009, MISCAN was validated to combined data from the 
Minnesota Colon Cancer Control Study, the Nottingham study and Funen study of 
biennial gFOBT screening. Based on this study the assumptions for test performance 
were adjusted.190 In 2011, we validated the model to U.K. Flexible Sigmoidoscopy 
Study data, and updated the model’s adenoma dwell time assumptions.50,192 Current 
estimated mortality risks for patients in colonoscopy surveillance are in line with 
long-term National Polyp Study observations (Figure 2.6).193 Another validation 
project which uses data from the Norwegian Colorectal Cancer Prevention study on 
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flexible sigmoidoscopy is in progress.194 Finally, within CISNET, efforts are ongoing to 
develop methodology to allow for meaningful comparisons of model differences.195
Figure 2.6 Simulated versus observed colorectal cancer mortality in the National Polyp Study
In this thesis, we validated the model to trial data from the National Colonoscopy 
Study data (chapter 6), to observational screening data from Kaiser Permanente 
Northern California (chapter 7), and to published adenoma surveillance data from 
the 1990’s and early 2000’s (appendix 11).
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aBstract
BACKGROUND: The National Colorectal Cancer Roundtable, a national coalition of 
public, private and voluntary organizations, has recently announced an initiative to 
increase colorectal cancer (CRC) screening rates to 80% by 2018 in the United States. 
We evaluated the potential public health benefits of achieving this goal.
METHODS: We simulated the 1980-2030 United States population of 50-100 year-old 
persons using microsimulation modeling. Test-specific historical screening rates were 
based on 1987-2013 National Health Interview Survey data. The effects of increasing 
screening rates from approximately 58% in 2013 to 80% in 2018 were compared 
to a scenario in which the screening rate remained approximately constant. The 
outcomes were cancer incidence and mortality rates and number of CRC cases and 
deaths counts during short-term follow-up (2013-2020) and extended follow-up 
(2013-2030).
RESULTS: Increasing CRC screening rates to 80% by 2018 would reduce CRC inci-
dence rates by 17% and mortality rates by 19% during short-term follow-up and by 
22% and 33%, respectively, during extended follow-up. These reductions would 
amount to a total of 277,000 averted new cancers and 203,000 averted CRC deaths 
from 2013 through 2030.
CONCLUSION: Achieving the goal of increasing the colorectal cancer screening 
uptake in the United States to 80% by 2018 may have a considerable public health 
impact by averting approximately 280,000 new cancer cases and 200,000 cancer 
deaths within less than two decades.
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introDuction
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer for both sexes 
combined and the second leading cause of cancer death in the United States, with 
an estimated 136,800 new cancer cases and 50,300 deaths in 2014.196 Registry data 
from the past decade indicate that both disease incidence and mortality decreased 
approximately 3% per year,197 largely due to increased use of screening.198,199 Despite 
the effectiveness of screening and the availability of various screening options, only 
58% of United States adults ages 50-75 years had received guideline-recommended 
testing in 2013.200 Previous studies show that a substantial proportion of CRC deaths 
are attributable to nonuse of screening.201,202 This rallied a recent initiative from 
the National Colorectal Cancer Roundtable (NCCRT), a national coalition of public, 
private and voluntary organizations, to aim for screening rates of 80% by 2018 in the 
United States.203 However, an estimate of the potential benefits of increasing uptake 
by an additional 22% in terms of the number of CRC cases and deaths averted is 
needed to inform public discourse and policy on this initiative and to project the 
short- and long-term public health ‘return on investment’. In this study, we used 
advanced modeling approaches to estimate the potential benefits in terms of new 
CRC cases and deaths averted from achieving the NCCRT goal.
metHoDs
This study was based on men and women ages 50-100 years, simulated to match the 
1980-2030 United States population in terms of their life expectancy, risk of CRC, 
and past and future use of screening. The analyses utilized the MISCAN-colon model 
(chapter 2), which has been used to inform United States Preventive Services Task 
Force screening recommendations.204
source data
Demography estimates were obtained from the United States Census Bureau;205 
overall life-expectancy was based on generational United States life tables from the 
Berkeley mortality database.206 Historical use of colonoscopy, fecal occult blood 
tests and sigmoidoscopy in the United States were derived from 1987–2013 National 
Health Interview Survey (NHIS) data.200 In 2013, 58% of the population ages 50-75 
years reported up-to-date on screening. The percentages reporting up-to-date on 
each specific test were 54% for colonoscopy, 8% for fecal occult blood tests, and 4% 
for sigmoidoscopy.
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screening scenarios
In the analysis, we evaluated a scenario in which the screening rate increased lin-
early from 58% in 2013 to 80% in 2018, with no further increase through 2030. 
We compared this scenario to one in which screening rates remained constant at 
approximately 60%. We evaluated the magnitude of the reduction in CRC incidence 
and mortality rates per year during short-term (2013-2020) and extended follow-up 
(2013-2030). Screening consisted of a mix of colonoscopy, sigmoidoscopy and fecal 
occult blood testing in accordance with estimates from NHIS. Patients with a positive 
fecal occult blood test or sigmoidoscopy (for adenomas or cancer) were referred 
to diagnostic colonoscopy, and patients with adenomas detected were referred for 
colonoscopy surveillance according to United States guidelines.139 Patient adher-
ence to diagnostic colonoscopy and surveillance colonoscopy was assumed to be 
80%.207,208
role of funding for this study
This study was conducted within the NCI-funded Population-Based Research Opti-
mizing Screening through Personalized Regimens (PROSPR) consortium (NCI grant 
U54 CA163262), which aims to conduct multi-site, coordinated, trans-disciplinary 
research to evaluate and improve cancer screening. The modeling for this study was 
also supported by CISNET (NCI grant U01 CA152959). Dr. Jemal received financial 
support from the Intramural Research Department of the American Cancer Society.
results
incidence rates and avoidable new cancer cases
Under the assumption of approximately constant CRC screening levels in the United 
States between 2013 and 2030, the crude CRC incidence rate per 100,000 per year 
would increase from 137 in the first year of follow-up (2014) to 149 in 2030 (Figure 
3.1a), due to aging of the population. If screening uptake increased from 58% in 
2013 to 80% in 2018, the incidence rates (per 100,000) would decrease from 164 
in 2014 to 117 in 2030. Compared to a scenario of constant CRC screening levels, 
‘80% by 2018’ would initially increase CRC incidence rates by 20% in 2014 because 
of early detection of CRC in previously unscreened individuals, but subsequently 
decrease the incidence rates by 17% by 2020, and by 22% by 2030. With an increase 
of the estimated population ages 50-100 years from 108 million in 2014 to 133 million 
by 2030, the above effects on incidence and mortality rates would result in 43,000 
averted cases per year by 2030, and a total of 277,000 cases averted from 2013 
through 2030 (table 3.1).
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Figure 3.1a,b Crude colorectal cancer incidence (1a) and mortality rates (1b) in the United States 
population	of	age	50	and	older,	under	two	scenarios	of	screening	uptake.	In	the	first	scenario	re-
ported screening rates remained at a constant level of approximately 60% from 2013 through 2030; 
in the other scenario screening rates increased from 60% to 80% by 2018 and remained constant 
after that.
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Table 3.1 Difference in the number of CRC cases and deaths per year when achieving 80% CRC 
screening rates in the United States by 2018, compared to constant 60% CRC screening rates
Calendar year
2014 2018 2022 2026 2030
Difference in number of CRC cases (x1,000)
Per year 29 27 -30 -38 -43
Cumulative 29 141 28 -112 -277
Difference in number of CRC deaths (x1,000)
Per year -1 -7 -13 -18 -21
Cumulative -1 -17 -60 -123 -203
Abbreviations: CRC = colorectal cancer.
mortality rates and avoidable cancer deaths
There would be an immediate mortality benefit for 80% CRC screening by 2018. 
While under constant 60% screening levels the crude CRC mortality rate per 100,000 
would increase from 44 in 2014 to 48 in 2030, the mortality rate would decrease 
from 43 to 32 with 80% screening by 2018. Thus, the relative effect of ‘80% by 2018’ 
would be a 1% decrease in the CRC mortality rate by 2014, 19% in 2020, and 33% in 
2030 (Figure 3.1b). This would translate to 21,000 averted cancer deaths per year 
by 2030, and a total of 203,000 averted deaths from 2013 through 2030 (table 3.1).
Discussion
We used microsimulation modeling to estimate the potential United States public 
health impact of achieving the NCCRT goal to increase CRC screening rates from just 
under 60% in 2013 to 80% by 2018. Our results suggest that achieving this goal may 
produce a reduction of 22% in CRC incidence rates and 33% in CRC mortality rates 
by 2030, which translates to approximately 280,000 averted new cases and 200,000 
averted deaths from 2013 through 2030.
The 20% increase in screening uptake from 60% to 80% has a projected high 
impact on CRC mortality (33% reduction). This 33% matches well with our recent 
estimate that the majority (60%) of current CRC mortality is attributable to nonuse 
of screening.209 The increase in screening uptake from 60% to 80% decreases the 
number of underscreened people by half and consequently reduced overall CRC 
mortality by roughly half the ‘population attributable fraction’.
Within the underscreened population, the impact of ‘80% by 2018’ will be larger 
than the 20-30% overall reductions in incidence and mortality for the population, 
because the majority of avoidable cases and deaths occur within the 40% of the 
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population that is underscreened. Underscreened individuals tend to have lower 
educational levels and income and lack health insurance.89 Thus, a desirable effect 
of achieving ‘80% by 2018’ is the potential to reduce CRC health disparities in the 
United States – an important HealthyPeople 2020 objective.210
To our knowledge, no prior study estimated the public health benefits of ‘80% by 
2018’. Several studies have estimated the potential contribution of screening to de-
creases in CRC incidence and mortality in the United States.198,199,211,212 Our estimates 
of screening benefits appear to be somewhat smaller than those from Ladabaum and 
Song211 and larger than those from Edwards et al.198 and Yang et al.199 This is likely 
due to different study designs or periods, and differences in assumptions regarding 
the effectiveness of colonoscopy screening. For colonoscopy, the effectiveness of 
screening is less well-established than for other recommended screening tests due 
to the absence of evidence from randomized controlled trials. The effectiveness of 
endoscopy screening in the MISCAN model was recently increased based on the out-
comes of the UK flexible sigmoidoscopy study.117 This change explains the slightly 
higher impact of increasing screening uptake in this study compared with earlier 
studies.198,212 We evaluated a more conservative assumption for colonoscopy efficacy 
where colonoscopy sensitivity was decreased by 50%; this decreased the impact of 
‘80% by 2018’ on incidence, but did not substantively influence the mortality benefits 
(data not shown).
There are some limitations to this study. First, we evaluated only one of two 
possible ways to increase screening rates in the United States, namely by expanding 
screening to previously unscreened people. An alternative way is to reduce the 
number of people who have been screened but not according to screening recom-
mendations. In the latest NHIS from 2013, the proportion of the population which 
ever received a CRC test, but not within the recommended intervals, was 7.4%.200 
Thus, in a strategy of encouraging both higher guideline adherence in previously 
screened people and the participation of previously unscreened people, the former 
approach could contribute one third (7.4%) to the overall targeted increase of 22% 
in screening rates. This may lead to a somewhat lower public health impact of ‘80% 
by 2018’ than we found, because the impact of screening is lower in previously 
screened people compared to unscreened people.
Second, we assumed that the proportion of endoscopy versus fecal-based exams 
and its quality remained the same in the population when increasing screening 
uptake, while higher uptake of FIT or other stool-based tests may be needed to 
achieve the ideal of 80% screening.83,85 A higher proportion of stool-based tests than 
modeled may affect the projected benefits of increased screening uptake, although 
modeling analyses show that the potential benefit of 10-yearly colonoscopy and an-
nual FIT may be comparable.204 Colonoscopy quality is known to vary widely among 
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providers and is highly correlated with disease outcomes.124 If expanding screening, 
in part, was achieved through examiners with lower detection rates then the benefits 
may be less than projected.
Finally, there may be CRC disparities between screened and underscreened 
populations beyond those attributable to screening.213 If the background CRC risk in 
the underscreened population is higher and/or CRC survival poorer, the impact of 
reaching 80% screening by 2018 may be even larger.
The outcomes of this study were confined to CRC incidence and mortality in the 
population, and did not include years of life lost to CRC, costs and potential harms 
of screening. Previous analyses have indicated that CRC screening is likely highly 
cost-effective,214,215 and may even be cost-saving,28 making increasing screening not 
only desirable from a cancer-control perspective but also from a financial perspec-
tive. However, these analyses usually do not consider potential overuse of screening 
and surveillance,62 program costs,100 and especially, resources needed to bring in the 
people to reach 80% uptake of screening.
There are many barriers to increasing CRC screening uptake in the U.S., only some 
of which are the target of health care reforms under the Affordable Care Act .82,216 
Substantial coordinated effort is needed to achieve the goal of 80% CRC screening by 
2018 goal in the United States. The results of our study indicate that such investments 
may be well-rewarded with long term reductions in CRC incidence and mortality 
of 22% and 33%, respectively, and the avoidance of 280,000 new CRC cases and 
200,000 CRC deaths in less than two decades.
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aBstract
BACKGROUND: In 2014 a national campaign was launched to increase colorectal 
cancer (CRC) screening rates in the U.S. to 80% by 2018; it is unknown if there 
is sufficient colonoscopy capacity to reach this goal. We estimate the number of 
colonoscopies needed to screen 80% of the eligible population with fecal immuno-
chemical testing (FIT) or colonoscopy, and if there is sufficient colonoscopy capacity 
to meet the need.
METHODS: The Microsimulation Screening Analysis-colon (MISCAN-colon) model 
was used to simulate CRC screening test use in the U.S. (2014-2040), assuming the 
implementation of a national screening program in 2014 with FIT or colonoscopy 
with 80% participation. The 2012 Survey of Endoscopic Capacity (SECAP) estimated 
the number of colonoscopies that were performed and the number that could be 
performed.
RESULTS: If a national screening program started in 2014, by 2024, approximately 
47 million FITs and 5.1 million colonoscopies would be needed annually to screen 
the eligible population with a program using FIT as the primary screening test; 
approximately 11 to 13 million colonoscopies would be needed annually to screen 
the eligible population with a colonoscopy only screening program. Based on the 
SECAP survey, an estimated 15 million colonoscopies were performed in 2012 and 
an additional 10.5 million colonoscopies could be performed.
CONCLUSIONS: The estimated colonoscopy capacity is sufficient to screen 80% of 
the eligible U.S. population with FIT, colonoscopy, or a mix of tests. Future analyses 
should take into account the geographic distribution of colonoscopy capacity.
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introDuction
Although screening for colorectal cancer has been shown to effectively reduce the 
incidence of and mortality from the disease, only 58% of adults aged 50-75 years 
were up-to-date with CRC screening in 2013.217 A recent initiative from the National 
Colorectal Cancer Roundtable (NCCRT), a coalition of public, private, and voluntary 
organizations, aims to increase CRC screening prevalence to 80% in the eligible 
population by 2018. Recent analyses estimated that reaching this goal would avert 
280,000 new cases of and 200,000 deaths from CRC by 2030 and that 24.4 million 
people would need to be screened.218,219 No studies have estimated the number of 
CRC screening tests that would need to be performed each year if 80% prevalence is 
achieved, and whether current colonoscopy capacity would meet increased demand. 
Over the past decade, colonoscopy use has increased rapidly and has become the 
most commonly used test to screen for CRC, while relative use of fecal occult blood 
testing has declined.
We used microsimulation modeling to estimate the expected number of colonos-
copies to screen 80% of the eligible population with either fecal immunochemical 
tests (FIT) or colonoscopy over 10 years. We also conducted a national Survey of 
Endoscopic Capacity (SECAP) to estimate the number of colonoscopies performed 
in a year in the U.S., and the number of additional colonoscopies that could be per-
formed (capacity). Resources, or capacity, are defined as non-monetary resources, 
such as number of staff, facility space, equipment and time needed to perform 
colonoscopies, and does not include the actual cost of the procedures paid for by 
individuals or insurers.
metHoDs
estimation of screening test need
The MISCAN-colon model (chapter 2) was used to simulate CRC screening test 
use in the U.S. (from 2014 to 2040), assuming the implementation of a nationwide 
screening program in 2014. The main outcome of the model was the number of 
colonoscopies required per year to screen 80% of the population. Screening was 
implemented over 10 years using FIT or colonoscopy as the primary screening test.
simulated scenarios
Age-specific use rates of colonoscopy, flexible sigmoidoscopy, and fecal occult blood 
test (FOBT) until the start of a hypothetical national screening program in 2014 were 
based on National Health Interview Survey (NHIS) data from 1987 through 2010.217 
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Based on these data, it was estimated that in 2013, 67% of U.S. adults aged ≥50 years 
had ever been screened with any test, 8.8% had a home FOBT within the last year, 
4% had a sigmoidoscopy within the last 5 years, and 55% had a colonoscopy within 
the past 10 years. We assumed that there was no further increase in overall screening 
uptake in the period from the last NHIS to the start of the hypothetical screening 
program.
The model enrolled all U.S. adults aged 50 to 75 years into a national screening 
program over 10 years, starting with the first cohort in 2014, consisting of 1/10 of the 
age-eligible population. The model assumed that the remaining eligible population 
would continue to be screened at a projected estimate based on 2010 NHIS data 
until enrollment into the hypothetical national program. People were not invited 
for screening in the program until 1 year after their last FOBT, 5 years after their 
most recent sigmoidoscopy, or 10 years after their most recent colonoscopy. In 
the first scenario, we evaluated a program of annual FIT in which 80% of eligible 
adults participated; in the second scenario, we evaluated a program colonoscopy 
every 10 years with 80% participation. People with a positive FIT were referred for 
follow-up colonoscopy and people with an adenoma detected were followed with 
colonoscopy surveillance, with the interval (3 to 5 years) dependent on the number 
and size of adenomas detected on the most recent colonoscopy.139,220
sensitivity analysis
In a sensitivity analysis we evaluated various alternative modeling scenarios, to inform 
readers on implications of other possible screening tests and adherence rates. Al-
ternative modeling scenarios included: alternative primary screening tests, including 
annual guaiac fecal occult blood testing (gFOBT), 10-yearly computed tomographic 
colonography (CTC), and 5-yearly flexible sigmoidoscopy (FSIG); higher assumed 
participation rates (100%) for FIT and colonoscopy screening; and a scenario of 
currently observed test use patterns in NHIS (with both under- and over-use), with 
an assumed linear increase in overall screening participation rates from 58% in 2013 
to 80% by 2018. Test performance characteristics used in the primary and sensitivity 
analysis are provided in Supporting Information, supplementary table 4.1.
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estimation of endoscopic capacity
The Survey of Endoscopic Capacity II (SECAP II) was conducted in 2012. The survey 
methodology was unchanged from the original SECAP study; a detailed description 
of the survey methodology has been published previously.221 In brief, a list of all 
U.S. medical facilities known to have purchased or leased lower endoscopic equip-
ment between January 1, 2006 and December 31, 2010 was obtained from three 
major endoscopic equipment manufacturers: Olympus America, Inc., Fujinon, Inc., 
and Pentax Precision Instrument Corporation. The lists were merged and dupli-
cates removed to create a sampling frame. A random sample of 2100 facilities (31% 
of all facilities), stratified by region and location (urban or rural), was selected to 
participate in the survey. A telephone screening questionnaire was administered to 
confirm study eligibility and to identify the person in charge of endoscopy. Of the 
2100 facilities, 258 (12%) were found to be ineligible (did not currently perform 
screening sigmoidoscopy or colonoscopy on adults or could not be located). A self-
administered questionnaire, personalized cover letter, postage-paid return envelope, 
and $40.00 incentive were sent by Federal Express to a person identified by each 
eligible facility. Respondents were asked to provide an estimate of the total number 
of sigmoidoscopies and colonoscopies performed by all endoscopists at the practice 
site per week, the percentage of procedures performed by endoscopist specialty, 
and the additional number of sigmoidoscopies and colonoscopies that could be 
performed with no other investment of resources.
Of the 1842 eligible facilities, 1269 returned valid surveys (overall response rate 
68.9%). To provide national capacity estimates, the universe of facilities was adjusted 
based on the ineligibility rate, and survey data were weighted to adjust for the 
sampling weight and non-response. Annual estimates of capacity were obtained by 
multiplying the weighted weekly estimates of current and potential capacity by the 
number of workweeks per year (50 weeks). Survey data were analyzed with Stata 
12.1.
For the estimation of endoscopic capacity, two questions were critical to the analy-
sis: 1) the number of procedures currently performed and 2) the additional number 
of procedures that could be performed. If answers to both of these questions were 
missing, the survey was excluded from analysis. If the survey was missing data for 
one of the two key question, then these values were imputed using a variation of the 
hot-deck method, as described previously.221
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results
simulation results
Based on recent CRC screening patterns, an estimated 8.4 million FOBTs and 14 
million colonoscopies were performed in 2013. Of these, approximately 3.3 million 
colonoscopies were estimated to have been performed for diagnostic and surveil-
lance purposes (Figure 4.1a).
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Figure 4.1a Number of colorectal cancer tests per year before and after start of hypothetical national 
screening program with FIT* in 2014, by test type
Abbreviations: FOBT = fecal occult blood test; FIT = fecal immunochemical test.
Fit scenario
Assuming the introduction of a FIT screening program in 2014, a total of 3.3 million 
FITs would need to be performed to screen 80% of eligible adults aged 50 to 75 
invited to the first round of screening (1/10 of the eligible population). The total 
number of colonoscopies needed in 2014 would be 13.4 million: 3.5 million for 
diagnostic or surveillance purposes, and 9.9 million for screening performed outside 
the program (Figure 4.1b). By 2024, approximately 47 million FITs and 5.1 million 
diagnostic (32%) and surveillance (68%) colonoscopies would have to be performed. 
The number of FITs would gradually increase to approximately 60 million tests 
annually by 2030, but the number of colonoscopies would remain steady.
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colonoscopy scenario
The introduction of a colonoscopy screening program in 2014 would require 12.8 
million screening colonoscopies and 3.4 million diagnostic and surveillance colo-
noscopies (Figures 4.2a-b). By 2024, 11 to 13 million colonoscopies would have 
to be performed annually, with ~57% being performed for screening and~43% for 
surveillance, and remain level through 2030.
sensitivity analysis
Estimated colonoscopy requirements assuming 80% participation of all eligible adults 
were similar for annual FIT, annual gFOBT, and 5-yearly CTC testing (Figure 4.3). 
FSIG every 5 years would require 16.3 colonoscopies in 2014, and 18-19 million 
sigmoidoscopies and colonoscopies annually by 2030. Continuation of currently 
observed test use patterns with 80% participation would require 23 million colonos-
copies annually by 2030.
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Figure 4.1b Number of colonoscopies per year, before and after start of a hypothetical national 
screening program with FIT, by colonoscopy indication
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Figure 4.2a Number of colorectal cancer tests per year before and after start of a hypothetical na-
tional screening program with colonoscopy, by test type
Abbreviations: FOBT = fecal occult blood test.
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Figure 4.2b Number of colonoscopies per year, before and after start of a hypothetical national 
screening program with colonoscopy, by colonoscopy indication
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Figure 4.3 Predicted colonoscopy use under various modeling scenarios (in millions).
FIT = Fecal Immunochemical Test; COL = Colonoscopy; gFOBT = guaiac Fecal Occult Blood Test; 
FSIG = Flexible Sigmoidoscopy; Opport. = Opportunistic; part = participation.
a Annual testing with Hemoccult II.
b 10-yearly testing with CT colonography.
c	5-yearly	testing	with	flexible	sigmoidoscopy.	Numbers	represent	sigmoidoscopy	and	colonoscopy	
use.
d In the scenario with opportunistic screening, we assumed future screening patterns according to 
age and type of test were similar to those observed in 2013 National Health Interview survey data. 
The screen rate was increased linearly from approximately 60% to 80% from 2013 to late 2018.
The required colonoscopy capacity with either FIT or colonoscopy screening with 
100% participation was approximately one-third higher than the capacity needed for 
the base-case of 80% assumed participation. The 100% FIT scenario would require 
14.3 million colonoscopies in 2014, and would require 68 million FITs and 6.9 mil-
lion colonoscopies annually by 2030. The 100% colonoscopy scenario would require 
14.1 million colonoscopies in 2014 and 17 million colonoscopies annually by 2030.
survey
Of the 1269 facilities included in the final analysis, 767 (60.9%) were hospital depart-
ments, 403 (31.8%) were ambulatory endoscopy or surgery centers, 98 (7.7%) were 
physician practices and 1 was unknown (data not shown). The majority of survey 
respondents identified themselves as nurse administrators/managers (60.2%). The 
majority of sites were classified as urban (68.2%). After weighting, there were an 
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estimated 5988 (95% confidence intervals [CI] 5832 to 6144) facilities in the U.S. that 
performed any lower endoscopy in 2012. Of these, 5858 (97.8%) facilities reported 
performing colonoscopy and 1831 (30.6%) reported performing sigmoidoscopy.
Survey respondents estimated that 51.1 (95% CI 46.1 to 56.1) colonoscopies were 
performed per week (table 4.1). Respondents estimated that 43.2% of colonosco-
pies were performed for screening. The total mean potential maximum number of 
colonoscopies that could be performed per week was 87.
Table 4.1 Current	and	potential	number	of	colonoscopies,	Survey	of	Endoscopic	Capacity	II	-	2012
Total	(SE)	a
Number of facilities b 5858 (202.6)
Current weekly number (mean) 51.1 (2.5)
Percent performed for screening (in millions) 43.2 (0.6)
Potential Maximum weekly number (mean) 87.0 (5.4)
Current annualc volume (in millions) 15.0 (1.2)
Potential annualc volume (in millions) 25.5 (2.4)
Available annualc capacity (in millions) 10.5 (2.6)
a	SE	=	Standard	error
b	Facilities	included	hospitals,	ambulatory	surgery	centers,	and	physician	offices	where	colonosco-
pies were performed for the purpose of colorectal cancer screening of adults.
c Assuming 50 work weeks per year
Survey responses were weighted to determine national estimates for current and 
potential capacity to provide colonoscopies in the U.S. In 2012, approximately 15 
million total colonoscopies were performed (table 4.1). Respondents reported they 
could increase their colonoscopy volume to 25.5 million annually for an available 
capacity of 10.5 million colonoscopies annually.
Discussion
This report estimates the number of colonoscopies that would be needed to screen 
80% of the eligible population and compares this need to estimates of colonoscopy 
capacity. The MISCAN microsimulation model estimated that 13.4 million colonos-
copies would be needed in the first year of a population CRC screening program 
with FIT, gradually declining to 5.2 million colonoscopies with full implementation 
of the program after 10 years. A colonoscopy program implemented over 10 years 
would require 16.2 million colonoscopies in the first year, and 12 to 13 million 
colonoscopies annually with full implementation. According to the survey, in 2012, 
15 million colonoscopies were performed, of which respondents estimated that 
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42.3% (6.3 million) were performed for screening. Respondents indicated that an ad-
ditional 10.5 million colonoscopies could be performed per year, suggesting that the 
increased demand for screening colonoscopy could be absorbed. The FIT screening 
program would require no screening colonoscopies, and the demand for diagnostic 
and surveillance colonoscopies could presumably be met by shifting currently avail-
able resources. The colonoscopy screening program would require approximately 7 
million screening colonoscopies and 5 million surveillance colonoscopies annually. 
Assuming no change in available capacity, the increased demand for screening and 
surveillance colonoscopies is matched by currently available colonoscopy capacity 
as reported. Given that a colonoscopy screening program is, for a given participa-
tion level, the strategy with the highest colonoscopy demand, there would also be 
sufficient capacity to meet colonoscopy demand for most of the scenarios modeled 
in the sensitivity analysis (FIT only or colonoscopy only with 100% participation, and 
annual gFOBT, 5-yearly CTC or FSIG with 80% participation). If recently observed 
CRC test use patterns continued with 80% participation, estimated capacity could 
meet colonoscopy need within the estimated standard error (22-24 million needed 
annually vs. 23.1-27.9 estimated annual capacity).
The percentage of the adult population that is up-to-date with CRC screening 
has steadily increased over the past decade, primarily through increased use of 
colonoscopy.89,222,223 Our data do not show a concomitant increase in the number of 
colonoscopies performed annually. Although the SECAP survey is cross-sectional, 
and may not have captured a true rise and subsequent decline in the number of 
colonoscopies performed, at least one other study found that the use of screening 
colonoscopy increased prior to the recent economic recession, then subsequently 
declined.224 After rapid growth from 2000 to 2006, a decline in the number of colo-
noscopies performed per Medicare beneficiary has also been noted.225
The MISCAN microsimulation model estimated that approximately 13.7 million 
colonoscopies were performed in 2012 for screening and follow-up; analysis of the 
2012 Behavioral Risk Factor Surveillance System (BRFSS)226 and of the 2010 NHIS217 
estimated that 14.9 million people and 11.4 million people respectively had a colo-
noscopy within the past year. The 2012 SECAP estimate of 15 million colonoscopies 
performed closely matches these estimates. Of note, the number of adults aged 50 
years or older that reported sigmoidoscopy or colonoscopy within the previous year 
remained largely unchanged from the 2003 (11.3 million) to the 2010 (11.8 million) 
NHIS, despite a substantial increase in the proportion of adults in this age group that 
reported being up-to-date with CRC screening by colonoscopy within 10 years.217
In the base-case analysis, future test use for a national CRC screening program 
with either FIT or colonoscopy estimated that 5 to 16 million colonoscopies would 
be needed annually, assuming 80% of the eligible population would participate. 
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These model projections included only colonoscopies performed for screening, 
diagnostic, or surveillance purposes and assumed no under- or overuse of screen-
ing and therefore may have under-estimated actual test need in these scenarios. 
The 2012 SECAP survey estimated that 43.2% of colonoscopies were performed 
for screening purposes consistent with previous estimates of 38% to 49.7%.224,227 
Surveillance colonoscopies have accounted for up to one-quarter of colonoscopies 
performed, suggesting that a substantial proportion of colonoscopies performed are 
for reasons other than screening or surveillance (i.e., diagnostic).227,228 Several stud-
ies of the Medicare population have found over- and under-use of both screening 
and surveillance colonoscopies.62,63,229-233 In our sensitivity analysis, continuation of 
current CRC test use patterns, reflecting current patterns of under- and overuse, 
required substantially more colonoscopies than even the colonoscopy only scenario. 
The modeled colonoscopy need may also have been overestimated as we assumed 
80% adherence to screening and surveillance. Despite concerted efforts to increase 
CRC screening rates in the population, rates remain well below 80% due to a variety 
of patient, provider, and system level factors.222,234,235 Among those who are screened 
for CRC with FIT or other tests that require follow-up with colonoscopy, adherence 
to follow-up is well below 100%.236,237
Full implementation of a national CRC screening program with FIT would re-
quire approximately 5 million diagnostic and surveillance colonoscopies annually. 
While the number of colonoscopies required is practically achievable, a national 
FIT program would also require nearly 60 million FITs annually by 2040. FIT does 
not require many resources on the part of the patient (can be done at home, does 
not require bowel preparation or dietary changes), but a complete FIT screening 
program can require substantial additional resources to ensure that test kits are 
distributed to the eligible population, remind people to complete and return the kits, 
ensure complete follow-up for those with positive results, process all returned kits in 
the provider’s office or in the lab, and to ensure that all eligible adults repeat the test 
annually.238,239 It is unknown if adequate resources exist to implement a FIT screen-
ing program on such a large scale. Our model estimates that a national colonoscopy 
screening program would require substantially more colonoscopies annually than a 
FIT program. It is unknown if it is feasible to shift resources towards more screening 
and surveillance and if sufficient capacity would remain to perform colonoscopies 
needed for other reasons.
This study is subject to some other limitations. First, our model estimates of future 
test need for a national CRC screening program were based on recent population 
projections, currently available screening methods, and current screening guidelines 
which may not apply to the entire time horizon of the study. Second, we could not 
validate directly the number of colonoscopies that survey respondents indicated they 
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were performing or could perform. Respondents were asked to estimate the number 
of additional colonoscopies they could do without additional resources, but it is 
unknown if the estimate truly reflects what could be done without changes to cur-
rent practice or if it reflects shifting resources away from other procedures. Analysis 
of additional SECAP questions indicated that there were limiting factors to increasing 
capacity and, if needed, facilities would invest in additional resources (physicians, 
nurses, equipment, etc.) to increase capacity (Supporting Information, supplemen-
tary tables 4.2-3). As described earlier, our estimate of annual colonoscopy volume 
was consistent with estimates from other sources.217,226 Third, the survey sampling 
frame included facilities that purchased or leased equipment between 2006 and 
2010. This excludes facilities that use equipment purchased or leased outside of 
this time frame and may underestimate the number of colonoscopies currently per-
formed and available capacity. Fourth, the study was not designed to model market 
forces as it relates to the supply of colonoscopy in response to increasing demand 
(e.g., the market could respond by increasing the supply of endoscopists). Fifth, 
this study could not account for the geographic distribution of CRC screening need 
or of colonoscopy capacity. The survey was not designed to estimate colonoscopy 
capacity at the local level, and simulating future screening need at this level would 
require an impractical number of models (to account for population size and past 
screening behavior for each geographical unit).
CRC screening is conducted with a variety of tests, most commonly colonoscopy 
and less frequently with FOBT or FIT. While it is unlikely that all eligible adults 
will be screened with a single test type, this analysis shows that the estimated colo-
noscopy capacity would be sufficient to screen with a mix of tests. Future analyses 
should take into account the geographic distribution of colonoscopy capacity and 
screening need, to determine if there is a surplus of capacity in some areas of the 
country and insufficient capacity in others.
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APPENDIX 4 
Supplementary Table 4.1 Colorectal cancer screening test performance assumptions, Microsimu-
lation Screening Analysis-Colon (MISCAN-colon)
Performance characteristic Test
Optical Colono-
scopy
Flexible 
Sigmoido-scopy
CT 
Colonography
FIT (OC-Sensor, 
>20 ng/g cutoff)
FOBT 
(Hemoccult II)
Sensitivity per lesion
Adenomas	≤	5	mm 75% 75% 0.0% 0.0% 0.0%
Adenomas 6 - 9 mm 85% 85% 75.7% 4.4% 1.3%
Adenomas	≥	10	mm 95% 95% 85.9% 13.1% 6.5%
Early	stage	I-IV	cancer	a 95% 95% 95% 52% 18.2%
Late stage I-IV cancer a 95% 95% 95% 83.5% 50.8%
Specificity	b 100% 100% 91.4% 97.6% 98%
Completeness c 98% - - - -
FIT = Fecal Immunochemical Test; FOBT = Fecal Occult Blood Test.
a We assumed that fecal testing is more sensitive in preclinical cancers that are close time-wise to 
becoming symptomatic, i.e. towards the end of the occult invasive period. This assumption showed 
good concordance with guaiac fecal occult blood test trial results.
b The probability of a false positive result was random in the base-case analysis, and independent of 
person	or	lesion.	We	assumed	perfect	specificity	for	colonoscopy	and	sigmoidoscopy	with	pathologi-
cal follow-up examination.
c This is the proportion of colonoscopies visualizing the maximum point of reach of the endoscope, 
i.e.	the	cecum.	Sigmoidoscopy	was	assumed	to	reach	the	splenic	flexure	in	80%	of	examinations.
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Supplementary Table 4.2 Primary limiting factor to performing additional colonoscopies a, Survey 
of	Endoscopic	Capacity	II	–	2012.
Primary Limiting Factor Percentage of Facilitiesb	(SEc)
Insufficient	time	(few	open	appointments) 6.5% (0.6)
Insufficient	utilization	due	to	cancellations	(“no	shows”) 5.7% (0.6)
Insufficient	number	of	physicians	available	to	perform	procedures 34.0% (1.2)
Insufficient	nursing	staff	to	assist	with	procedures 8.9% (0.7)
Insufficient	ancillary	staff	to	help	with	room	turnover 0.6% (0.2)
Insufficient	staff	or	physicians	to	monitor	sedation	or	anesthesia 2.1% (0.4)
Insufficient	procedure	rooms 6.9% (0.7)
Insufficient	preparatory	and/or	recovery	areas 8.2% (0.7)
Insufficient	endoscopes	or	monitors 3.6% (0.5)
Insufficient	reimbursement 4.0% (0.5)
Other d 19.5% (1.0)
a	Respondents	were	asked	“What	are	the	limiting	factors	to	performing	more	colonoscopies	at	this	
practice	site?”,	then	were	asked	“What	is	the	primary	limiting	factor?”	Percentages	reflect	the	propor-
tion of respondents that chose the option as the primary limiting factor.
b	Facilities	included	hospitals,	ambulatory	surgery	centers,	and	physician	offices	where	colonosco-
pies were performed for the purpose of colorectal cancer screening of adults.
c	SE=Standard	error.
d Most commons responses to other were competition from other facilities and lack of patient refer-
rals.
Supplementary Table 4.3 Measures to address increased need for colonoscopy a,	Survey	of	Endo-
scopic	Capacity	–	2012
Measure Percentage of Facilitiesb	(SEc)
Increase proportion of work day allotted to procedures 59.3% (1.3)
Modify block scheduling 56.9% (1.3)
Use	patient	navigators	or	reminder	calls	to	decrease	“no	shows”	or	
cancellations
37.3% (1.2)
Increase physician staff 55.3% (1.3)
Increase/hire non-physician endoscopists to do procedures 5.4% (0.6)
Increase nursing staff to assist with procedures 68.1% (1.2)
Increase ancillary staff to help with room turnover 51.6% (1.3)
Increase staff or physicians to help monitor sedation/anesthesia 41.2% (1.3)
Establish	a	larger	screening	unit/more	procedure	rooms 36.5% (1.2)
Establish	additional	preparatory	and/or	recovery	areas 39.9% (1.3)
Purchase or lease more equipment 52.0% (1.3)
Other 4.5% (0.5)
Not applicable, not planning to perform more procedures 8.6% (0.7)
a	In	response	to	the	question	“If	the	demand	for	colonoscopies	were	to	exceed	this	practice	site’s	cur-
rent capacity to perform colonoscopies, what steps would this practice site take to meet that increased 
demand?”	Respondents	could	select	all	options	that	applied.
b	Facilities	included	hospitals,	ambulatory	surgery	centers,	and	physician	offices	where	colonoscopies	
were performed for the purpose of colorectal cancer screening of adults.
c	SE=Standard	error.
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aBstract
PURPOSE: Screening is a major contributor to colorectal cancer (CRC) mortality 
reductions in the U.S., but is underutilized. We estimated the fraction of CRC deaths 
attributable to nonuse of screening to demonstrate the potential benefits from tar-
geted interventions.
METHODS: The established MISCAN-colon microsimulation model was used to 
estimate the population attributable fraction (PAF) in people aged ≥50 years. The 
model incorporates long-term patterns and effects of screening by age and type 
of screening test. PAF for 2010 was estimated using currently available data on 
screening uptake; PAF was also projected assuming constant future screening rates 
to incorporate lagged effects from past increases in screening uptake. We also com-
puted PAF using Levin’s formula to gauge how this simpler approach differs from 
the model-based approach.
RESULTS: There were an estimated 51,500 CRC deaths in 2010, about 63% (N~32,200) 
of which were attributable to non-screening. The PAF decreases slightly to 58% 
in 2020. Levin’s approach yielded a considerably more conservative PAF of 46% 
(N~23,600) for 2010.
CONCLUSIONS – The majority of current U.S. CRC deaths are attributable to non-
screening. This underscores the potential benefits of increasing screening uptake 
in the population. Traditional methods of estimating PAF underestimated screening 
effects compared with model-based approaches.
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introDuction
Both the absolute number of cases as well as the incidence and disease-related 
mortality rates for colorectal cancer (CRC) have declined over the last three decades 
despite a high prevalence of risk factors, in contrast to trends observed in some 
other countries.45 Evidence indicates that the increasing use of CRC screening has 
been the major contributor to the declining incidence and mortality rates in the U.S. 
from this disease.198,199 However, screening remains underutilized, suggesting that 
a substantial proportion of current CRC deaths in the U.S. are avoidable. This has 
galvanized public action on increasing the uptake of screening;240 however, lack of 
clarity persists regarding the proportion of current CRC deaths occurring as a result 
of nonuse of screening, and thus the potential public health benefits from increasing 
screening uptake.
The population attributable fraction (PAF) proposed by Morton Levin in 1953 has 
been widely used to assess the proportion of a disease outcome that occurs as a 
result of exposure to a risk factor, and thus the potential benefits from public health 
interventions to eliminate that exposure.241 This concept, which is a function of the 
level of exposure to the risk factor and the size of the effect of exposure on the dis-
ease outcome, has been previously applied to assess the impact of underutilization 
of CRC screening on disease mortality.201 Using this approach, Stock and colleagues 
reported that about 28 – 44% of deaths from CRC in the U.S. in 2005 may be attribut-
able to nonuse of colonoscopy. However, this study used somewhat conservative 
estimates for the effect of colonoscopy screening that may not be applicable for the 
U.S.242-244 Also, the study did not consider specific features of CRC epidemiology 
that are important for valid estimation of PAF. First, apart from colonoscopy, flexible 
sigmoidoscopy or fecal occult blood tests are also used for screening in the U.S., and 
therefore need to be considered in estimating PAF. Second, CRC is a heterogeneous 
disease characterized by a long latency between risk factor exposure and outcome. 
Mortality benefits from screening are derived not only from cancer detection, but 
also from the detection and treatment of precursor or early more curable invasive 
lesions. Thus, valid estimates of PAF require the consideration of benefits of screen-
ing that are realized over long time periods after the test date. Finally, patterns of 
exposure to CRC screening have evolved since the 1980s. According to data from 
the National Health Interview Survey (NHIS), the proportion of the U.S. population 
recently exposed to CRC screening tests increased from about 39% in 2000 to 58% 
in 2010.89,222
In the present study, we used microsimulation modeling to estimate the PAF of 
U.S. CRC deaths from non-screening. We compared these PAFs with an estimate of 
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PAF using Levin’s formula to gauge how this simpler more accessible approach may 
differ from the microsimulation approach.
metHoDs
Population attributable fraction
The population attributable fraction (PAF) for CRC is defined as the proportion of 
CRC deaths in adults who are age 50 years or older that is due to non-receipt of 
screening as recommended by national guidelines. Analogous to the first definition 
discussed by Rockhill and colleagues, a short treatise on the most common defini-
tions used for PAF, this is expressed algebraically as:245
  (1)
where RT is the observed CRC mortality risk within the population per year, R0 is 
the risk in those screened (unexposed) per year, and RRT/0 is the ratio. We used the 
MISCAN-colon model (chapter 2) to generate the entries RT and R0 in definition (1). 
To compare the model approach and simple approach, the risk in the absence of 
screening, R1, was also assessed. Since the use of screening, disease incidence and 
mortality, and risk of death from competing causes change over a person’s lifetime, 
we derived PAF according to three age strata (age 50–64, 65–74, 75 and older). It 
was first derived for calendar year 2010 based on observed patterns of exposure to 
non-screening from national survey data up to 2010, and then extended to 2030, 
assuming a constant rate of exposure to screening after 2010 to explore the lagged 
effects from recent increases in screening uptake. See the supplementary appendix 
for more precise definitions of PAF according to stratum and calendar year.
This study was conducted within the National Cancer Institute’s (NCI) Cancer 
Research Network (CRN) and as part of the NCI-funded Population-Based Research 
Optimizing Screening through Personalized Regimens (PROSPR) consortium. The 
aim of PROSPR is to conduct multi-site, coordinated, trans-disciplinary research to 
evaluate and improve cancer screening processes.
miscan-colon microsimulation population
The MISCAN-colon microsimulation model was used to stochastically generate a 
virtual population similar to the U.S. population in terms of the life expectancy and 
the natural history and occurrence of CRC. This model was defined for the 1980 – 
2030 period, to cover both historical and possible future patterns of screening use 
and the corresponding CRC mortality effects. U.S. birth and all-cause mortality for 
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the model were based on U.S. Census Bureau population estimates from 2000205 and 
generational U.S. Berkeley Mortality tables,206 respectively.
exposure to non-screening
To derive PAF, we simulated two scenarios on the uptake of screening in the U.S. 
First, we closely replicated age- and test-specific screening patterns for the U.S. 
as observed in 8 waves of NHIS from 1987 – 2010 (Figure 5.1). The NHIS is a 
cross-sectional survey with a complex design on a nationally representative sample 
of the U.S. population.200 Questions regarding the use of CRC screening tests were 
asked during the following survey years: 1987, 1992, 1998, 2000, 2003, 2005, 2008, 
and 2010. The estimated overall screening rate in 2010 (ages 50-100 years) was 59%. 
We assumed screening rates levelled off at ~60% (i.e. a 40% non-screening rate) 
after 2010. Screening as measured in the NHIS is comprised of home-based fecal 
occult blood testing, and endoscopy (particularly flexible sigmoidoscopy, or optical 
colonoscopy).
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Figure 5.1 Colorectal cancer screening trends in National Health Interview Survey data and MIS-
CAN. a
Abbrevations:	NHIS	=	National	Health	 Interview	Survey;	FOBT	=	 fecal	occult	blood	 test;	Endo	=	
endoscopy.
a The red line plots the proportion of U.S. population which had a home FOBT in the previous year, 
the blue and green lines plot the proportions which had an endoscopy in the previous 5 or 10 years, 
respectively.
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In the second scenario to assess the mortality risk from CRC that persisted despite 
complete screening of the population, after 1980 everyone was assumed to be fully 
compliant with using a single test (screening colonoscopy) at ages 50, 60 and 70 in 
accordance with U.S. guideline recommendations.246
In the first scenario above patients screened with a positive fecal test or sigmoid-
oscopy were invited for a diagnostic colonoscopy. The assumed adherence rate was 
80%. In both of the above scenarios patients in whom precancerous adenomas were 
detected during colonoscopy were invited for surveillance colonoscopy at 3 – 5 
yearly intervals in accordance with U.S. guideline recommendations for polyp size, 
number and histology.139 The adherence rate for surveillance colonoscopy was 80% 
and 100%, respectively, for the two scenarios.
screening and treatment effects
The effects of screening follow from the test performance assumptions in table 5.1. 
We defined for each test the sensitivity and specificity for adenomas and adenocarci-
nomas, and in the case of endoscopic procedures, the extent of the colon evaluated 
by the exam. For detected incident adenomas, we assumed a 100% efficacy of treat-
ment; for detected cancers, stage-specific survival was based on SEER mortality data 
for people with CRC diagnosed between 2000 – 2003. A model including these test 
characteristics was previously validated to data from trials on the effectiveness of 
sigmoidoscopy247 and of fecal occult blood tests (chapter 2).157,188,189 The latter also 
included validation of the effect of colonoscopy after a positive test.
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Table 5.1 Test performance assumptions in MISCAN
Performance characteristic Colono-scopy a Sigmoido-scopy b FOBT c
Sensitivity:
Adenomas	≤	5	mm 0.75 0.75 -
Adenomas 6 - 9 mm 0.85 0.85 0.013
Adenomas	≥	10	mm 0.95 0.95 0.065
Stage I adenocarcinoma 0.95 0.95 0.182 / 0.508
Stage II adenocarcinoma 0.95 0.95 0.182 / 0.508
Stage III adenocarcinoma 0.95 0.95 0.182 / 0.508
Stage IV adenocarcinoma 0.95 0.95 0.182 / 0.508
Specificity: NA NA 0.02
Reach endoscope: Cecum Splenic Flexure NA
Completeness rate:d 0.98 0.8 NA
Abbreviations: FOBT = Fecal Occult Blood Testing; NA = Not Applicable
a Colonoscopy sensitivity for each adenoma, and completeness of colonoscopy were based on a sys-
tematic review of adenoma miss rates in tandem colonoscopy studies by Van Rijn and colleagues.163
b Sensitivity of sigmoidoscopy was also based on van Rijn and colleagues.163
c We assumed that fecal occult blood testing is more sensitive in preclinical cancers that are close 
time-wise to becoming symptomatic. This assumption showed good concordance with Fecal Occult 
Blood Test trial results.190
d This is the proportion of endoscopies visualizing the maximum point of reach of the endoscope.
absolute crc mortality risks
The CRC mortality risk was determined by the model assumptions for the risk of 
CRC, levels of screening uptake, and the effects of screening and treatment. The 
2010 (baseline) mortality rate over all ages was aligned with the SEER mortality 
database by scaling the CRC incidence rate in the model (Figure 5.2).248 Absolute 
mortality numbers for 2010 were derived by multiplying the mortality rates with 2010 
population estimates from the U.S. Census bureau.249
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Figure 5.2 U.S. age-standardizeda colorectal cancer (CRC) mortality rates by calendar year in Sur-
veillance	Epidemiology	and	End	Results	program	(SEER)	data	and	MISCAN
a Adjusted to the total 2000 U.S. standard population
Table 5.2a U.S. colorectal cancer deaths in 2010 attributable to nonuse of screening according to 
MISCAN
Variable Population subgroup by age
50-64 65-74 75-100 All
Total population (million) a 59.1 21.9 18.6 99.6
Estimated	number	of	CRC	deaths	without	screening	(MISCAN) 19,800 23,000 51,800 93,400
Actual number of CRC deaths in the population b 12,700 12,300 26,500 51,500
Estimated	number	of	CRC	deaths	with	full	uptake	of	screening	(MISCAN)	c 7100 4200 7300 19,300
CRC deaths prevented by current screening (deaths if theoretical no 
screening	–	actual	deaths)
7100 10,800 25,200 41,900
CRC	deaths	attributable	to	residual	non-screening	(actual	deaths	–	deaths	
if 100% screening)
5600 8000 19,200 32,200
Attributable fractions:
Fraction of CRC deaths attributable to non-screening if theoretical no 
screening, %
64% 82% 86% 79% d
Fraction of actual CRC deaths attributable to non-screening, % 44% 65% 72% 63%
Abbreviations: CRC = Colorectal cancer
a Population estimates were based on U.S. Census Bureau population estimates249. The overall 
population size in MISCAN was scaled to this number.
b	CRC	mortality	numbers	were	derived	by	multiplying	CRC	mortality	rates	from	2010	SEER	data	with	
the population estimates from the U.S. Census Bureau.248,249
c	This	was	defined	as	having	screening	colonoscopy	at	ages	50,	60	and	70	and	lifetime	surveillance	
follow-up of patients with adenomas detected in screening.
d Thus, the estimated overall relative risk for colonoscopy screening according to guideline recom-
mendations was 0.21.
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alternative approach to assess PaF
We also derived PAF using the formula as proposed by Morton Levin in 1953, to help 
gauge the difference of this simpler more accessible approach with the model-based 
estimate.241 Similar to the second definition in Rockhill and colleagues, this can be 
expressed algebraically as:245
   (2)
Here P1 is the population proportion exposed to nonuse of screening, and the RR1/0 
is the ratio of the CRC mortality risks or rates in the non-screened versus the ad-
equately screened population. This approximation is based on the assumption that 
the risk in the total population can be derived by linear interpolation of the risks in 
the non- and adequately screened groups (RT ~ P1R1 + (1 – P1) R0), which is valid only 
under stringent conditions such as no confounding.245 In this study, the parameters 
for equation (2) were derived from the same NHIS data used to inform the model 
on screening uptake in the U.S., and a large prospective cohort study for the effect 
of colonoscopy use.166 Since the formula allows for a single parameter on screening 
uptake, we used the most recent (2010) NHIS wave to estimate the proportion 
exposed to non-screening (supplementary table 5.1). As risk ratio we used the 
age-adjusted hazard rate for colonoscopy use of 0.32 (95% CI: [0.24, 0.45]) derived by 
Nishihara and colleagues.166 Again, more precise definitions according to age stratum 
and calendar year are provided in the supplementary appendix.
results
In 2010, the overall estimated number of CRC deaths in the U.S. was 51,500 (table 
5.2a). From this total, an estimated 12,700 occurred within the age stratum 50 – 64, 
12,300 occurred within the age stratum 65 – 74, and 26,500 occurred within age 
stratum 75 and older.
In an ideal scenario of 100% uptake of screening (i.e. 100% uptake of 10-yearly 
colonoscopy screening), the microsimulation model estimated the expected number 
of CRC deaths to be 19,300 (table 5.2a). This means that 32,200 CRC deaths out of 
the actual total of 51,500 in 2010 were attributable to nonuse of screening, which 
equates to a PAF of 63%. In analyses stratified according to age, the PAF was 44% for 
persons 50 – 64 years of age, but was 65% for those aged 65-74. On the assumption 
that screening rates remained at the 2010 level of ~60% into future years, the fraction 
of CRC deaths attributable to nonuse of screening decreased slightly over time to 
58% in 2020 (Figure 5.3).
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Figure 5.3 Projected CRC mortality fractions attributable to nonuse of screening a
a The mortality rates were not standardized for age; future estimates were based on a scenario of 
constant screen rates of ~60% after 2010
Levin’s formula approach to estimate PAF yielded more conservative estimates of 
the fraction of CRC deaths attributable to underuse of screening. With this formula, 
23,600 CRC deaths out of 51,500 in 2010 were attributable to underuse of CRC 
screening for a PAF of 46% (table 5.2b, Figure 5.4). For the 50-64 year-old age 
group, the PAF was 49%, whereas for those 65-74 years old, the PAF was 41%, which 
was substantially lower than the result of the microsimulation approach.
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Figure 5.4 Proportion of U.S. colorectal cancer deaths in 2010 attributable to nonuse of screening 
by two approaches
Table 5.2b. U.S. colorectal cancer deaths in 2010 attributable to nonuse of screening according to 
Levin’s formula
Variable Population subgroup by age
50-64 65-74 75-100 All
Total population (million) a 59.1 21.9 18.6 99.6
Estimated number of CRC deaths without screening (MISCAN) - - - -
Actual number of CRC deaths in the population b 12,700 12,300 26,500 51,500
Estimated	number	of	CRC	deaths	with	full	uptake	of	screening	(MISCAN)	c 6400 7300 14,100 27,900
CRC deaths prevented by current screening (deaths if theoretical no 
screening – actual deaths)
- - - -
CRC	deaths	attributable	to	residual	non-screening	(actual	deaths	–	deaths	
if 100% screening)
6200 5000 12,400 23,600
Attributable fractions:
Fraction of CRC deaths attributable to non-screening if theoretical no 
screening, %
68% 68% 68% 68%
Fraction of actual CRC deaths attributable to non-screening, % [Min,Max] d 49%
[36,59]
41%
[28,50]
47%
[34,57]
46%
[33,56]
Abbreviations: CRC = Colorectal cancer
a Population estimates were based on U.S. Census Bureau population estimates249. The overall 
population size in MISCAN was scaled to this number.
b	CRC	mortality	numbers	were	derived	by	multiplying	CRC	mortality	rates	from	2010	SEER	data	with	
the population estimates from the U.S. Census Bureau248,249. Likewise, numbers corresponding with 
the attributable fraction of CRC mortality were derived by multiplying the estimated PAF based on 
relative mortality rates with the observed number of deaths.
c Based on the age-adjusted hazard rate for colonoscopy use derived by Nishihara and colleagues 166
d	The	minimum	to	maximum	range	was	based	on	using	respectively	the	95%	upper	and	lower	confi-
dence	bound	for	the	efficacy	of	screening	reported	by	Nishihara	and	colleagues166.
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Discussion
In the present study we used a Microsimulation Screening Analysis (MISCAN) model 
to assess the fraction of colorectal cancer (CRC) deaths in the U.S. population among 
people aged 50 or older that is attributable to nonuse of screening as recommended 
by U.S. national guidelines. Of the estimated 51,500 CRC deaths in 2010 in the U.S., 
about 63% (N~32,200) were attributable to non-screening. Under a scenario in which 
the screening rates attained in 2010 remained unchanged until 2030, the future 
population attributable fraction (PAF) attributable to nonuse of screening decreased 
to about 58% by 2020 due to the long-term cancer-preventive effects of adenoma 
removal after recent increases in screening uptake. Compared with the model-based 
approach, the traditional approach using the formula proposed by Levin, which uti-
lizes static measures of screening and risk, resulted in a more conservative estimate 
of 46% (N~23,600) of CRC deaths in 2010 that were attributable to non-screening.
The PAF is an informative concept in providing public health policy makers with 
a ceiling for potential risk reductions achievable through interventions targeting the 
elimination of risk factors.245 In this study we found that considerable reductions 
in CRC mortality of up to 63% are possible if the screening uptake in the U.S. is 
maximized (100% uptake). Unfortunately, the likelihood of this outcome occurring in 
the foreseeable future seems small. Healthcare accessibility is still a serious problem 
for roughly one quarter of the U.S. population,70 and screening is underutilized par-
ticularly by populations with lower socioeconomic status, including the uninsured.82 
Even if recent health insurance reforms fulfill their promise of minimizing financial 
barriers to access for underserved populations,250 the question remains whether 
uptake will get beyond a level of 80%. Integrated health care delivery systems have 
been successful in achieving compliance rates of around 80%, such as in the Kaiser 
Permanente Northern and Southern California member populations,95 where all 
eligible adults not up-to-date with screening by endoscopic methods receive a fecal 
hemoglobin test over the mail (out-reach), and are reminded during primary care 
visits (in-reach).239 This 80% screening rate has also been declared a national goal 
for the U.S. by 2018;203 the observation that it has already been achieved in some 
large populations suggest this goal is, at the least, feasible. Assuming linearity in the 
effects of screening to screening uptake (the basic assumption behind the formula 
by Morton Levin241), our results indicate that a reduction of ~30% (half of the effect 
when attaining full compliance) in CRC mortality might be expected if the US suc-
ceeds in attaining the 80% screening rate.
The model-based approach resulted in a substantially higher PAF than the tra-
ditional approach using Levin’s formula. This stemmed from a number of factors. 
First, the model incorporated long-term patterns and effects of screening in the 
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population, while the simpler approach used a static measure for the proportion 
exposure to nonuse of screening. Thus the traditional approach, for example, could 
not incorporate in its calculation of CRC mortality for 2010, the benefits from cancer 
prevention from the removal of adenomas provided by screening exams received 
many years earlier. Given the steep increase of screening rates in recent years, this 
may have contributed to the underestimation of the 2010 PAF with this method. The 
model suggests that this underestimation may have accounted for about one-quarter 
to one-third of the difference between the approaches, given the narrower gap 
between the two approaches for 2020.
The remainder of the difference in PAF between model-based and simple approach 
was attributable to different assumptions for the efficacy of screening. First, while 
in MISCAN the risk ratio over all ages corresponding with the use of colonoscopy 
screening according to guidelines was approximately 0.21 (table 5.2a), a ratio of 
0.32 for colonoscopy use in general was used in the simple approach. This larger 
risk reduction for screening leveraged the model-based PAF. Assuming a lower risk 
ratio of 0.21 the simple approach would have generated a PAF closer to the model 
estimate. Further, while the model allowed for disparities in effects of screening 
according to age and current versus optimal screening practice, a uniform risk ratio 
was applied in the simple approach. Because the model settings induced stronger 
effects of screening in the older age strata, the PAF difference was most pronounced 
in higher ages. The simpler (non-model based) approach in this study did lead to 
an overall PAF similar to the 44% found for 2005 in the previous study by Stock and 
colleagues,201 who also utilized the simpler traditional approach to derive PAF.
We used NHIS data to inform this study on the current and past exposure to screen-
ing in the U.S., which is subject to potential biases. First, NHIS is a cross-sectional 
survey with repeated measurements over time. With changes in the items used on 
the survey to reflect changes in screening patterns and potential interference from 
re-sampling, estimates cannot be directly compared across survey years. Further, 
NHIS relies on self-reported measures of screening use, which may have caused an 
overestimation of the true screen rates, particularly in some demographic groups.251 
Nevertheless, the survey provides one of the best estimates of the use of screening 
in the U.S.
The outcomes of the model strongly depend on the test performance assumptions 
for colonoscopy. There are currently no trial data available to validate the effective-
ness of colonoscopy in our model.86 Thus, we used adenoma miss rates from tandem 
colonoscopy studies to determine its efficacy,163,252 and validated these estimates 
indirectly to outcomes of FOBT trials including colonoscopy follow-up of positive 
FOBT,157,188,189,253,254 and the UK flexible sigmoidoscopy trial.247 In our study screening 
alone was considered a sufficient explanation for the decrease in CRC mortality 
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between 1980 and 2000 and beyond (Figure 5.2). This may have overestimated the 
effects of screening; a previous microsimulation analysis suggested that treatment 
and risk factor developments also contributed to the decrease.198 In a sensitivity 
analysis with a 50% reduced sensitivity for adenomas of ≤5 mm in diameter, the PAF 
for 2010 was lower than our base case estimate, but remained 52%. Under these 
assumptions, the age-adjusted relative risk for CRC mortality corresponding with 
colonoscopy screening was similar to the hazard ratio of 0.32 recently reported for a 
prospective cohort study with 22 years of follow-up.166
A limitation of using the PAF as a proxy for the potential returns of public health 
interventions is that it requires estimates of screening rates, an unproven constant 
estimate of the true magnitude of the benefit from screening and an approximation 
of the absolute disease risk in the population, all of which may change over time. 
Our estimates were based on currently available knowledge for each of these factors, 
but may not be applicable in future years, if more interventions to increase screening 
rates are implemented. We used PAF over other estimations such as the prevented 
fraction,255,256 because the PAF metric can be used to provide policymakers estimates 
of potential future benefits of increased screening beyond current benefits of past 
exposure.
To conclude, a model-based approach estimated that more than half of the current 
CRC mortality risk in the U.S. is attributable to nonuse of screening. This underscores 
the need to increase screening uptake in the U.S. population. A model-based ap-
proach provided a higher estimate of screening benefit than the traditional, simpler 
approach to assess PAF. Valid estimation of the effects of screening requires the 
consideration of variable screening patterns over time, which may require more 
complex models than traditionally used to assess PAF.
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Supplementary Table 5.1 2010 National Health Interview Survey use and nonuse rates of colorec-
tal cancer screening
Variable Age strata (years)
50-64 65-74 75+
% Up-to-date (1-P1;s) a 54.3% 67.9% 58.8%
% Not up-to-date (P1;s) 45.7% 32.1% 41.2%
a The % of US adults age 50 years or older which had a colonoscopy in the last 10 years, a sigmoid-
oscopy in the last 5 years or a home fecal occult blood test in the last year.
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Definition of PaF
We used the following symbols/acronyms:
s,t,i indicators for stratum, calendar year and screening test
PAF population attributable fraction
pds,t the proportion of all risk events (deaths) occurring in stratum s and calendar 
year t
P1;s,t proportion exposed to nonuse of screening, by stratum and calendar year
RT;s,t outcome risk in the total population, by ,,
R0;s,t outcome risk in the absence of exposure, by ,,
R1;s,t outcome risk in the presence of exposure, by ,,
RRx/y risk ratio of situation x over y
PAF was defined by stratum and calendar year as:
    (1)
Aggregate PAF per calendar year was obtained by weighing with the proportion of 
deaths occurring in each stratum:
 
  (2)
Levin’s approach approximated (1) using the following formula:
    (3)
RR1/0;s,t is the inverse of the risk (/rate) ratio corresponding with exposure to screening:
 
  (4)
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aBstract
IMPORTANCE: Colonoscopy and fecal testing are recommended for colorectal cancer 
screening partly supported by modeling analyses with assumed 100% patient adher-
ence. Differences in actual patient adherence may affect the long-term effectiveness 
of each test.
OBJECTIVE: Comparing the effectiveness of a program of ten-yearly colonoscopy 
versus annual sensitive guaiac-based fecal occult blood testing (FOBT) with ob-
served longitudinal patient adherence.
DESIGN: Microsimulation model informed by observed National Colonoscopy Study 
data.
SETTING: Simulated randomized clinical trial from the United States
PARTICIPANTS: 3523 average-risk patients aged 40-69 years
EXPOSURES: We simulated a screening strategy of ten-yearly colonoscopy versus 
annual FOBT. Assumed adherence, FOBT positivity, and diagnostic colonoscopy 
adherence in FOBT-positive patients were based on observed National Colonoscopy 
Study data (≥4 FOBT rounds). For reference, we also simulated hypothetical sce-
narios of no screening and 100% screening adherence.
MAIN OUTCOMES: Estimated 15-year colorectal cancer incidence and mortality per 
1000 patients with 95% probability intervals (95%PI) from multivariate probabilistic 
sensitivity analysis.
RESULTS: With no screening, the simulated incidence and mortality risks were 20.9 
[95%PI, 15.8-26.9] and 6.9 [95%PI, 5.0-9.2] per 1000 patients, respectively. In the 
hypothetical case of 100% adherence, only colonoscopy was estimated to result in 
lower incidence (13.1 [95%PI, 9.7-17.0] for colonoscopy versus 20.9 [95%PI, 16.1-
29.2] for FOBT), however, both tests lowered estimated mortality to a similar level 
(2.1 [95%PI, 1.6-2.9] versus 2.5 [95%PI, 1.9-3.5], respectively). Observed National 
Colonoscopy Study adherence levels were higher for colonoscopy (86%) than FOBT 
(80% completing at least one test), resulting in a larger loss in effectiveness for FOBT 
compared to screening with 100% adherence. Colonoscopy with observed patient 
adherence decreased estimated incidence to 14.2 [95%PI, 10.6-18.3] and mortality to 
2.8 [95%PI, 2.1-3.8], while annual FOBT with observed patient adherence did not 
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influence estimated incidence [20.8, 95%PI, 15.9-27.7] and reduced mortality to 3.9 
[95%PI, 3.0-5.5].
CONCLUSION: If patient adherence is as observed in NCS rather than assumed for 
current guideline recommendations, modeling suggests that colonoscopy may result 
in substantially greater reductions in colorectal cancer mortality than a program of 
annual FOBT.
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introDuction
While over the past decades several independent randomized controlled trials have 
demonstrated that both invasive and fecal tests can be effective for colorectal cancer 
screening,117,119,120,154-156,162,188 most currently recommended tests have not been directly 
evaluated in any trial.86,122,257 Observational data suggest that screening colonoscopy 
exposure may have long-term preventive effects of 50-90%,107 however, few com-
parable data exist on the effects of sensitive FOBT or fecal immunochemical testing 
(FIT).105,258 United States Preventive Services Task Force screening recommendations 
to use colonoscopy or fecal testing for screening were partly informed by microsimu-
lation modeling analyses with assumed 100% patient adherence for all tests.259 Actual 
patient adherence rates for colonoscopy and fecal testing methods may differ and 
influence the long-term effectiveness of each test.260 While fecal testing may have 
higher initial acceptance rates,83-86 patients’ willingness to comply with annual fecal 
colorectal cancer testing methods over longer periods of time is uncertain.90-92,261
In this study, we estimated the long-term colorectal cancer incidence and mortality 
effects for colonoscopy versus a program of annual FOBT using microsimulation 
modeling with adherence and outcome data from NCS.
metHoDs
national colonoscopy study
NCS is a screening feasibility trial of colonoscopy versus a program of annual sensi-
tive FOBT conducted in three clinical centers from geographically and demographi-
cally diverse areas in the United States. Participating centers include Group Health 
Cooperative (GHC) in Puget Sound, Washington, the University of Minnesota (MIN), 
Minneapolis, in Minnesota, and the Louisiana State University (LSU) in Shreveport, 
Louisiana. Participants for the study were recruited from current health plan mem-
bers (GHC), health program participants (LSU, or mailing list members (UMN).
Participants for the study were recruited from current health plan members (GHC), 
health program participants (LSU), or mailing list members of the participating study 
centers between October 2004 and June 2008. Patients were aged 40-69 years at LSU, 
and 50-69 years in the two other centers. Earlier age for screening was instituted 
at LSU to allow for a pilot study in African Americans and whites of ages 40-49 
years. Excluded were patients with a personal history of colorectal cancer, familial 
adenomatous polyposis, Lynch syndrome, or inflammatory bowel disease, as well as 
patients who had a prior colonoscopy or a flexible sigmoidoscopy within the last 5 
years, or patients with serious comorbidities or an implanted defibrillator.
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NCS recruited patients via a 2-step process. First, patients received an introduc-
tory letter with information about colorectal cancer, study intent and eligibility, and 
voluntary consent. Patients were also informed that participation in screening was 
free of charges. Next, those eligible and willing to participate were randomized to 
once-only screening colonoscopy, or a program of annual FOBT (see CONSORT 
flow chart). Randomization was conducted in a 1:1 fashion, with permuted blocks 
of varying sizes (2-6) for each study center developed by MSK. Those assigned to 
screening colonoscopy were contacted for scheduling by the clinical center; those 
assigned to annual FOBT were given the FOBT (Hemoccult SENSA) slides with 
instructions. Screening colonoscopy was offered no longer than one year. FOBT was 
offered up to 7 times. Patient navigators served both study arms comparably.
NCS data were collected by the individual study centers, but stored and analyzed 
centrally at MSK in New York. Outcomes used to inform this study include colo-
noscopy and FOBT adherence, FOBT positivity, diagnostic colonoscopy adherence, 
adenoma detection rates, advanced neoplastic lesions (adenomas ≥10mm in diam-
eter, adenomas with high-grade dysplasia, or cancer), and cancers. Test adherence 
was defined as test completion within 1 year from each offering. FOBT positivity was 
assessed by two experienced laboratory technicians from the MSK Clinical Chem-
istry Laboratory. Colonoscopies were performed by board-certified endoscopists, 
and findings were histologically confirmed by an experienced pathologist at Boston 
University who was blinded to the exam indication and study arm.
Follow-up ended on the first of several events: cancer incidence, death, study 
close date (October 31, 2011), or other loss to follow-up. A full protocol of the study 
is enclosed as a supplementary file.
microsimulation model
This study used the MISCAN-colon model (chapter 2). In MISCAN-colon, the mod-
eled effects of screening follow from a test’s assumed ability to detect lesions within its 
reach or scope (supplementary table 6.1).163,262 The simulated effects are concordant 
with randomized controlled trial data for screening with guaiac fecal occult blood 
tests190 and sigmoidoscopy.117 Estimated incidence and mortality effects of colonoscopy 
screening are consistent with the reported range in observational studies.107
analysis
We simulated the NCS study population in terms of the age and sex distribution 
at enrolment. For patients in the colonoscopy arm, we simulated screening with an 
adherence rate equal to the observed overall colonoscopy completion rate in NCS. 
Colonoscopy was repeated after 10 years with similar assumed adherence. For patients 
in the FOBT arm, we simulated screening with long-term cumulative test adherence, 
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diagnostic colonoscopy adherence following a positive FOBT result, and potential 
crossover to screening colonoscopy derived from observed NCS data for up to 7 
annual screening rounds. As the main determinant of FOBT positivity, assumed test 
specificity was varied to replicate observed positivity. Patients with detected adenomas 
received surveillance according to guidelines with assumed 80% adherence.207
For model validation purposes, simulated adenoma detection and cancer diagnosis 
during the study period were compared to the observed data. We then compared simu-
lated long-term colorectal cancer outcomes between both study arms. For FOBT, we 
estimated outcomes both including and excluding colonoscopy crossover. For reference, 
we also estimated cancer incidence and mortality in hypothetical scenario of no and 
100% adherence, to compare simulated screening benefits in the case of actual observed 
adherence to the maximum theoretical benefits in case of 100% adherence. Primary 
outcomes were simulated 15-year risks of colorectal cancer incidence and mortality.
Multivariate probabilistic analysis was conducted to derive 95% confidence intervals 
for all base-case model outcomes. We varied 16 key parameters along uniform, beta, 
or lognormal distributions in 1000 simulation runs of 10 million persons (supplemen-
tary table 6.1).263
sensitivity analysis
In sensitivity analyses, we re-assessed outcome differences for colonoscopy and FOBT 
successively excluding patients who did not complete the first offered test and assuming 
100% adherence with follow-up colonoscopy of positive FOBTs; separately evaluating 
outcomes for each participating study center; for once-only colonoscopy screening; 
assuming 50% lower colonoscopy sensitivity for diminutive adenomas (in accordance 
with previous estimates);263 assuming lower FOBT specificity;259 applying estimated FIT 
performance characteristics for FOBT;259 and, excluding patients aged 40-49 years.
study oversight
The institutional review board of each study center participating in NCS approved 
the study, and ascertained informed consent for included patients. The study was 
coordinated by MSK. MISCAN-colon was developed and employed for this study at 
the Erasmus MC Department of Public Health, Rotterdam, Netherlands. This study is 
funded by the United States National Cancer institute.
results
A total of 3523 patients were enrolled in NCS, of whom 1761 were assigned to screening 
colonoscopy and 1762 were assigned to annual FOBT screening (Figure 6.1). Patients 
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in both study arms were comparable in terms of age (mean 55, SD 5.5), gender (50% 
versus 48% male), and race/ethnicity (81% Caucasian) (supplementary table 6.2).
Randomized (n=3523) 
Allocated to COL(n=1761) Allocated to FOBT (n=1762)
Screening 1
Received COL (n=1761)
Completed COL (n=1516)
Declined COL (n=245)
Screening 1
Received FOBT (n=1762)
Completed FOBT (n=1290)
Declined FOBT (n=472)
Analyzed (n=1761) Analyzed (n=1762)
Discontinued FOBT (n=263)
Follow-up COL (n=50)
Other COL (n=182)
Other (n=31)Screening 2
Received FOBT (n=1499)
Completed FOBT (n=983)
Declined FOBT (n=516)
Discontinued FOBT (n=188)
Follow-up COL (n=25)
Other COL (n=141)
Other (n=22)Screening 3
Received FOBT (n=1311)
Completed FOBT (n=834)
Declined FOBT (n=477)
Discontinued FOBT (n=127)
Follow-up COL (n=21)
Other COL (n=83)
Other (n=23)Screening 4
Received FOBT (n=1134)
Completed FOBT (n=706)
Declined FOBT (n=478)
Screening 5
Received FOBT (n=832)
Completed FOBT (n=452)
Declined FOBT (n=380)
Screening 6
Received FOBT (n=405)
Completed FOBT (n=228)
Declined FOBT (n=177)
Screening 7
Received FOBT (n=140)
Completed FOBT (n=76)
Declined FOBT (n=64)
Discontinued FOBT (n=352)
Follow-up COL (n=11)
Other colonoscopy (n=73)
Other, censoring (n=268)
Discontinued FOBT (n=427)
Follow-up COL (n=10)
Other COL (n=27)
Other, censoring (n=390)
Discontinued FOBT (n=265)
Follow-up COL (n=7)
Other COL (n=7)
Other, censoring (n=251)
Figure 6.1. National	Colonoscopy	Study	flow	diagram	(CONSORT)
Of the 1761 patients randomly assigned to colonoscopy screening, 1516 (86%) 
completed the examination (Figure 6.1, supplementary table 6.3). Of the 1762 
patients assigned to FOBT screening, 1290 (73%) completed the first test; 1184 pa-
tients were offered ≥4 FOBT, and of these 948 (80%) patients completed at least 
one test, 840 (71%) completed at least two, and 585 (50%) completed all four tests; 
a subset of 140 early study participants were offered 7 tests, and of these 119 (85%) 
completed at least one test, and 61 (46%) completed all 7 tests. Positive tests varied 
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from 51 (4.0% of completed FOBTs) in round 1, to 11 (2.0%) in round 4, to 3 (4.0%) 
in round 7. Of all 139 patients with a positive test throughout the study, 127 (91%) 
completed a diagnostic colonoscopy. A total of 513 (29%) patients in the FOBT arm 
received colonoscopies for reasons other than a positive FOBT result.
model calibration and validation
The MISCAN-colon model replicated observed colonoscopy adherence and cumula-
tive FOBT adherence, as well as observed FOBT positivity for 7 rounds (Figure 6.2). 
Simulated short-term adenoma findings were higher than observed NCS findings 
(FOBT non-significantly). Simulated advanced adenoma detection rates and cancer 
diagnosis rates were within or on 95% probability bounds around the observed 
(supplementary table 6.4).
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Figure 6.2a-b. Observed (solid) versus simulated (dashed lines) FOBT adherence (a) and positivity 
(b) a
a Analysis here excludes patients who crossed over to colonoscopy. Round 6-7 data represent one 
study center.
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cancer incidence and mortality
Without any screening, the model estimated that the 15-year colorectal cancer inci-
dence risk for the NCS study population was 20.9 [95%PI, 15.8-26.9] per 1000. The 
estimated cancer mortality risk without screening was 6.9 [95%PI, 5.0-9.2] per 1000.
Colonoscopy screening with observed NCS adherence rates was estimated to de-
crease colorectal cancer risk to 14.2 [95%PI, 10.6-18.3] per 1000 (-32% compared to 
no screening), and mortality risk to 2.8 [95%PI, 2.1-3.8] per 1000 (-59%) (Figure 6.3a). 
FOBT screening with observed NCS adherence rates without crossover colonoscopy 
was estimated in the model to result in similar cancer risk of 20.8 [95%PI, 15.8-28.1] per 
1000 (-1% compared to no screening), however, it decreased estimated cancer mortality 
to 3.9 [95%PI, 2.9-5.4] per 1000 (-43%) (Figure 6.3b). Including crossover colonoscopy, 
screening in the FOBT arm reduced simulated incidence and mortality to 19.2 [95%PI, 
14.1-23.4] per 1000 (-8%) and mortality 3.5 [95%PI, 2.6-4.5] per 1000 (-49%), respec-
tively. The estimated relative risk of colorectal cancer mortality in those screened with 
colonoscopy versus those screened with FOBT was 0.72 [95%PI, 0.65-0.77].
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Figure 6.3a-b. Simulated colorectal cancer incidence and mortality in two screening strategies
Abbreviations: COL = colonoscopy.
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loss in effectiveness from incomplete adherence
With 100% assumed patient adherence, colonoscopy screening was estimated to re-
sult in 15-year incidence and mortality risks of 13.1 [95%PI, 9.7-17.0] per 1000 (-38% 
compared to no screening) and 2.1 [95%PI, 1.6-2.9] per 1000 (-69%), respectively, 
while FOBT screening resulted in risks of 20.9 [95%PI, 15.8-29.4] per 1000 (-0%) and 
2.5 [95%PI, 1.8-3.4] per 1000 (-64%). Compared to screening with full patient adher-
ence, the actual use of colonoscopy screening was associated with a relative loss 
of 14% in screening effectiveness to reduce 15-year cancer mortality risks (Figure 
6.4a). FOBT without crossover colonoscopy was associated with a relative loss of 
33% (22%, including colonoscopy crossover) (Figure 6.4b).
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Figure 6.4a-b. Loss	in	estimated	screening	benefit	with	actual	versus	100%	patient	adherence	a
Abbreviations: COL = colonoscopy.
a The comparative test is FOBT in Figure 6.4a and colonoscopy in Figure 6.4b.
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sensitivity analysis results
Estimated relative mortality benefits compared to no screening increased to 69% for 
colonoscopy versus 56% for FOBT when including only attenders for colonoscopy 
and initial FOBT (absolute risks 2.1 versus 3.0 per 1000) (table 6.1). Estimated 
mortality benefits varied less across participating study centers (supplementary 
table 6.5), with once-only colonoscopy screening, for higher ages, or with alterna-
tive diagnostic test performance assumptions.
Table 6.1. Simulated colorectal cancer mortality risks across sensitivity analyses
Analysis
Screening modality
None Colonoscopy FOBT
Risk % Diff Risk % Diff
1. Base-case 6.9 2.8 -59% 3.9 -43%
2. First round attenders only a 2.1 -69% 3.0 -56%
3. By center
a. GHC 2.9 -58% 4.0 -42%
b. LSU 3.1 -54% 4.3 -38%
c. MINN 2.6 -62% 3.4 -50%
4. Once-only colonoscopy 3.0 -56% 3.9 -43%
5. Lower COL sensitivity b 3.1 -54% 4.1 -40%
6.	Lower	FOBT	specificity	c 2.8 -59% 3.7 -47%
7. FIT characteristics d 2.8 -59% 3.5 -48%
8.	Age	≥50y 7.4 3.0 -59% 4.1 -45%
Abbreviations: GHC = Group Health Cooperative; LSU = Louisiana State University; MINN = Univer-
sity of Minnesota; FIT = fecal immunochemical test.
a	Only	patients	who	completed	the	first	offered	test	were	included	in	the	analysis.	Assumed	diagnos-
tic colonoscopy adherence was 100%.
b Assumed colonoscopy sensitivity for small adenomas up to 5 mm in diameter was 50% lower than 
the base-case.
c	Assumed	FOBT	specificity	is	similar	to	US	Preventive	Services	Task	Force	analysis.259
d Assuming similar test use over time, we applied FIT characteristics instead of FOBT performance 
characteristics.259
Discussion
We used NCS adherence and outcome data with microsimulation modeling to esti-
mate the long-term colorectal cancer effects for colonoscopy versus a program of 
annual sensitive FOBT. The observed proportion of patients completing screening 
colonoscopy was 86% versus only 50% for FOBT who completed all tests after 4 
rounds and 80% who completed ≥1. Although these adherence levels were associ-
ated in the model with substantial estimated mortality reductions for both tests, the 
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disparity in adherence translated in a greater mortality reduction for colonoscopy 
compared to FOBT, and a smaller loss in mortality benefit compared to screening 
with 100% patient adherence of 14% for colonoscopy versus 33% for FOBT.
In the NCS, there was frequent colonoscopy use in the FOBT arm. Of the patients 
assigned to annual FOBT, 29% received a colonoscopy outside the study. Indica-
tions for the exams were unknown, but likely, most of them were opportunistic 
screening exams. Considering opportunistic colonoscopy use in the FOBT arm, the 
overall proportion of patients who completed any screening test was approximately 
similar to that in the colonoscopy arm. When we included colonoscopy crossover in 
our analyses, the estimated outcomes differences between colonoscopy and FOBT 
screening were smaller (50% vs 59% mortality reduction).
The estimated effectiveness differences between colonoscopy and FOBT were 
robust for a number of factors evaluated in sensitivity analyses. First, we adjusted the 
result comparison for disparities in nonuse of screening. In colonoscopy screening, 
14% of all patients had not completed the exam, while in annual FOBT, of the 
patients offered at least 4 tests, approximately 20% had not completed any of the 
offered tests. Adherence with diagnostic follow-up in case of positive FOBT results 
was also less than 100%. In a comparison of patients who completed colonoscopy 
versus those who completed at least one FOBT and potential diagnostic colonos-
copy, the effectiveness differences were not influenced substantively (table 6.2). 
This suggests that persistent high FOBT adherence is required to observe more 
similar benefits for FOBT and colonoscopy.
Further, despite differences in adherence and estimated outcomes across partici-
pating study centers, colonoscopy resulted in substantially greater estimated mortal-
ity reductions for all centers (supplementary table 6.5). Once-only colonoscopy 
screening had nearly similar estimated outcomes as colonoscopy screening every 10 
years over a 15 year risk period. Results were also robust for alternative test perfor-
mance assumptions. Previous studies have suggested that our base-case assumptions 
for colonoscopy sensitivity for small adenomas may be overly optimistic,263 poten-
tially overstating the effects of colonoscopy screening. Similarly, assumed FOBT 
specificity was higher in this study than in previous studies to accommodate for the 
relatively low observed positivity rate in the trial,259 which may have underestimated 
the use of colonoscopy and chance findings in FOBT screening, and therefore the 
overall benefits of FOBT. Further, many settings use FIT instead of FOBT, which may 
have more favorable performance characteristics.262 However, we found only mod-
est effects on relative mortality reductions for each of the assumptions (maximum 
5% point). Finally, exclusion of patients under 50 years of age (n=370), for whom 
regular screening generally is not recommended in the United States,264 also did not 
affect the study conclusions.
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Compared to previous randomized clinical trials investigating comparative test 
adherence, observed colonoscopy adherence in NCS was relatively high. Most stud-
ies directly comparing colonoscopy and FOBT or FIT in a single round reported 
higher adherence rates for stool-based tests.83-86 The participation rates in our study 
reflect those of patients providing consent to participate in screening with either 
colonoscopy or FOBT. Further, colonoscopy costs were completely covered within 
the context of this study, which may have given patients an incentive to get a colo-
noscopy within the study setting. This suggests that our results for the comparison 
of colonoscopy versus FOBT are applicable primarily to patients who are willing to 
undergo colonoscopy screening. Although this may represent a limited subgroup of 
the total population for some settings, in the United States, screening colonoscopy 
is widely used for screening.89
In contrast to colonoscopy adherence rates, FOBT participation rates in our study 
were similar to observed adherence rates for previous low-sensitivity guaiac fecal 
occult blood testing trials.188,265 Interestingly, they were also comparable to cumula-
tive FIT adherence rates from recent population-based studies (for ≤4 rounds) with 
systems in place to track and remind non-adherent patients.90-92,261 Many national pro-
grams are known to have much lower population adherence rates.5 The consistency 
with observational studies suggests that our results for FOBT may be generalizable to 
other settings with patient tracking and reminding. In settings without such services, 
outcomes of screening in general may be less favorable.
A recently published comparative modeling analysis for the U.S. Preventive Ser-
vices Task Force (USPSTF) found more similar effects for colonoscopy and FOBT.259 
Our analysis differs from that study in two important ways. First, the analysis for 
the USPSTF assumed 100% patient adherence for both tests. In general, modeling 
studies assume either full, or a fixed lower level of patient adherence with screening. 
111,123,211,266 To our knowledge, the present study is the first to closely replicate long-
term observed test adherence patterns for FOBT in order to assess the associated 
benefits. As we showed, the observed adherence disparity for colonoscopy and 
FOBT had profound implications for the screening benefits.
Another difference with the analyses used to inform the USPSTF is our use of 
longitudinal FOBT positivity data to derive test performance assumptions. The ob-
served test positivity rate in the initial round was 4%, which is substantially lower 
than the 7.6% assumed false positivity rate elsewhere.259 Positivity rates decreased 
further after the first round to approximately 2.5%, similar to a another report.267 The 
decline in test positivity could not be explained entirely in the model by higher first 
round prevalence of cancer and adenoma cases, and thus, we assumed that the rate 
of false positivity decreased over time similar to another recent study.268 This reduced 
the number of colonoscopy examinations for asymptomatic blood loss. Although the 
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sensitivity analysis indicated that this has only modest health outcome effects, it may 
influence the efficiency of the test.
Similar to the recent USPSTF analysis,259 we modeled the effects of colonoscopy 
and sensitive FOBT screening by combining observational data on their diagnostic 
performance,163 with randomized controlled trial data on flexible sigmoidoscopy,117 
and low-sensitivity guaiac-based FOBT screening.154,156,188 Our simulated short-term 
advanced adenoma and cancer detection rates were consistent with observed NCS 
data (supplementary table 6.4). We overestimated overall adenoma detection 
rates for both colonoscopy and FOBT (cancer detection rates non-significantly). 
This may suggest that the NCS study population had lower-than-average risk, as 
observed before for the Minnesota Colorectal Cancer Control Study.156 In contrast 
to the Minnesota study, we found no preventive effect for annual guaiac FOBT 
screening, despite a higher sensitivity of Hemoccult Sensa for adenomas compared 
to the Hemoccult II test. We assumed in our study that patients received no screening 
prior to participating in the study, which increased detection of cancer cases in initial 
screening years (i.e. prevalence screening rounds). With longer simulated follow-up 
(lifetime), we did find a substantial incidence reduction in line with Minnesota trial 
results (results not shown).259
NCS is the first study to assess FOBT adherence and outcomes during more than 
4 subsequent rounds. The model was able to accurately replicate data for up to 5 
rounds. A limitation of the study is that there was a relatively high rate of loss to 
follow-up for rounds 5-7. Observed data for round 6 and 7 represent a single study 
center out of three total participating study centers, and may be less representative 
therefore of the general population. To minimize the potential bias from loss to 
follow-up, our microsimulation model gave the most weight to earlier years in fitting 
and projecting FOBT adherence and positivity (Figure 6.2).
To conclude, with observed patient adherence data from NCS rather than as-
sumptions used in current guideline recommendations, colonoscopy results in a 
substantially greater reduction in colorectal cancer incidence and mortality than a 
program of annual FOBT. These results imply that if patients are willing to undergo 
colonoscopy, this may result in superior outcomes to annual FOBT due to likely 
suboptimal long-term adherence for the latter test. In offering stool-based tests to 
average-risk patients age 50 and older, guidelines need to emphasize the importance 
and effect of high patient adherence.
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Supplementary Table 6.1. Key modeling assumptions
Base-case value PSA value Refs
Demography
All-cause mortality U.S. lifetables 176
Natural History g
Adenoma onset Nonhomogeneous Poisson process 181,182,185
Exponential(λµ)	time	to	event
λ~Gamma(1;2)	risk	dispersion	factor Unif(-20%+20%)
µ=260-18	for	age	25-80y Unif(-10%+10%)
Adenoma progression 117
State transitions 0-89% progressive for age 0-100y Unif(-10%+10%)
30% size 6-9mm progress to cancer
70%	size	6-9mm	first	become	10+mm
State durations, y (total) Exponential(λ=130) λ~Unif(-10%+10%)
Preclinical cancer 
progression
157,188,189
Stage transitions a 0-31% stI become clinical for age 0-100y Unif(-10%+10%)
18-58% stII become clinical for age 0-100y Unif(-10%+10%)
58-49% stIII become clinical for age 0-100y Unif(-10%+10%)
Stage durations, y 
(average)
Exponential(2.5) Unif(-10%+10%)
Colorectal cancer 
incidence (without 
exposure to screening)
See Figure 2.3-4 SEER	1975-79	
175
5y Colorectal cancer 
survival b
58-71% stI, depending on location SEER	2000-10	
175
58-62% stII, depending on location
33% stIII
6% stage IV
Colonoscopy performance
Sensitivity, % b
adenomas 0-5mm 75 Beta;SE:3.5
adenomas 6-9mm 85 Beta;SE:3.5 163
adenomas	≥10mm 95 Beta;SE:2.5 163
malignant neoplasia Beta;SE:2.5
Specificity,	%	c 100 Beta;SE:5 269,270
Complete colonoscopy 
examination, % d
95 Beta;SE:2.5
Complication rates, %
with polypectomy Age-dependent (50-100 years): 271,272
Serious GI complications 0.2-2.9 LogN;SE:10%
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Supplementary Table 6.1. Key modeling assumptions
Base-case value PSA value Refs
Fatal complications 0.0033 LogN;SE:50%
Other GI complications 0.2-2.6 LogN;SE:10%
CV complications 0.1-2.5 LogN;SE:10%
without polypectomy e -
FOBT performance 259
Sensitivity, %
adenomas 0-5mm 0
adenomas 6-9mm 4.3 Beta;SE:2.5
adenomas	≥10mm 14.7 Beta;SE:3.5
malignant neoplasia f 56.8 / 85.9 Beta;SE:3.5
Specificity,	%	c 97.1 Beta;SE:3.5
Abbreviations: PSA= probabilistic sensitivity analysis; CDC = U.S. Centers for Disease Control and 
Prevention;	Poisson	=	Poisson	distribution;	Unif	=	uniform	distribution;	Exp	=	exponential	distribu-
tion;	SEER	=	Surveillance	Epidemiology	and	End	Results	program;	Beta	=	beta	distribution;	SE	=	
standard error; GI = gastrointestinal; LogN = lognormal distribution.
a In multiway probabilistic sensitivity analyses the model parameters were varied randomly accord-
ing to Uniform, Beta or Lognormal distributions. To limit the degrees of freedom, several parameters 
were assumed to be perfectly correlated: adenoma onset related parameters, adenoma progression-
related variables, cancer progression-related variables, sensitivity for small adenomas with sensitiv-
ity for medium adenomas, sensitivity for large adenomas with sensitivity for cancer, all complication 
types. b	Sensitivity	was	defined	as	the	probability	of	detecting	an	adenoma	that	was	present	at	the	
time of exam. Based on baseline-detection rates in our data, sensitivity for colorectal cancers was 
assumed to be unrelated to ADR.
c The occurrence of false positive FOBT results was assumed non-random for some patients. We 
assumed	perfect	specificity	for	colonoscopy	including	pathological	examination	of	detected	lesions.
d Colonoscopy was considered complete if the cecum was reached. In the 2% incomplete examina-
tions, the endpoint was assumed to be distributed uniformly over the colon/rectum.
e Colonoscopy without polypectomy was not associated with a higher risk of complications. The 
risk of complications for polypectomy increased exponentially with age. Complications include seri-
ous GI events such perforation and gastrointestinal bleeding requiring blood transfusions; other GI 
events such as paralytic ileus, nausea, vomiting and dehydration, abdominal pain; and cardiovas-
cular events such as myocardial infarction or angina, arrhythmias, congestive heart failure, cardiac 
or respiratory arrest, or syncope, hypotension, or shock. The fatal perforation rate was derived from 
estimates of the incidence of perforation and case-fatality for perforation.271 272
f We assumed that fecal occult blood testing is more sensitive in cancers towards the end of the oc-
cult invasive period (close, time-wise, to becoming symptomatic): for preclinical cancers which will 
become symptomatic within the same stage, assumed test sensitivity was higher. This assumption 
showed good concordance with guaiac fecal occult blood test trial results.190
g More details regarding the calibrated natural history parameters and other model elements are 
provided in Chapter 2.
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Supplementary Table 6.2. Baseline patient characteristics
Colonoscopy FOBT Total
Total patients, n 1761 1762 3523
Demographics
Average age, y (SD) 55 (5.50) 55 (5.5) 55(5.54)
Men, n (%) 845 (48%) 881 (50%) 1726 (49%)
White, n (%) 1426 (81%) 1428 (81%) 2854 (81%)
College graduate, n (%) 704 (40%) 634 (36%) 1304 (37%)
Risk factors
Obese, (Body Mass Index > 30) n (%) 511 (29%) 581 (33%) 1092 (28%)
Regular multivitamin use, n (%) 881 (50%) 793 (45%) 1674 (48%)
Aspirin use, n (%) 546 (31%) 511 (29%) 1057 (30%)
Hormone use (Women), n (%) 652 (37%) 652 (37%) 1304 (37%)
Current Smoker, n (%) 211 (12%) 211 (12%) 422 (12%)
Family history (First Degree Relatives with CRC), n (%) 158 (9%) 142 (8%) 300 (8%)
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Supplementary Table 6.3. National Colonoscopy Study adherence and outcomes
Outcome
Colonoscopy FOBT
Round 
1
Round 
2
Round 
3
Round 
4
Round 
5
Round 
6
Round 
7
Number invited / mailed 1761 1762 1499 1311 1184 832 405 140
Adherence (marginal) 1516
(86%)
1290 
(73%)
983 
(66%)
834
(64%)
706
(60%)
452
(54%)
228
(56%)
76
(54%)
Adherence (cumulative) a n.a. 1290 
(73%)
914
(61%)
716
(55%)
585
(50%)
362
(45%)
180
(46%)
61
(46%)
Cross-over (marginal) b n.a. 182
(10%)
141
(9%)
83
(6%)
73
(6%)
27
(3%)
7
(2%)
-
Cross-over (cumulative) c n.a. 182
(10%)
323
(18)
406
(23%)
479
(27%)
506
(29%)
513
(29%)
513
(29%)
Positive tests n.a. 51
(4%)
28
(2.8%)
23
(2.8%)
14
(2.0%)
11
(2.4%)
9
(4.0%)
3
(4.0)
Adherence to Dx COL n.a. 50
(98%)
25
(89%)
21
(91%)
11
(79%)
10
(90%)
7
(78%)
3
(100%)
DR NAA d 344
(20%)
189
(11%)
DR AA d 83
(5%)
73
(4%)
Cancers d 3
(0.2%)
6
(0.5%)
Dx COL = Diagnostic colonoscopy after a positive FOBT; DR = detection rate; NAA = non-advanced 
adenoma; AA = advanced adenoma.
a Proportion of patients having returning all mailed FOBT from to the total number invited up to that 
round.
b Proportion of patients assigned to FOBT who had a screening colonoscopy outside the study with-
out having a preceding positive FOBT result.
c Cumulative proportion of patients crossing over relative to the total number of enrolled patients.
d	Only	screen-detected	findings	included,	for	FOBT	across	all	rounds.
Supplementary Table 6.4. Simulated versus observed adenoma detection and cancer diagnosis in 
the National Colonoscopy Study a
Finding
Colonoscopy FOBT
Observed Simulated Observed Simulated
Mean 95% CI Mean 95% CI
Adenomas, % 19.5 17.7-21.4 23.3 3.8 2.9-4.7 4.8
Advanced adenomas, % 4.7 3.7-5.7 4.6 2.3 1.6-3 2.6
Cancer, % 0.2 0-0.4 0.4 0.5 0.2-0.8 0.8
a	This	comparison	reflects	screen-detected	findings.
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Supplementary Table 6.5. Adherence by National Colonoscopy Study center
Study 
center
Colonoscopy FOBT
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 Round 7
GHC 198/233 
(85%)
180/235 
(77%)
151/214 
(71%)
146/200 
(73%)
136/180 
(75%)
52/83 
(63%)
34/52 
(65%)
8/15 
(53%)
LSU 399/504 
(79%)
310/503 
(62%)
229/438 
(52%)
196/410 
(48%)
154/381 
(40%)
117/295 
(40%)
54/116 
(47%)
11/27 
(41%)
UMN 919/1024 
(90%)
800/1024 
(78%)
603/847 
(71%)
492/701 
(70%)
416/623 
(67%)
283/454 
(62%)
140/237 
(59%)
57/98 
(58%)
Total 1516/1761 
(86%)
1290/1762 
(73%)
983/1499 
(66%)
834/1311 
(64%)
706/1184 
(60%)
452/832 
(54%)
228/405 
(56%)
76/140 
(54%)
Abbreviations: GHC = Group Health Cooperative; LSU = Louisiana State University; UMN = Univer-
sity of Minnesota
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aBstract
IMPORTANCE: Colonoscopy is the most commonly used colorectal cancer screening 
test in the United States. Its quality, as measured by adenoma detection rates, varies 
widely between physicians with unknown consequences for the cost and benefits of 
screening programs.
OBJECTIVE: To estimate the lifetime benefits, complications and costs of a colonos-
copy screening program at different levels of adenoma detection.
DESIGN, SETTING and PARTICIPANTS: This study used microsimulation modeling 
with data from a community-based healthcare system on adenoma detection rate 
variation and cancer risk among 136 physicians and 57,588 patients for 1998-2010.
EXPOSURE: Using modeling, no screening was compared to screening initiation 
with colonoscopy according to adenoma detection rate quintiles (averages 15.3, 
21.3, 25.6, 30.9, and 38.7%) at ages 50, 60 and 70 with appropriate surveillance of 
adenoma patients.
MAIN OUTCOMES: Estimated lifetime colorectal cancer incidence, mortality, number 
of colonoscopies, complications and costs per 1,000 patients, all discounted at 3% 
per year and including 95% confidence intervals from multiway probabilistic sensitiv-
ity analysis (95%CI).
RESULTS: In simulation modeling, among unscreened patients, the lifetime risks 
of colorectal cancer incidence and mortality were 34.2 (95%CI:25.9-43.6) and 13.4 
(95%CI:10.0-17.6) per 1,000, respectively. Among screened patients, simulated 
lifetime incidence decreased with lower to higher adenoma detection rates (quin-
tile 1 versus 5: 26.6, 95%CI:20.0-34.3 versus 12.5, 95%CI:9.3-16.5) as did mortality 
(5.7, 95%CI:4.2-7.7 versus 2.3, 95%CI:1.7-3.1). Compared to quintile 1, simulated 
lifetime incidence and mortality were on average 11.4% (95%CI:10.3-11.9) and 12.8% 
(95%CI:11.1-13.7) lower, respectively, for every 5 percentage-point higher adenoma 
detection rate. Total colonoscopies and associated complications were higher from 
quintile 1 (2,777, 95%CI:2,626-2,943 and 6.0, 95%CI:4.0-8.5) to subsequent quintiles 
(quintile 5: 3,376, 95%CI:3,081-3,681 and 8.9, 95%CI:6.1-12.0). Estimated net screen-
ing costs were, however, lower from quintile 1 (US $2.1 million, 95%CI:1.8-2.4) to 
quintile 5 (US$1.8 million, 95%CI:1.3-2.3) due to averted cancer treatment costs. 
Results were stable across sensitivity analyses.
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CONCLUSIONS-RELEVANCE: Using microsimulation modeling, we found that higher 
adenoma detection was associated with lower lifetime colorectal cancer incidence 
and mortality without higher overall costs. Future research is needed to assess if 
increasing adenoma detection would be associated with improved patient outcomes.
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introDuction
Screening colonoscopy reduces colorectal cancer mortality risk through detection 
and treatment of precursor adenomatous or early cancerous lesions,165-167 but its 
effectiveness depends upon exam quality.163,273,274 A currently recommended colo-
noscopy quality indicator, the adenoma detection rate (ADR), has been found to vary 
at least 3-fold across physicians.124,128,275 A recent large United States study found that 
this variation is associated with patient outcomes: compared to patients of physicians 
with the highest ADRs, patients of physicians with the lowest ADRs had a nearly 50% 
higher risk of colorectal cancer and a 60% higher risk of fatal disease during up to 10 
years of follow-up after colonoscopy.124 This suggests that higher adenoma detection 
is associated with both better disease detection and disease management. However, 
little is known about the consequences of different levels of ADR for the lifetime 
benefits, risks and cost in a program using colonoscopy as the initial and primary 
screening test in an average-risk population. Higher ADRs may accrue mostly from 
increased detection of small low-risk polyps, resulting in an increased number of 
subsequent surveillance colonoscopies and complications for polyps that may never 
cause fatal disease. Thus, any benefits of higher ADR may be outweighed by the 
corresponding harms.141
In the present study, we evaluated various outcomes for a colonoscopy-based 
colorectal cancer screening strategy according to different adenoma detection rate 
levels, including lifetime colorectal cancer incidence and mortality, the number of 
colonoscopies and related complications, and screening and treatment costs.
metHoDs
We used microsimulation modeling of screening in a United States population 
cohort with community-based data on ADR variation and cancer risk. This study 
was approved by the Kaiser Permanente Northern California (KPNC) institutional 
review board, and conducted as part of the United States National Cancer Institute 
(NCI)-funded consortium Population-Based Research Optimizing Screening through 
Personalized Regimens (PROSPR), which aims to conduct multi-site, coordinated, 
trans-disciplinary research to evaluate and improve cancer screening.
KPnc data
Physician-level (ADR) and patient-level (age, sex, race/ethnicity, cancer diagnosis) 
data were from KPNC, an integrated healthcare delivery system.124 The data for this 
study were confined to screening colonoscopies performed by 136 gastroenterolo-
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gists between January 1, 1998 and December 31, 2010. Outcomes were ascertained 
in the 6-month to 10-year period after initial colonoscopy through December 31, 
2010. The screening indication excluded patients who had prior: adenomas or 
colorectal cancer; inflammatory bowel disease within 10 years; colonoscopy within 
10 years, sigmoidoscopy within 5 years; positive fecal hemoglobin test within 1 year; 
or abdominal symptoms within 6 months. ADRs, the proportion of a physician’s 
screening colonoscopies that detect ≥1 histologically confirmed adenomas, ranged 
from 7.3% to 52.5%; the averages (and ranges) for ADR quintiles 1 through 5 were 
15.32% (7.35-19.05%), 21.27% (19.06-23.85%), 25.61% (23.86-28.40%), 30.89% (28.41-
33.50%) and 38.66% (33.51-52.51%), respectively.
natural history of colorectal cancer
The MISCAN-colon model assumes that colorectal cancer develops progressively 
from small (≤5mm) through medium (6-9 mm) or large adenomas (≥10mm) (chap-
ter 2). An early stage tumor may progress to an advanced-stage tumor without 
symptoms, or become symptomatic during any stage and be clinically diagnosed. 
Some patients die of the disease and lose life-years, while others die from compet-
ing causes before or after developing cancer. Serrated adenomas are not modeled 
distinct from conventional adenomas.56
Performance characteristics of colonoscopy
The modeled effectiveness of colonoscopy screening depends on assumptions re-
garding its completeness and sensitivity for adenomatous lesions (table 7.1). For 
this study, we used observed data from KPNC to derive sensitivities for colonoscopy 
at the five ADR quintiles, while assuming no underlying differences in adenoma 
prevalence.276
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Table 7.1 Key modeling assumptions.
Input parameter Base-case assumption PSA assumptiona References
Demography
All-cause mortality U.S. Lifetables CDC 2010h
Natural history
Adenoma onset Age-dependent (non-
homogeneous Poisson)
Unif(-20%+20%) h
Adenoma progression
State transitions Age-dependent Unif(-10%+10%) h
State duration, years (total) Exp(λ=130) λ~Unif(-10%+10%) h
Cancer progression (preclinical)
Stage transitions Age-dependent Unif(-10%+10%) h
Stage durations, years Exp	(λ=2.5) λ~Unif(-10%+10%) h
Colorectal cancer incidence (without 
exposure to screening)
Age-/Stage-/Location-dependent SEER	1975-79h
Colorectal cancer survival Age-/Stage-/Location-dependent SEER	2000-10h
Colonoscopy quality
Sensitivity, % b ADR quintile-dependent:
adenomas 0-5mm 14.7-29.6-41.0-66.2-98 Beta;SE:3.5 h
adenomas 6-9mm 39.6-65.8-85.0-94.3-98 Beta;SE:3.5 h,163
adenomas	≥10mm 88.0-92.2-95.0-96.8-98 Beta;SE:2.5 h,163
malignant neoplasia 98 Beta;SE:2.5 h
Specificity,	%	c 85 Beta;SE:5 269,270
Complete colonoscopy examination, 
% d
98 Beta;SE:2.5 286,287
Complication rates, %
with polypectomy Age-dependent (50-100 years): 271,272
Serious GI complications 0.2-2.9 LogN;SE:10%
Fatal complications 0.0033 LogN;SE:50%
Other GI complications 0.2-2.6 LogN;SE:10%
Cardiovascular complications 0.1-2.5 LogN;SE:10%
without polypectomy e -
Costs, US $ f
Colonoscopy CMS 2007152
without polypectomy 899 LogN;SE:5%
with polypectomy 1,140-1,270 for ADR q1-5 LogN;SE:5%
Complication 6,129 CMS 2007277
Per life-year with cancer care g Stage-dependent (I-IV): CMS 2007278
Initial year, stage I-IV 37,185-78,876 LogN;SE:1.1-1.9%
Ongoing, stage I-IV 3,092-12,350 LogN;SE:4.4-5.7%
Terminal year, stage I-IV 64,693-89,600 LogN;SE:1.2-2.2%
Terminal year, stage I-IV 19,427-50,552 LogN;SE:8.4-10%
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In a separate analysis, patient populations in each ADR quintile were simulated 
using the age distribution at screening (appendix 7). We derived 5 different sets 
of parameters for per-lesion sensitivity by polyp size to reproduce the average ADR 
for each quintile. These were constrained by assuming: (1) sensitivity for cancer was 
98% across all quintiles; (2) sensitivity for medium to large adenomas varied less 
than for small adenomas, and increased according to a fixed rule from the lowest 
← Table 7.1 Legend Key modeling assumptions.
Abbreviations: PSA= probabilistic sensitivity analysis; CDC = U.S. Centers for Disease Control and 
Prevention;	Poisson	=	Poisson	distribution;	Unif	=	uniform	distribution;	Exp	=	exponential	distribution;	
SEER	=	Surveillance	Epidemiology	and	End	Results	program;	ADR	=	adenoma	detection	rate;	Beta	
=	beta	distribution;	SE	=	standard	error;	GI	=	gastrointestinal;	LogN	=	lognormal	distribution;	CMS	=	
Centers for Medicare and Medicaid Services.
a In multiway probabilistic sensitivity analyses the model parameters were varied randomly accord-
ing to Uniform, Beta or Lognormal distributions. To limit the degrees of freedom, several parameters 
were assumed to be perfectly correlated: sensitivity for small adenomas with sensitivity for medium 
adenomas, sensitivity for large adenomas with sensitivity for cancer, all complication types, costs of 
colonoscopy with and without polypectomy, and all treatment costs. Other parameters were varied 
independently.
b	Sensitivity	was	defined	as	the	probability	of	detecting	an	adenoma	that	was	present	at	the	time	of	
exam. Based on baseline-detection rates in our data, sensitivity for colorectal cancers was assumed 
to be unrelated to ADR.
c	The	lack	of	specificity	indicates	how	many	of	the	exams	that	did	not	detect	adenomatous	lesions	
included polypectomy for non-adenomatous lesions.
d Colonoscopy was considered complete if the cecum was reached. In the 2% incomplete examina-
tions, the endpoint was assumed to be distributed uniformly over the colon/rectum.
e We assumed that colonoscopy without polypectomy was not associated with a higher risk of compli-
cations. The risk of complications for polypectomy was assumed to increase exponentially with age. 
Serious GI events included perforation and gastrointestinal bleeding requiring blood transfusions; 
other GI events included paralytic ileus, nausea, vomiting and dehydration, abdominal pain; and 
cardiovascular events included myocardial infarction or angina, arrhythmias, congestive heart fail-
ure, cardiac or respiratory arrest, or syncope, hypotension, or shock. The fatal perforation rate was 
derived from estimates of the incidence of perforation and case-fatality for perforation.271 272
f Screen- and treatment costs include patient time costs (opportunity costs of spending time on 
screening or being treated for a complication or colorectal cancer), but do not include travel costs, 
costs of lost productivity, and unrelated health care and non-health care costs in added years of life. 
Patient time was valued at the median US wage in May 2013 ($16.87 per hour), and we assumed 
that colonoscopies involve 8 hours of patient time. Patient time costs were already included in the 
estimates for the costs of life-years with cancer care obtained from a study by Yabroff et al.278
g Care for colorectal cancer was divided in three clinically relevant phases: the initial, continuing, and 
terminal	care	phase.	The	initial	care	phase	was	defined	as	the	first	12	months	after	diagnosis;	the	
terminal	care	phase	was	defined	as	the	final	12	months	of	life;	the	continuing	care	phase	was	defined	
as all months in between. In the terminal care phase, we distinguished between cancer patients dy-
ing from the disease and cancer patients dying from another cause. For patients surviving less than 
24	months,	the	final	12	months	were	allocated	to	the	terminal	care	phase	and	the	remaining	months	
were allocated to the initial care phase.
h More details regarding the calibrated natural history parameters and other model elements are 
provided in Chapter 2.
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to the highest quintile (fixed detection likelihood (sensitivity/[1-sensitivity]) ratios 
for adjacent quintiles) while matching estimates for average practice in the middle 
quintile (85% for medium adenomas, 95% for large adenomas)163; (3) maximum 
sensitivity for adenomas was 98%. Sensitivity for adenomas was then varied to match 
ADR values with 0.1 point precision. The estimates were independent of adenoma 
location. KPNC data on cancer diagnoses after colonoscopy were compared to the 
cancer incidence predicted by the model.
complication risk of colonoscopy
Adverse events for colonoscopy including polypectomy used age-specific complica-
tion rates derived from published literature (table 7.1).271,272
costs of screening and treatment
Approximate societal costs of colonoscopy, complications and colorectal cancer 
treatment utilized 2007 Medicare payment rates and co-payments (table 7.1) [er-
ratum: treatment cost data represent the period 1998-2003].152,277,278 All costs included 
patient time valued at median US wage in 2013, updated to December 2013 based on 
general Consumer Price Index.279 Costs of colonoscopy with polypectomy included a 
variable component for polyp resection and pathology based on number of polyps 
resected.
outcomes
Outcomes included were colorectal cancer incidence, mortality, years of life lost, 
number of colonoscopies, complications, and the costs of screening and treatment in 
unscreened persons and in those screened according to ADR quintiles. In addition, 
we estimated the average outcome differences associated with 5 percentage-point 
higher ADRs using linear regression. Outcomes were discounted to 2010 at a fixed 
annual rate of 3% and reported with uncertainty ranges.
analysis
We simulated a US population cohort of 10 million men and women born January 1, 
1960. For patients reaching the age of 50 without having colorectal cancer diagnosed 
(9.4 million), we compared the outcomes of no screening, or of screening colo-
noscopy at ages 50, 60 and 70 by physicians from one of the five ADR quintiles.246 
Patients with adenomas detected were assumed to receive surveillance according to 
current United States guidelines.139 We assumed that the same physician performed 
all screening and surveillance colonoscopies in each individual patient, and thus, 
ADR exposure level remained constant during the life-course.
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Multiway probabilistic sensitivity analyses were conducted to derive 95% CI’s for 
all outcomes evaluated.280,281 In 1,000 simulation runs of 10 million persons we varied 
13 key parameters along uniform, beta, or lognormal distributions (table 7.1).
sensitivity analysis
We evaluated the robustness of results using several alternative modeling scenarios. 
Between-quintile ADR variation was attributed either: entirely to exam sensitivity for 
small lower-risk adenomas; equally to exam sensitivity for small, medium and large 
adenomas; or partially to exam sensitivity and to adenoma prevalence or colonos-
copy completion rates (~1% higher per percentage-point higher ADR). Adenoma 
patients received either more intensive or no surveillance. We also evaluated a 50% 
increased colonoscopy cost level and undiscounted outcomes.
To evaluate data uncertainty, we performed a bootstrap analysis on the association 
between observed average ADR and interval cancer rates across ADR quintiles and 
contrasted the resulting weak and strong association samples (2.5-97.5th percentile) 
to the modeling scenarios.
statistical software
For microsimulation modeling we used Delphi 7.0 (Borland Software Corp). Ad-
ditional data analyses were performed using Stata 13.1 (StataCorp).
results
A total of 57,588 screening colonoscopies were performed by 136 KPNC physicians 
during 1998-2010 (table 7.2). After exclusion of patients with less than 6 months 
follow-up (n=7,718), there were 179,812 person-years of follow-up time. Interval 
colorectal cancer incidence per 100,000 person-years varied from 66.6 (95% CI: 43.2-
97.0) in ADR quintile 1 to 39.0 (95% CI: 22.7-62.4) in quintile 4, but was 49.7 (95% 
CI 27.8-81.9) in quintile 5.
126 Chapter 7
Table 7.2 Kaiser Permanente Northern California patient and physician characteristics according to 
quintile of adenoma detection rate.
Variable Quintiles of adenoma detection rate Total
1 2 3 4 5
Physician characteristics
Physicians, n 27 27 28 27 27 136
Adenoma detection rate
Mean 15.32 21.27 25.61 30.89 38.66 26.45
Median 16.56 21.50 25.70 30.96 38.86 25.70
Range 7.35-19.05 19.06-23.85 23.86-28.40 28.41-33.50 33.51-52.51 7.35-52.51
Patient characteristics
Screened adults, n 11,799 10,579 10,978 12,918 11,314 57,588
Cancer diagnosed within 6 
months
114 93 106 176 119 608
Less than 6 months of 
follow-up
1,452 1,253 1,179 1,421 1,805 7,110
Proportion male, % 42.8 43.4 44.1 45.0 44.5 44.0
95% CI (34.6, 51.0) (36.0, 50.8) (36.2, 51.9) (37.3, 52.7) (37.1, 51.9) (36.1, 51.8)
Mean age, years 61.3 61.3 62.0 62.0 61.9 61.7
95% CI (59.3, 63.2) (59.5, 63.1) (59.1, 64.9) (60.1, 64.0) (59.5, 64.3) (59.3, 64.1)
Age groups, %
50-54 years 25.6 25.4 23.5 23.6 24.0 24.4
55-59 years 21.4 20.6 19.9 19.8 19.8 20.3
60-64 years 20.7 21.9 20.7 20.2 20.8 20.8
65-69 years 14.9 15.4 15.0 16.2 15.4 15.4
70-74 years 9.7 9.2 11.4 10.5 10.8 10.3
75-84 years 6.9 6.9 8.9 8.6 8.4 7.9
>85 years 0.8 0.7 0.7 1.0 0.8 0.8
Race/ethnicity, %
Non-Hispanic white 69.0 73.0 67.9 65.7 66.5 68.3
Hispanic 5.9 5.5 8.2 7.1 8.1 7.0
Non-Hispanic black 7.8 5.3 4.4 4.5 4.0 5.2
Asian 7.4 7.8 10.2 14.5 13.0 10.7
Native Americans 0.3 0.3 0.4 0.4 0.3 0.4
Other 2.3 2.2 2.5 2.5 2.9 2.5
Unknown 7.2 5.8 6.4 5.4 5.2 6.0
Patients with adenomas 
detected, n a
1,808 2,250 2,811 3,991 4,374 15,234
Person-years of follow-up b 39,033 33,251 33,564 43,635 30,200 179,682
Interval cancers diagnosed c 26 18 14 17 15 90
Incidence per 100,000 yr-1 66.6 54.1 41.7 39.0 49.7 50.1
95% CI (43.2,97.0) (32,85.3) (23.1,70.8) (22.7,62.4) (27.8,81.9) (40.3,61.6)
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simulated interval cancer incidence
To replicate the average detection rate per ADR quintile in the KPNC cohort in the 
model, colonoscopy sensitivity was varied according to adenoma size from: 14.7% 
in quintile 1, 41.0% in quintile 3 to 98% in quintile 5 for small adenomas; 39.6 to 
98% for medium adenomas; and 88.0 to 98% for large adenomas (see table 7.1 
for estimates per ADR quintile). The model closely reproduced observed colorectal 
cancer incidence in the lower four ADR quintiles, but underestimated incidence in 
the upper quintile (supplementary Figure 7.2).
lifetime colorectal cancer outcomes without and with screening
The model estimated average overall life expectancy without exposure to screen-
ing and surveillance was 81.1 years, the lifetime colorectal cancer risk was 
34.2/1,000 (95%CI:25.9-43.6), lifetime colorectal cancer mortality risk was 13.4/1,000 
(95%CI:10.0-17.6), and 138.7 life-years per 1,000 patients (95%CI:103.0-184.0) were 
lost due to colorectal cancer, which is 10.4 years per cancer death (table 7.3). 
Among screened patients, simulated lifetime risk of colorectal cancer incidence was 
on average 19.1/1,000 (95%CI:14.3-24.8), mortality was 3.8/1,000 (95%CI:2.8-5.2); 
and 42.7 (95%CI:30.9-57.5) life-years per 1,000 patients were lost to the disease.
← Table 7.2 Kaiser Permanente Northern California patient and physician characteristics according 
to quintile of adenoma detection rate.
Abbreviations: yr-1=	per	person-year;	CI	=	confidence	interval.
a	Including	only	histologically	confirmed	adenomas	by	pathologists.
b	Patients	were	followed	from	the	date	of	their	index	colonoscopy	until	the	first	of	the	following	events:	
negative follow-up colonoscopy, diagnosed cancer, death or departure from membership, 10 years 
follow-up, or study end (31 December 2010).
c	 Interval	cancers	were	colorectal	adenocarcinomas	diagnosed	≥	6	months	and	≤	10	years	of	the	
index colonoscopy
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The modeled risks were inversely related to the level of adenoma detection (table 
7.3). The simulated lifetime risk of colorectal cancer per 1,000 was 26.6 (95%CI:20.0-
34.3) for patients of physicians in ADR quintile 1, and was monotonically lower for 
subsequent quintiles; in ADR quintile 5, the simulated lifetime colorectal cancer risk 
was 12.5 (95%CI:9.3-16.5). Compared to ADR quintile 1, simulated lifetime risk of 
colorectal cancer was on average 11.4% (95%CI:10.3-11.9) lower per 5 percentage-
point higher ADR (Figure 7.1). Similarly, the simulated lifetime risk of colorectal 
cancer death and associated years-of-life lost per 1,000 patients were lower from 
quintile 1 (5.7, 95%CI:4.2-7.7 and 61.4, 95%CI:44.4-82.9) to quintile 5 (2.3, 95%CI:1.7-
3.1 and 27.0, 95%CI:19.5-36.2). The simulated lifetime risk of colorectal cancer death 
was on average 12.8% lower (95%CI:11.1-13.7) for every 5 percentage-point higher 
physician ADR.
colonoscopy volume and complications
The model’s total estimated number of colonoscopies per 1,000 patients was pro-
gressively higher from ADR quintile 1 (2,777, 95%CI:2,626-2,943) to quintile 5 (3,376, 
95%CI:3,081-3,681) (table 7.4), an average of 4.6% (95%CI:3.6-5.7) for every 5-point 
higher ADR (Figure 7.1). This difference was related to more frequent surveillance 
in patients of physicians with higher ADR. The simulated lifetime risk (per 1,000) 
of serious gastrointestinal complications such as post-polypectomy bleeding and 
perforation was also higher from ADR quintile 1 (2.2, 95%CI:1.5-3.1) to quintile 5 
(3.2/1,000, 95%CI:2.3-4.4), as were the overall complications (6.0, 95%CI:4.0-8.5 to 
8.9, 95%CI:6.1-12.0) and fatal complications (0.03 to 0.05). Overall, the simulated 
risk of complications was on average 9.8% (95%CI:7.5-13.2) higher for every 5-point 
higher ADR.
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(relative to the lowest quintile)
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scenario
ADR variation attr. to
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ADR variation attr. to
adenoma of all sizes c
ADR variation attr. to
exam completeness c
ADR variation attr. to
adenoma prevalence c
Intensified
surveillance d
No surveillance
Colonoscopy
cost +50%
Not discounted
95% CI e
Scenarios
Figure 7.1 Sensitivity analysis results: The adenoma detection rate-outcome relationship for various 
modeling scenarios. a
Abbreviations: ADR = adenoma detection rate; attr. = attributed.
a	95%	confidence	intervals	were	relatively	narrow	because	we	applied	the	same	assumptions	for	the	
natural history of colorectal cancer to all patients (Table 7.1). Colonoscopy sensitivity was the only 
assumption varied independently for each ADR quintile.
b Results were similar for years of life lost to cancer.
c We evaluated four alternative causal models for the observed cancer incidence differences across 
the ADR quintiles: in scenario 2 all variation in ADR was attributed to sensitivity of colonoscopy for 
small adenomas under 5 mm, which varied from 5.4 in the lowest quintile to98% in the highest quin-
tile; in scenario 3 all ADR variation was attributed equally to sensitivity for small, medium and large 
adenomas, which varied from 26.0 to 98%; in scenario 4 it was assumed that the rate of complete-
ness of colonoscopy along with differences in colonoscopy sensitivity accounted for the observed 
ADR-variations, varying from 75% to 98%; in scenario 4 adenoma prevalence was assumed to be 
up to a relative 25% higher with higher ADR.
d	Under	intensified	surveillance,	we	assumed	that	all	patients	with	adenomas	detected	at	colonos-
copy underwent surveillance at 3 years after the procedure, and patients with a negative surveillance 
colonoscopy underwent surveillance at 5 years. For reference, in the base-case analysis, patients 
with adenomas detected at colonoscopy were referred for surveillance after 3 or 5 years, depending 
on the number and size of the adenomas detected. Likewise, patients with a negative surveillance 
colonoscopy were referred for a follow-up colonoscopy in 5 or 10 years, depending on whether the 
preceding interval was 3 or 5 years.
e	95%	confidence	intervals	were	derived	by	multiway	probabilistic	sensitivity	analysis.
f The mean differences in simulated outcomes per 5 percentage-point higher ADR were derived by 
linear regression, and presented relative to the model outcomes for ADR quintile 1 (formula: 5 x 
betaols / outcomeq1).
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estimated costs of screening and treatment
For ADR quintile 1, estimated colonoscopy-related costs in US dollars per 1,000 
patients were $2.7 million (95%CI:2.4-3.1), and estimated treatment costs were $2.4 
million (95%CI:1.8-3.1), for an estimated total of $5.2 million (95%CI:4.4-6.0) without 
adjustment and $2.1 million (95%CI:1.8-2.4) with adjustment for the estimated costs 
without screening (table 7.4). For higher ADR quintiles, estimated colonoscopy 
costs were higher, but estimated treatment costs were lower, for lower estimated 
total costs ($4.9 million, 95%CI:4.1-5.6) and net screening costs ($1.8 million, 
95%CI:1.3-2.3) in quintile 5. Estimated net screening costs were on average 3.2% 
lower (95%CI:0.8-6.4) for every 5-point higher ADR.
sensitivity analyses
The simulations were stable to various assumptions regarding colorectal carcinogen-
esis, colonoscopy efficacy and surveillance intervals (Figure 7.1). Although simu-
lated costs were more unstable, the absolute corresponding cost differences were 
small (supplementary table 7.1). Without discounting, the estimated benefits of 
higher ADR were approximately twice as large as with discounting (supplementary 
table 7.2-3).
For ADR quintiles 1 to 4, strong and weak association scenarios from the bootstrap 
analysis for observed ADR and cancer incidence data were within the predicted 
ranges of the sensitivity analysis models (supplementary Figure 7.2b).
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Discussion
This study used data from a large community-based United States healthcare system 
in a microsimulation model to estimate the lifetime outcomes and costs of colonos-
copy screening at different levels of adenoma detection.124 Our results suggest that 
higher adenoma detection rates may be associated with up to 50-60% lower lifetime 
colorectal cancer incidence and mortality without higher net screening costs despite 
a higher number of colonoscopies and polypectomy-associated complications.
The model’s differences in observed interval colorectal cancer incidence were 
assumed to result from differences in the sensitivity of the exam, particularly for 
small-to-medium-sized adenomas. However, ADR may act as a surrogate for other 
aspects of colonoscopy quality, such as the test completeness, adequacy of lesion 
resection, and removal of more aggressive lesions such as sessile serrated polyps.282 
Although some of these alternative explanations were evaluated in sensitivity analy-
ses, with similar long-term results (Figure 7.1), we could not establish which factors 
accounted for the observed differences (supplementary Figure 7.2b), and whether 
others might be involved.
The frequency and intensity of surveillance of adenoma patients may also con-
tribute to patient outcome differences, because higher ADRs increase the number of 
patients for active surveillance.139 However, sensitivity analyses indicated that surveil-
lance did not account for the simulated survival benefits for patients of physicians 
with higher ADRs (Figure 7.1). Future research is needed to assess whether the 
current intensity of surveillance is still appropriate if test sensitivity further increases.
Prior studies have shown an inverse relationship between ADR level and the 
patient’s risk of colorectal cancer up to 5 years after colonoscopy.125,127,283 A recent 
large study found that patients of physicians in the highest ADR quintile had a 48% 
lower disease risk and a 62% lower mortality risk compared to the lowest quintile.124 
Adenoma detection rates may relate to patient outcomes over a lifetime of colo-
noscopy screening and surveillance. Our model estimated that discounted lifetime 
incidence and mortality risks averaged 11-13% lower for every 5-point higher ADR, 
which translates to overall differences of 53-60% between the lowest and highest 
ADR quintiles. Higher ADR was associated in the model with up to 34.4 additional 
life-years saved per 1,000 patients, which represents about 10 years per prevented 
cancer death, 2 weeks per average patient, and one-third of the maximum potential 
mortality benefit derived from screening (5 weeks per patient).
Screening colonoscopy is considered cost-effective for preventing colorectal can-
cer through adenoma detection and removal.102,246 However, it has been suggested 
that incentivizing higher adenoma detection, for example through value-based 
purchasing programs,284 could lead to unacceptably higher cost because of more 
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frequent surveillance in patients with low-risk adenomas.141 Our model suggests that 
higher detection rates are associated with only a moderately higher total number of 
colonoscopies: although the average surveillance patient in the modeling analysis 
received about twice as many procedures as a patient without detected adenomas, 
the additional proportion of patients undergoing surveillance with higher detection 
rates was limited to a maximum of 17%. By evaluating the costs for screening, sur-
veillance, screening-associated complications and cancer care, our model suggested 
that ADR is not associated with higher overall costs.
Another theoretical disadvantage of higher ADRs is a higher risk of complica-
tions due to more colonoscopies and polypectomies. The model suggested that for 
every 5-point higher ADR the lifetime complication risk is on average 10% higher. 
The corresponding absolute risk difference of 0.6/1,000 was counterbalanced in the 
model by a 3.0/1,000 lower risk of colorectal cancer and a 0.7/1,000 lower risk of 
disease-related mortality (supplementary table 7.1). Our model included mild 
gastrointestinal symptoms such as nausea or abdominal pain and rare fatal complica-
tions. The model’s complication rates are somewhat lower than those presented by 
other studies,282 because we adjusted our estimates for the risk of similar events in 
the group unexposed to colonoscopy.271
The model predicted all colorectal cancer outcomes to be lower for every higher 
quintile of adenoma detection. These predictions closely replicated the observed in-
terval cancer incidence in the lower four ADR quintiles, but underestimated adenoma 
detection and interval cancer incidence for the highest quintile (supplementary 
Figures 7.2-3). Although this suggests more uncertainty for the associations beyond 
approximately 30% (quintile 4 average), in a much larger sample of colonoscopies 
for all indications from the same data source, a plateau in outcome differences across 
ADR quintiles was not observed.124
This study has some other potential limitations. First, we confined the ADR es-
timates and analyses to screening colonoscopies. This decreased the number of 
interval cancers and therefore the precision. However, sensitivity analyses indicated 
that this did not have a strong effect on long-term model projections (supplemen-
tary Figure 7.2b). Second, modeled colorectal adenomas and cancer risk without 
screening included >10-year-old data. Uncertainty in corresponding model param-
eters was assessed with probabilistic sensitivity analysis. Third, our findings for the 
average association between ADR and patient outcomes do not necessarily mean 
that modifying ADR alone in individual physicians would lead to fewer interval can-
cers for their patients, given modeling cannot prove causal relationships. Fourth, our 
estimates assumed compliance with screening and surveillance guidelines and that 
patients receive colonoscopies from physicians with similar ADRs throughout their 
lifetimes. Finally, our cost estimates used Medicare rates and co-payments without 
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supplemental anesthesia costs, and thus may not represent true societal screening 
costs.285 We also assumed that there was no overuse of surveillance or screening.62 
However, sensitivity analyses suggested that these surveillance and cost-related fac-
tors may not have a large net effect (Figure 7.1, supplementary table 7.1).
conclusions
In this microsimulation modeling study, higher adenoma detection rates in screening 
colonoscopy were associated with lower lifetime risks of colorectal cancer incidence 
and mortality without being associated with substantially higher overall costs. Future 
research including other direct colonoscopy quality indicators is needed to assess 
why adenoma detection rates vary, and if increasing adenoma detection would be 
associated with improved patient outcomes.
aPPenDix 7
To derive point estimates of per-lesion sensitivity of colonoscopy for each quintile of 
adenoma detection in the Kaiser Permanente Northern California (KPNC) data, we 
simulated the screened populations in each quintile in terms of the age distribution 
at the time of screening. Population size was inflated in the model to 1 million 
lives per adenoma detection rate (ADR) quintile to reduce random variability in 
model outcomes. Two main simplifications were that: (1) although we simulated 
the age distribution of patients per ADR quintile, inter-provider differences in terms 
of patient risk factors such as age and sex were assumed to be negligible. Thus, 
apart from the different age distributions per ADR quintile, all simulated patients 
were selected randomly from an average-risk US population; (2) it was assumed that 
patients did not get screened previously, whereas the data included some individuals 
with a negative prior colorectal cancer test (≥10 years ago). Any misclassification 
was assumed to be non-differential given random assignment to each ADR quintile.
To validate the model including the point estimates for colonoscopy sensitivity in 
terms of the predicted interval cancer incidence after screening, we also simulated the 
follow-up time as included in the KPNC data. Because the incidence rate is variable 
over time and depends on whether a person had adenomas detected at baseline, we 
exactly replicated the person-years of follow-up after 1, 2, …, 10 years, stratifying 
patients with a positive and negative baseline colonoscopy (for adenomas). Because 
the interval cancers in the data included cancers detected by opportunistic screening 
or surveillance colonoscopies, we also simulated the proportion of patients with a 
repeat colonoscopy in years 1, 2, …, 10.
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The 5 different sets of parameters for per-lesion sensitivity by polyp size were 
derived to reproduce the average ADR for each quintile. The parameters were con-
strained by assuming that: (1) sensitivity for cancer was 98% across all quintiles; (2) 
sensitivity for medium to large adenomas varied less than for small adenomas, and 
increased according to a fixed rule from the lowest to the highest quintile (fixed 
detection likelihood (sensitivity/[1-sensitivity]) ratios for adjacent quintiles) while 
matching estimates for average practice in the middle quintile (85% for medium 
adenomas, 95% for large adenomas);163 (3) maximum sensitivity for adenomas was 
98%. Sensitivity for adenomas was then varied to match ADR values with 0.1 point 
precision. The estimates were independent of adenoma location. From the lowest to 
the highest ADR quintile, resultant sensitivity was 14.7% in quintile 1, 41.0% in quin-
tile 3 and 98% in quintile 5 for small adenomas, 39.6 to 98% for medium adenomas, 
and 88.0 to 98% for large adenomas (see table 7.2 for estimates per ADR quintile).
KPNC data on cancer diagnoses after colonoscopy were compared to the cancer 
incidence predicted by the model. The model closely reproduced observed incidence 
in the lower four ADR quintiles, but underestimated incidence in the upper quintile 
(supplementary Figure 7.2-3).
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Supplementary Figure 7.1 Bootstrap analysis for average cancer incidence and adenoma detec-
tion rates at Kaiser Permanente Northern California. a
a We performed a parametric bootstrap analysis for average observed adenoma detection and in-
cidence rates per ADR quintile (100,000 scenarios, 10,000 shown). Incidence was varied along the 
lognormal distribution (with Poisson standard errors) and adenoma detection was varied along the 
normal distribution (with binomial standard errors). Weak and strong association scenarios represent 
the resulting 2.5th (average 2.4-6th ) and 97.5th (97.4-6th) percentile of bootstrap scenarios in terms of 
the	linear	regression	coefficient	for	incidence	to	ADR.
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b Alternative scenarios 
Supplementary Figure 7.2a-b Simulated versus observed average cancer incidence and adenoma 
detection rates at Kaiser Permanente Northern California. a
Abbreviations: Ad. = Adenoma; prev. = prevalence; assoc . = association.
*	In	the	base-case	model	the	adenoma	prevalence	of	37%	was	insufficient	to	reproduce	ADR	levels	
observed for the upper quintile in the KPNC data (the curve stops below 37% due to imperfect sen-
sitivity). The dashed scenario in panel a with higher simulated adenoma prevalence reproduced the 
observed ADR level and led to similar overall results as the base-case model (not shown).
a In panel b, supplementary eFigure 5 in the legend corresponds to Supplementary Figure 7.1 in 
this thesis, and  Figure 1 corresponds with Figure 7.1 in this thesis.
Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening 139
 
 
Supplementary Figure 7.3a-e Simulated ver-
sus observed cancer incidence rates (cumula-
tive) in the Kaiser Permanente Northern Cali-
fornia data.
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aBstract
OBJECTIVE: To estimate how variation in colonoscopy quality, as measured by ad-
enoma detection rate (ADR), influences the benefits of fecal immunochemical testing 
(FIT) compared with primary colonoscopy screening for colorectal cancer.
DESIGN: Using an established microsimulation model, we estimated the benefits of 
annual FIT screening at differing ADR levels (quintiles; averages 15.3-38.7%), with 
colonoscopy screening as comparator. Assumptions used community-based data 
on physician ADRs and patient’s post-colonoscopy risk of cancer. Primary study 
outcomes were simulated lifetime colorectal cancer incidence and mortality per 1000 
patients with probability intervals (PI) from probabilistic sensitivity analysis.
RESULTS: For patients receiving FIT screening with potential follow-up colonoscopy 
by physicians from the highest ADR quintile, simulated lifetime cancer incidence and 
mortality were 28.8 (95%PI, 19.8-42.6) and 5.4 (95%PI, 3.5-8.4) per 1000, respectively, 
versus 20.6 (95%PI, 15.4-27.1) and 4.4 (95%PI, 3.2-5.9) for primary colonoscopy 
screening (risk ratios, RR=1.40; 95%PI, 1.09-1.89, and RR=1.22; 95%PI, 0.92-1.75). 
With every 5% point ADR decrease, lifetime cancer incidence was estimated to 
increase on average 8.6% (95%PI, 5.5-11.4) for FIT versus 12.3% (95%PI, 11.1-12.9) 
for colonoscopy, and mortality increased 9.4% (95%PI, 6.0-12.7) and 13.3% (95%PI, 
11.8-14.2), respectively. In ADR quintile 1, simulated mortality was lower for FIT 
than colonoscopy screening (10.1; 95%PI, 7.3-13.5, versus 11.8; 95%PI, 8.6-15.8, 
RR=0.85; 95%PI, 0.82-0.93), while incidences were more similar.
CONCLUSION: Relative cancer incidence and mortality reductions for FIT versus 
colonoscopy screening may differ by ADR. There may be fewer deaths for colo-
noscopy screening in higher ADR settings and fewer deaths for FIT in lower ADR 
settings.
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introDuction
Colorectal cancer is a leading cause of cancer deaths that is largely preventable through 
screening.103,197 Colonoscopy is indispensable for colorectal cancer screening, as either 
a primary screening test or for diagnostic follow-up of positive tests results from other 
screening methods. Colonoscopy quality, as measured by adenoma detection rate (ADR), 
or the proportion of a physician’s screening exams detecting adenomas, varies widely 
across providers. ADR has been shown to be inversely related to subsequent cancer 
incidence and mortality risks among patients undergoing screening colonoscopy.124,263
Annual fecal immunochemical testing (FIT) is increasingly used as either a primary 
colorectal cancer screening method or as an adjunct to colonoscopy-based screening 
programs to increase overall population screening rates.4 FIT and colonoscopy screen-
ing strategies each have their advantages and disadvantages. Colonoscopy screening 
is more sensitive for cancers and adenomas and has a long screening interval. FIT 
may be more acceptable to patients because of the lack of dietary restrictions, the 
non-invasive nature, and lower risk.86 Although FIT screening requires diagnostic colo-
noscopy follow-up of positive results, the overall effectiveness of FIT-based screening 
may also be affected less by lower ADR levels than primary colonoscopy screening 
given FIT primarily detects more advanced lesions.161 However, currently no data exist 
to compare the benefits of colonoscopy and FIT screening at different ADR levels.
The purpose of this study is to use microsimulation modeling with community-
based data,124 to compare the benefits of a program of annual FIT versus colonoscopy 
every ten years at various ADR levels.
metHoDs
This study used the Microsimulation Screening Analysis-Colon (MISCAN-Colon) 
model, developed by the Erasmus MC University Medical Center, Rotterdam, Neth-
erlands (chapter 2). The model, its main assumptions, and results for colonoscopy 
screening have been published.263
test performance assumptions
In this study, assumed variation in colonoscopy performance was based on previ-
ously published data from Kaiser Permanente Northern California, an integrated 
healthcare delivery system in the United States with a well-defined denominator 
population.124,263 In Corley et al, ADR quintile averages (ranges) varied: 15.3% (7.35-
19.05) for quintile 1; 21.3% (19.06-23.85) for quintile 2; 25.6% (23.86-28.40) for 
quintile 3; 30.9% (28.41-33.50) for quintile 4; and 38.7% (33.51-52.51) for quintile 
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5.124 Corresponding estimates of per-lesion sensitivity of colonoscopy were estimated 
to vary from quintile 1-5: 14.7-98% for adenomas of 0-5mm in diameter, 39.6-98% 
for adenomas of 6-9mm, and 88.0-98% for adenomas of ≥10mm (table 8.1).263 The 
assumed rate of colonoscopy completeness was fixed at 98% for all ADR quintiles.
The modeled effectiveness of FIT-based screening (OC Sensor test with a positivity 
cutoff of 20 µg/g cutoff) is based both on the sensitivity and specificity of FIT and 
the sensitivity and completeness of the colonoscopy exam used for follow-up of 
positive FIT results. Colonoscopy performance assumptions were varied as above for 
colonoscopy screening according to ADR level. Assumed per-lesion sensitivity of FIT 
was derived from recently published observational data, and was 4.9% for adenomas 
of 6-9mm, 16.2% for adenomas ≥10mm, and 64-89% for cancer (table 8.1).161
Table 8.1. Test performance assumptions in MISCAN
Performance characteristic, % Colonoscopy, by quintile a (screening, diagnostic, surveillance) FIT
1 2 3 4 5
Sensitivity per lesion b
Adenomas	≤	5	mm 14.7 29.6 41.0 66.2 98 0.0
Adenomas 6 - 9 mm 39.6 65.8 85 94.3 98 11.4 [2.5]e
Adenomas	≥	10	mm 88.0 92.2 95 96.8 98 15.9 [3.5]e
Stage I-IV cancer 98 98 98 98 98 63/89 [3.5]e
Specificity	c 100 100 100 100 100 96.4 [2.5]e
Completeness colonoscopy d 98 98 98 98 98 -
Abbreviations: FIT = fecal immunochemical test; ADR qi = adenoma detection rate quintile i.
a Adenoma detection rate (ADR) quintiles were derived from 57,588 colonoscopies performed by 
136 gastroenterologists in Kaiser Permanente Northern California, a large integrated healthcare de-
livery system in the United States. The averages (and ranges) of ADR for quintiles 1 through 5 were 
15.32% (7.35-19.05%), 21.27% (19.06-23.85%), 25.61% (23.86-28.40%), 30.89% (28.41-33.50%) 
and 38.66% (33.51-52.51%), respectively.124
b	The	adenoma	sensitivity	estimates	 for	FIT	 (OC	Sensor,	cutoff	>20	µg/g)	were	obtained	by	cali-
brating our model outcomes to the estimated per-person sensitivities from Imperiale et al.161 The 
per-person sensitivity of FIT for adenomas, advanced adenomas, and cancer was 7.6, 23.8, 73.8, 
respectively. We assumed that fecal occult blood testing is more sensitive in cancers towards the 
end of the occult invasive period (close, time-wise, to becoming symptomatic): for preclinical cancers 
which will become symptomatic within the same stage, assumed test sensitivity was higher. This as-
sumption showed good concordance with guaiac fecal occult blood test trial results.190 Colonoscopy 
sensitivity estimates were derived elsewhere.263
c The probability of a false positive result was random in the base-case analysis, and independent of 
person	or	lesion.	We	assumed	perfect	specificity	for	colonoscopy	including	pathological	examination	
of detected lesions.
d This is the proportion of colonoscopies visualizing the maximum point of reach of the endoscope, 
i.e. the cecum.
e Standard deviation for the probabilistic sensitivity analysis is shown in brackets. A Beta distribution 
was	assumed	to	reflect	uncertainty.
Impact of Adenoma Detection Rates on the Benefits of Fecal Testing versus Colonoscopy for Colorectal Cancer 149
analysis
For this study, MISCAN-Colon was used to generate an average-risk screening popu-
lation of ten million men and women born on January 1, 1965. Patients received 
annual FIT between the ages 50-75 years.246 Patients with a positive FIT received 
follow-up colonoscopy. Patients with adenomas detected in screening received 
colonoscopy surveillance according to the most current guidelines.139 We compared 
colorectal cancer outcomes for FIT according to level of adenoma detection. For 
reference, we also estimated outcomes with colonoscopy screening and without any 
screening.
Primary study outcomes were simulated lifetime colorectal cancer incidence and 
mortality according to ADR quintile (undiscounted). We also estimated the continu-
ous change in outcomes per 5% point increase in ADR using linear regression. Mul-
tivariate probabilistic sensitivity analysis was used to derive 95% probability intervals 
(95% CI) for all model outcomes. In 1000 simulation runs of 10 million persons we 
varied 13 key parameters along uniform, beta, or lognormal distributions.263 FIT 
performance assumptions were also varied (table 8.1).
We conducted one-way sensitivity analyses repeating our estimation of the con-
tinuous change in outcomes for every 5% point lower ADR, assuming 5-15% point 
lower or higher FIT sensitivity, 2.5% point lower or higher FIT specificity, and also 
varying the extent to which ADR variation was attributed by the model to colonos-
copy sensitivity for diminutive lesions. In the one extreme, all ADR variation was 
attributed to variation in small adenoma miss rates, in the other extreme, physicians 
were assumed to miss all sizes of lesions with equal probability.
Funding
MISCAN-colon is part of the Cancer Intervention and Surveillance Modeling Network 
(CISNET) sponsored by the United States National Cancer Institute (NCI). This work 
was supported by the NCI-funded consortium Population-Based Research Optimizing 
Screening through Personalized Regimens (PROSPR), the overall aim of which is to 
conduct multi-site, coordinated, transdisciplinary research to evaluate and improve 
cancer screening processes.
results
Among unscreened patients, the simulated lifetime risk of colorectal cancer was 66.8 
(95%PI, 50.7-85.1) per 1000, and the simulated risk of colorectal cancer mortality 
was 27.8 (95%PI, 20.8-36.5) per 1000 (Figure 8.1). Among patients screened with 
colonoscopy, the average simulated colorectal cancer incidence and mortality risks 
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across all ADR quintiles were 33.4 (95%PI, 24.8-42.8) and 7.7 (95%PI, 5.6-10.2) per 
1000, respectively. Among patients screened with FIT (with colonoscopy follow-up 
for positive results), the average simulated colorectal cancer incidence and mortality 
risks were 37.9 (95%PI, 27.8-52.3) and 7.4 (95%PI, 5.3-10.3) per 1000, respectively.
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Figure 8.1a-b. Simulated colorectal cancer incidence(a) and mortality(b) per ADR quintile. a
Abbreviations: ADRqi = Adenoma Detection Rate quintile i (i = 1,…,5). a Colonoscopy screening out-
comes were previously published.263 Whiskers represent 95% probability intervals from multivariate 
probabilistic sensitivity analysis.
Impact of Adenoma Detection Rates on the Benefits of Fecal Testing versus Colonoscopy for Colorectal Cancer 151
The outcomes of FIT screening and primary colonoscopy screening varied according 
to level of adenoma detection. Among patient receiving FIT screening with potential 
follow-up colonoscopy from providers in the highest ADR quintile, incidence was 
28.8 (95%PI, 19.8-42.6) and mortality 5.4 (95%PI, 3.5-8.4) (Figure 8.1). In contrast, 
for patients receiving colonoscopy screening from the highest ADR quintile provid-
ers, the simulated lifetime cancer incidence and mortality were 20.6 (95%PI, 15.4-
27.1) and 4.4 (95%PI, 3.2-5.9) per 1000, respectively (relative risks for FIT versus 
colonoscopy, RR=1.40; 95%PI, 1.09-1.89, and RR=1.22 (95%PI, 0.92-1.75) (Figure 
8.2). For every 5% point decrease in ADR, simulated incidence was estimated to 
decrease on average 8.6% (95%PI, 5.5-11.4) for FIT screening and 12.3% (95%PI, 
11.1-12.9) for colonoscopy screening (table 8.2, supplementary Figure 8.1). 
Thus, in ADR quintile 1, simulated lifetime cancer incidences were more similar, 
at 49.7 (95%PI, 37.5-64.8) per 1000 for FIT screening and 48.1 (95%PI, 36.1-62.2) 
per 1000 for colonoscopy screening (RR=1.03; 95%PI, 0.99-1.12) (Figure 8.1-2). 
For every 5% point decrease in ADR, estimated mortality increased by an amount 
similar to cancer incidence: by 9.4% (95%PI, 6.0-12.7) for FIT screening and 13.3% 
(95%PI, 11.8-14.2) for colonoscopy screening (table 8.2, supplementary Figure 
8.1). Simulated mortality in quintile 1 was lower with primary FIT than with primary 
colonoscopy, at 10.1 per 1,000 (95%PI, 7.3-13.5) versus 11.8 per 1000 (95%PI, 8.6-
15.8), respectively (RR=0.85; 95%PI, 0.82-0.93).
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Figure 8.2a-b. Simulated relative risks of colorectal cancer incidence(a) and mortality(b) for FIT 
versus colonoscopy screening. a
Abbreviations: ADRqi = Adenoma Detection Rate quintile i (i = 1,…,5).
a Whiskers represent 95% probability intervals from multivariate probabilistic sensitivity analysis. 
The	variable	width	of	confidence	intervals	from	the	probabilistic	sensitivity	analysis	was	due	to	in-
teraction of colonoscopy and FIT performance: in the model, lower ADRs decreased the outcome 
effect of FIT’s variable false positive rates and the associated colonoscopy receipt, and higher ADRs 
increased the effect.
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sensitivity analysis
Outcomes were sensitive to the assumed test characteristics for FIT and colonoscopy 
(table 8.2). The relative increase in cancer mortality per 5% point lower ADR was 
smaller for FIT screening when assuming lower FIT sensitivity (8.7%) or higher 
assumed FIT specificity (7.6%), and larger when assuming higher FIT sensitivity 
(10.8%) or lower specificity (11.3%). When ADR variation was attributed predomi-
nantly to small adenomas, the mortality change was lower for both colonoscopy 
(11.3%) and FIT (7.7%), while with more variation in detection of larger adenomas 
variation, mortality changes were large than the base-case (14.1% versus 12.6%, 
respectively). In all scenarios, the outcome gradient across ADR quintiles was larger 
for colonoscopy screening than FIT screening.
Table 8.2. Sensitivity analysis results: % change in outcomes per 5% point lower ADR. a
Scenario
Colonoscopy FIT
Incidence Mortality Incidence Mortality
1. Basecase 12.3 13.3 8.6 9.4
2.a Lower FIT sensitivity b 8.0 8.7
2.b Higher FIT sensitivity 9.7 10.8
3.a	Lower	FIT	specificity	c 10.2 11.3
3.b	Higher	FIT	specificity 7.0 7.6
4.a	More	emphasized	variation	in	adenoma	≤5mm	d 9.7 11.3 7.1 7.7
4.b	Less	emphasized	variation	in	adenoma	≤5mm 12.6 14.1 11.3 12.6
Abbreviations: FIT = Fecal immunochemical test, ADR = adenoma detection rate
a Mean simulated outcome differences per 5% decrease in ADR were derived by linear regression 
and	presented	relative	to	the	model	outcomes	for	ADR	quintile	1	(5	×	βols/outcomeq1). The actual ADR-
outcome relationship was slightly convex (rather than perfectly linear), particularly for FIT screening 
outcomes: for lower levels of ADR, the outcomes impact of changes in ADRs was somewhat larger 
(see Supplementary Figure 8.1).
b We assumed 5% point lower/higher sensitivity of FIT for adenomas, and 10-15% point lower/higher 
values for cancer.
c	We	assumed	2.5%	point	lower/higher	specificity	of	FIT.
d With more emphasis on small adenomas, all variation in ADRs was attributed to sensitivity of colo-
noscopy for adenomas smaller than 5 mm, which varied from 5.4%, lowest, to 98%, highest quintile. 
With less emphasis, all ADR variation was attributed equally to sensitivity for small, medium, and 
large adenomas, which varied from 26.0% to 98%.
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Discussion
Using microsimulation modeling, we estimated that there is an inverse relationship 
between physicians’ ADR and estimated colorectal cancer screening outcomes that 
may be stronger when primary screening is performed with colonoscopy than with 
FIT. Although FIT-based and colonoscopy-based screening strategies were similar 
on average in terms of their estimated mortality reduction,259 with providers from the 
highest ADR quintile, the model suggests that primary colonoscopy screening would 
result in fewer colorectal cancer cases and deaths than FIT screening. Conversely, 
FIT screening outperformed colonoscopy in terms of mortality reductions when 
physician ADRs levels were <20% (male and female patients combined).
The simulated outcome differences between FIT and colonoscopy screening can 
be explained by the different test characteristics. While colonoscopy, with relatively 
long screening intervals, provides long-term protection through removal of most 
existing lesions at the time of screening,166 the more frequent FIT screening with 
follow-up colonoscopy of positive results may primarily detect large adenomas and 
early-stage cancers before they progress to more advanced-stages.161 The model 
assumed that physicians with lower detection rates have a higher proclivity for miss-
ing small rather than large adenomas.163,263 Therefore, FIT outcomes were relatively 
more stable to varying ADRs than primary screening with colonoscopy (9.4% versus 
13.3% estimated increase in disease-related mortality per 5% point ADR decrease). 
In an alternative model with more variation in assumed sensitivity of colonoscopy 
for large adenomas, outcomes remained more stable for FIT than colonoscopy, but 
differences were smaller (12.6% versus 14.1% increase in mortality per 5% point ADR 
decrease).
Another consequence of the different test characteristics of colonoscopy and FIT 
was that, although FIT was more effective for preventing colorectal cancer deaths 
than low-quality screening colonoscopy, primary colonoscopy screening resulted in 
lower estimated colorectal cancer incidence across all ADR quintiles. This is an ad-
vantage for colonoscopy screening, which has induced some expert panels to favor 
colonoscopy over other less invasive modalities for colorectal cancer screening.115 In 
contrast, given the different risk and benefit profiles of the different strategies, the 
most recent recommendation by the United States Preventive Services Task Force 
(USPSTF) puts more emphasis on patient preferences and shared decision-making.103
To our knowledge, the present study is the first to have looked at the influ-
ence of ADRs on screening outcomes for a stool-based screening setting. Previous 
empirical studies have found inverse associations between physician ADR levels 
and post-colonoscopy cancer risk.125,127,283 In the largest study to this date, Corley 
and colleagues found associations between ADR and interval cancer risk that were 
Impact of Adenoma Detection Rates on the Benefits of Fecal Testing versus Colonoscopy for Colorectal Cancer 155
similar for screening, diagnostic, and surveillance exams.124 In a previous modeling 
study, we estimated that the observed ADR variation may translate to 50-60% differ-
ences in lifetime colorectal cancer outcomes for primary colonoscopy screening.263 
The present study suggests that variations in ADR may have less influence on the 
outcomes of FIT (maximum estimated differences of 42-44%).
The current study may overestimate the differences for fecal testing. While mul-
tiple studies have shown that there is substantial variation in ADRs from screening 
exams,124,128,275 there are much less data available on variation in adenoma detection 
during colonoscopies after positive fecal colorectal cancer screening test results. 
Physicians may examine a patient more carefully with evidence of gastrointestinal 
blood loss, which may improve the sensitivity of the examination, even for small 
adenomas that are unlikely to have caused the positive test result. Although ad-
enoma detection rates in diagnostic examinations are not directly comparable to 
those in screening exams, wide variation in detection rates from population-based 
FIT screening settings leaves room for substantial variation in miss rates.288,289 Higher 
observed risks of cancer after positive FITs followed by negative colonoscopies (for 
adenomas) could also be indicative of suboptimal quality.
A limitation of this study is the lack of direct experimental data to inform the 
model on efficacy of FIT and colonoscopy screening.86,122 We modeled the efficacy of 
FIT using an established approach used before to inform the United State Preventive 
Services Task Force.259 This approach combines evidence from guaiac fecal occult 
blood testing trial data190 with observational data on FIT’s diagnostic performance.161 
Colonoscopy efficacy estimates were derived similarly using flexible sigmoidoscopy 
trial results.117 The simulated mortality effects of FIT are consistent with results from 
a recent major population-based study,105 and colonoscopy effects are within the 
outcome range of observational studies,107 supporting the use of this approach for 
the present study.
A strength of this study is that we based our estimates for variable colonoscopy 
performance characteristics on community-based data regarding interval cancer 
incidence rates after colonoscopy screening according to physician ADR.124 Our as-
sumptions have been shown to match well with the observed decreasing incidence 
pattern from lower to higher ADRs.124,263 Alternative models with relatively more 
or less emphasis on variation in detection of diminutive lesions, as evaluated in 
sensitivity analyses, matched the data less well, which suggests that our base-case as-
sumptions are reasonable. However, we cannot rule out other possible explanations 
for the observed incidence pattern, such as an association of ADR with adequate 
polyp management290 or serrated polyp detection rates.131
Our study focused on the influence of observed ADR variation on screening effec-
tiveness. There may be other important, independent, modifiable outcome determi-
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nants for colonoscopy and FIT. Other studies have identified potential determinants 
in ambient FIT temperature,291 time from positive FIT to diagnostic colonoscopy 
follow-up,292 and particularly, patient adherence.260 We assumed 100% adherence 
with both colonoscopy and FIT screening, while in reality adherence may differ for 
colonoscopy and FIT.83-86 Patients’ willingness to comply with annual fecal colorectal 
cancer testing methods over longer periods of time is uncertain, with no studies 
having assessed adherence for >4 subsequent rounds.90-92 Future modeling studies 
should assess and rank the relative contribution of all outcome determinants for 
screening effectiveness to inform priorities of quality-related interventions.
This study has two main implications. First, our results confirm that physician ADR 
is an important indicator for colorectal cancer screening performance, irrespective of 
whether the primary screening modality is colonoscopy or FIT. This underscores the 
importance of ongoing efforts to measure and improve physicians’ ADR scores,131,293 
as formalized by some countries in quality assurance programs.116,294 Recent research 
suggests that endoscopist training programs may effectively increase ADR levels.295,296 
If large population-based studies confirm that such programs also have a favorable 
health impact, other screening programs should consider offering similar trainings to 
stimulate higher ADRs.
Our results further imply that ADR may be useful not only as a quality indicator for 
screening, but also as a predictor of comparative screening program performance and 
outcomes. We found that the benefits of FIT relative to colonoscopy screening may 
differ depending on the quality of colonoscopy achieved in a particular program. In 
high quality settings, colonoscopy may provide the best possible protection against 
colorectal cancer deaths, but in settings with lower ADR levels, the more frequently 
repeated FIT screening may be more effective. This propones colonoscopy quality 
as one of the relevant factors that policy makers may consider in selecting the most 
appropriate screening method for their particular setting. Research is needed to 
assess from what number of exams ADR can be reliably estimated and used as a 
predictor of both screening outcomes in general, and comparative performance of 
alternative screening methods in particular.
To conclude, the relative cancer incidence and mortality reductions for FIT versus 
colonoscopy screening may differ based on colonoscopy quality, as measured by 
ADR. Although the estimated mortality benefits are similar for FIT and colonoscopy 
with average ADR levels, colonoscopy screening may result in fewer cancer deaths 
in settings with higher ADR levels, while FIT screening may result in fewer deaths 
in lower ADR settings.
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Supplementary Figure 8.1a-b Simulated incidence(a) and mortality(b) per ADR level a
a Colonoscopy screening outcomes were previously published.263 Whiskers represent 95% prob-
ability intervals from multivariate probabilistic sensitivity analysis. Data points on the x-axis represent 
ADR quintile averages.
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aBstract
BACKGROUND-AIMS: Delays in diagnostic testing after a positive screening test 
result may undermine the benefits of colorectal cancer (CRC) screening, but little 
empirical data exist on the harms of such delays. We used microsimulation modeling 
to evaluate the consequences of time to colonoscopy following a positive fecal 
immunochemical test (FIT).
METHODS: An established microsimulation model was used to simulate a program 
of annual FIT screening, with colonoscopy follow-up of positive tests (cutoff 20 
µg/g) at various time intervals ≤12 months. Main outcomes were CRC incidence and 
mortality; additional outcomes were total life-years lost and net costs of screening.
RESULTS: For patients receiving diagnostic colonoscopy within two weeks of a 
positive FIT, the estimated lifetime CRC incidence and mortality risks were 35.5 
and 7.8/1000 patients, respectively. Every added month of time to colonoscopy was 
associated with 0.1/1000 increased cancer incidence (+0.3 compared to colonoscopy 
at ≤2 weeks) and mortality (+1.4%). When colonoscopy was received at 12 months 
after the result date, disease incidence and mortality were 37.0 (+4%) and 9.1/1000 
(+16%), respectively. Total years-of-life gained from screening for the entire screen-
ing cohort decreased from an estimated 93.7/1000 patients with almost immediate 
follow-up, to 84.8/1000 (-9%) with follow-up at 12 months, and cost-savings from 
screening decreased from US $208 to $100 per patient.
CONCLUSION: Modeling suggests that delays of up to 12 months in the follow-up 
of positive FITs may result, proportionally, in losses of up to nearly 10% in overall 
screening benefits. This underscores the importance of timely diagnostic follow-up 
of positive FITs.
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introDuction
As a two-stage screening strategy, the effectiveness of fecal occult blood testing 
depends on receiving adequate follow-up testing for positive results, generally with 
colonoscopy. There are no clear guidelines, however, for the appropriate time interval 
to follow-up colonoscopy. Some studies suggest that intervals of 6 months or longer 
are common in actual clinical practice.297,298 United States national patient safety goals 
emphasize the importance of prompt clinical evaluation of abnormal laboratory test 
results, but in the case of fecal colorectal cancer testing, the relationship between the 
time interval from the date of a positive result to diagnostic colonoscopy and colorectal 
cancer outcomes is not well known. A recent literature review identified two small 
studies on the subject,299 the largest of which suggested that longer intervals to receipt 
of colonoscopy may be associated with higher likelihood of advanced-stage colorectal 
cancer.300 However, the study was underpowered to detect statistical differences.
To inform patients, policy, and clinical decision-making on colorectal cancer 
screening, we used a microsimulation model approach to evaluate the effect of 
different lengths of time from a positive fecal immunochemical test (FIT) result to 
receipt of colonoscopy on colorectal cancer incidence, stage distribution, mortality, 
and the cost-effectiveness of screening programs. In sensitivity analyses we also 
evaluated other fecal colorectal cancer tests.
metHoDs
For this study, we used the MISCAN-colon model (chapter 2) to simulate an 
average-risk United States population cohort who received annual FIT screening 
between ages 50-75 years (see Supplementary Table 9.1 for the main model assump-
tions). For FIT screening, the simulated stage distribution of screen-detected cancers 
and the simulated mortality effects were consistent with data from population-based 
studies,105,301,302 supporting the use of this approach for assessing the effect of lag in 
diagnostic testing after a positive fecal test result.
outcomes
Outcomes evaluated were lifetime colorectal cancer incidence, stage and mortality 
in FIT positive patients for different time intervals to follow-up colonoscopy, as 
well as the benefits and cost of the FIT screening program as a whole. We also es-
timated the continuous outcome differences associated with each additional month 
to colonoscopy using linear regression. Life-years and costs were discounted at the 
conventional 3% per year.38
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analysis
We simulated 10 million men and women born January 1st, 1960. All patients without 
diagnosed colorectal cancer participated in and complied with annual FIT screen-
ing.114 We considered five scenarios for the average time from positive FIT (OC 
Sensor, cutoff level for a positive result is 20 µg/g [100 ng/ml]) to follow-up colonos-
copy: 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months and no follow-up 
colonoscopy. These lag-times were applied to each simulated patient and at every 
occurrence of a positive result. Patients with adenomas detected at colonoscopy 
received surveillance colonoscopy per guidelines after 3 – 5 years, depending on the 
size and multiplicity of adenomas detected.139
sensitivity analysis
In the sensitivity analysis, we evaluated two alternative colorectal cancer screen-
ing tests, including the gFOBT (Hemoccult II) and the multi-target stool DNA test 
(Cologuard) (table 9.1). We further evaluated several alternative model scenarios, 
including: biennial FIT screening, 50% longer or shorter average duration of the 
preclinical cancer phase (sojourn time); 5-15 percentage-point lower or higher 
sensitivity of colonoscopy depending on the lesion size (supplementary table 
9.1) (to account for variation in adenoma detection);263 5-15 percentage-point lower 
or higher sensitivity of FIT (supplementary table 9.1); 50% lower or higher FIT 
false-positive rates (1-specificity); and randomly distributed rather than deterministic 
time to diagnostic follow-up (Gamma[µ,1]; µ = 2 weeks or 3/6/12 months).
role of the funding source
This study was conducted within the Population-Based Research Optimizing Screen-
ing Through Personalized Regimens (PROSPR) consortium, which aims to conduct 
multisite, coordinated, trans-disciplinary research to evaluate and improve screening 
and is funded by the NCI. This work is also supported partly by resources from the 
Veterans Affairs Puget Sound Health Care System.
results
colorectal cancer outcomes in Fit positive patients
Among FIT screening participants with a positive test result, the lifetime risks of 
colorectal cancer incidence and mortality without any diagnostic follow-up were 
estimated as 82.8 and 34.4 per 1000 patients, respectively. Among patients who had 
diagnostic colonoscopy within two weeks, the risk of colorectal cancer was reduced 
to 35.5 per 1000 (Figure 9.1a) and the risk of death from colorectal cancer was 
reduced to 7.8 per 1000 (Figure 9.1b). Of the diagnosed cancers, 57% were stage 
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I, 24% stage II, 12% stage III, and 7% stage IV (Figure 9.2). For every additional 
month to diagnostic colonoscopy, estimated colorectal cancer incidence was higher 
by 0.1 per 1000 (or a 0.3% relative difference) compared to diagnostic colonoscopy 
within two weeks, as was cancer-related mortality (1.4% relative difference). For the 
scenario of diagnostic follow-up at 12 months from a positive FIT, colorectal cancer 
incidence was 37.0 per 1000, which was about 1.4 cases per 1000 (4%) higher than 
for almost immediate follow-up, and cancer-related mortality was higher by 1.3 
deaths per 1000 (16%). Diagnosed cancers shifted towards more advanced stages, 
with 50% diagnosed in stage I, 28% stage II, 14% stage III, and 8% stage IV, which is 
an absolute 7% lower share of stage I cancers.
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Figure 9.1a,b Lifetime colorectal cancer incidence (a) and mortality (b) in FIT positive patients.
a Relative to the scenario of follow-up within two weeks from a positive result.
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total benefits and cost of Fit screening for the entire screening cohort
Among all FIT screening participants, the lifetime risks of colorectal cancer incidence 
and mortality without any diagnostic follow-up of positive test results - the equiva-
lent of no screening - were 64.8 and 26.8 per 1000, respectively, and 133.5 years of 
life were lost per 1000 patients due to colorectal cancer (table 9.1). An annual FIT 
screening program in which diagnostic follow-up of positive tests occurred within 
two weeks averted 29.2 colorectal cancer cases, 19.4 colorectal cancer deaths and 
the loss of 93.7 life-years to the disease per 1000 patients. Screening with diagnostic 
follow-up within 2 weeks of positive results was cost-saving compared to no screen-
ing, with a net cost-saving of US $208 per screened patient. With follow-up at 12 
months, the number of prevented colorectal cancer cases and deaths decreased to 
27.8 and 18.5 per 1000 patients, respectively. Years-of-life saved were 8.9 (9%) lower 
than with almost immediate follow-up, and at 84.8 per 1000 patients; screening re-
mained cost-saving, but net cost-savings decreased to US $100 per screened patient.
Table 9.1 Simulated cost-effectiveness of FIT screening for the entire screening cohort.
Lifetime outcomes per 1000 Screening
patients Average time from positive FIT to colonoscopy (months)
None 0
(2 weeks)
1 2 3 6 12
Colorectal cancer outcomes
Cancer cases 64.8 35.5 35.6 35.7 35.9 36.2 37.0
Advanced cancer cases a 53.4 17.1 17.2 17.5 17.7 18.5 19.9
Cancer deaths 26.8 7.4 7.4 7.5 7.6 7.8 8.3
Years of life lost b 133.5 39.9 39.9 39.9 42.0 44.4 48.7
Effectiveness	of	screening
Cases prevented 29.2 29.2 29.0 28.9 28.5 27.8
Advanced cases prevented a 36.3 36.2 35.9 35.7 34.9 33.5
Deaths prevented 19.4 19.4 19.3 19.2 19.0 18.5
Years of life saved b 93.7 93.7 93.7 91.5 89.1 84.8
Healthcare costs, US $1000 b
Total costs of screening and 
treatment
5612 5404 5,411 5,420 5430 5459 5512
Incremental costs to no screening -208 -201 -193 -182 -153 -100
Cost-effectiveness ratio c.s. c.s. c.s. c.s. c.s. c.s.
Abbreviations: c.s. = cost-saving.
a Advanced-stage cancer cases are stage II-IV according to the 5th edition Cancer Staging Manual 
from the American Joint Committee on Cancer.
b Life-years and costs were discounted at the conventional 3% per year.
Consequences of time to diagnostic colonoscopy following a positive fecal colorectal cancer screening test 165
sensitivity analyses
The influence of time to diagnostic testing, per additional month to colonoscopy, 
was approximately twice as high for gFOBT as for FIT, but was similar for annual 
FIT versus stool DNA testing every three years (Figure 9.3). The results were stable 
to assumptions on FIT sensitivity and follow-up exam sensitivity for small adenomas, 
but sensitive to assumptions on test specificity, the length of screening intervals and 
cancer progression rates. With lower false positive rates or wider screening intervals 
the effects of time to diagnostic colonoscopy were more than 50% larger than the 
base-case. A random distribution of time to colonoscopy rather than a deterministic 
value made hardly any difference for our main outcomes.
0
20%
40%
60%
Stage I Stage II Stage III Stage IV
2 weeks
1 month
2 months
3 months
6 months
12 months
 Time to colonoscopy
Figure 9.2 Stages of newly diagnosed colorectal cancer cases in FIT positive patients according to 
time to diagnostic colonoscopy.
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0.12 (+1.6%)
0.08 (+1.1%)
0.2 (+2%)
0.12 (+1.5%)
0.1 (+1.4%)
0.1 (+1.1%)
0.12 (+1.8%)
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0.1 (+1.4%)
0.18 (+1.7%)
0.12 (+1.3%)
0.22 (+1.7%)
0.11 (+1.4%)Base-case analysis
gFOBT screening   b
(Hemoccult II)
sDNA screening b
(Cologuard)
Biennial screening
50% Longer preclinical
CRC duration
50% Shorter preclinical
CRC duration
5-15pp Higher colono-
scopy sensitivity c
5-15pp Lower colono-
scopy sensitivity c
5-15pp Higher FIT
sensitivity c
5-15pp Lower FIT
sensitivity c
50% Lower FIT
false-positive rate
50% Higher FIT
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Random time
to follow-up
Additional CRC deaths per 1000 patients a
Figure 9.3 Estimated	mortality	increase	per	additional	month	to	diagnostic	colonoscopy	in	FIT	posi-
tive patients, under various scenarios.
Abbreviation: CRC = colorectal cancer; pp = percentage point.
a	Effects	relative	to	the	scenario	of	follow-up	within	two	weeks	from	a	positive	result	are	presented	
within parentheses.
b See Supplementary Table 9.1 for the assumed test characteristics.
c See Supplementary Table 9.1 for assumed uncertainty in FIT and colonoscopy sensitivity accord-
ing to lesion size or stage.
Discussion
In the absence of high-quality observational data, we used an established micro-
simulation model to estimate the consequences of different times to colonoscopy 
following a positive FIT for the benefit and cost of colorectal cancer screening. 
Our results suggest that longer time to follow-up might lead to clinically relevant 
increases in the risks of colorectal cancer, advanced-stage colorectal cancer and 
colorectal cancer mortality. Although FIT screening remained cost-saving even with 
12 months to follow-up, cancer-related mortality in patients with a positive test 
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increased more than 15% relatively, and overall life-years gained from screening 
decreased nearly 10% relatively.
In our analyses, longer time to diagnostic colonoscopy slightly increased the to-
tal number of cancers diagnosed due to progression of adenomas to new cancers 
during that time interval. However, the relative increase in cancer-related mortality 
was more than three times larger than the relative increase in incidence. This differ-
ence stemmed from the relatively slow progression rate of adenomas compared to 
the more rapid rate of carcinomas progressing from early to more advanced stage 
disease. Therefore, later follow-up of positive FIT during the year after a positive 
test influenced the stage of diagnosis more than development of new disease. In our 
model, the shift to more advanced-stage of diagnosis was the primary driver for the 
relatively large mortality effect.
Our model results were robust using alternative assumptions regarding the sensitiv-
ity of the fecal tests and follow-up exam, but sensitive to assumptions on test speci-
ficity, the length of screening intervals and cancer progression rates (Figure 9.3). For 
patients with a positive gFOBT, longer time to follow-up resulted in larger estimated 
risk increases than the base case with FIT. This mainly reflects the differences in 
test specificity: using more specific screening tests resulted in a smaller cumulative 
number of false positive patients without a higher risk of cancer, and consequently, 
larger, less diluted effects of longer follow-up intervals for the true positive patients. 
Although we did not evaluate FIT with other-than-standard cutoff levels for positivity 
(>20 µg/g), by analogy to gFOBT, we would expect larger resulting effects with 
higher cutoffs, and smaller effects with lower cutoffs. Despite a lower test specificity, 
stool DNA testing every three years did not result in smaller mortality effects of time 
to follow-up than annual FIT due to the wider recommended screening intervals.115 
Because of the wider intervals there were fewer total screenings and false positive 
patients, which offset the effects of lower test specificity. Finally, the duration of 
the preclinical cancer phase is uncertain,50,303 and shorter durations increased the 
likelihood of disease progression and mortality in case of longer time to follow-up.
Some small prior observational studies have estimated the association of time to 
colonoscopy after positive gFOBT with cancer stage, however, gFOBT has different 
test characteristics than FIT. One study in 231 subjects found a large, but insignificant 
relative increase of 7% in the odds of advanced neoplasia (10 mm or more, >25% 
villous architecture, high-grade dysplasia or intramucosal carcinoma) per additional 
month to colonoscopy.300 Although this is larger than the effect we estimated for 
cancer, the relatively small size of the above study prohibits any meaningful conclu-
sions from such a comparison. Another study in 100 patients found no significant 
association between time to follow-up and colorectal cancer incidence and mortal-
ity.304 Clearly, both studies were underpowered to detect small-to-moderate effects 
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on incidence and mortality. In a statistical power analysis we estimated that a case-
control design would require at least 3000 cases of advanced-stage colorectal cancer 
and a history of preceding positive FIT, to demonstrate our model’s projected 2.7% 
estimated relative increase in stage II-IV disease per additional month to colonos-
copy, or the corresponding mortality effect (appendix 9, Statistical Power Analysis). 
Other studies have estimated the influence of time to diagnosis for any endoscopy 
(e.g. for symptoms), and have suggested no, or even inverse, associations,305-307 but 
these studies of symptomatic conditions may not be valid for inference of screening 
tests. In symptomatic patients, disease stage may influence the severity of symptoms, 
and thereby also the priority for follow-up.
In our analyses, FIT screening was suggested to be highly cost-effective (cost-
saving) compared to no screening, similar to other cost-effectiveness studies.111,266,308 
This was mainly due to averted treatment of (advanced-stage) colorectal cancer 
and the high associated costs. With only one gFOBT trial reporting significant ef-
fects on incidence,156 the effectiveness of FIT for cancer prevention, through the 
detection and removal of adenomas, is not well established. Superior performance 
characteristics of FIT to gFOBT-Hemoccult II and less demanding sample collection 
requirements suggest that FIT could be at least as effective,114 but no trial data 
exist.86 Our approach to estimating FIT efficacy is well-established, and has been 
used before in the decision analysis to inform the U.S. Preventive Services Task 
Force.204 The simulated stage-distribution for screen-detected cancers was consistent 
with observed data from population-based FIT screening programs,301,302 as were the 
estimated mortality effects,105
The present study has some limitations. First, in contrast with our assumptions, 
longer times to colonoscopy may not occur randomly, for example, they may be 
more common in elderly patients or in patients with comorbid conditions.298 These 
patients generally benefit less from screening,309 and may therefore also have smaller 
adverse consequences from longer times to examination after a positive FIT. Further, 
we assumed that false-positive results from asymptomatic benign bleeding occur 
randomly over individuals and that adenomas are missed randomly, while in reality, 
false-positive and false-negative results may cluster in specific patients or lesions, 
e.g. serrated polyps.56 Because FIT positive patients undergoing a diagnostic exami-
nation generally do not return to FIT screening for years, our assumptions may have 
understated the unknown long-term diagnostic performance of FIT, and therefore 
the effect of time to diagnostic colonoscopy (Figure 9.3).
The findings of this study are applicable primarily to patients who use fecal-based 
testing methods for colorectal cancer screening. Consequences of time to diagnostic 
colonoscopy may differ for patients who use a mix of tests for screening, including 
colonoscopy. Further, we focused our analysis on the effects of time to diagnostic 
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testing after a positive test result. However, time to therapy in patients with diag-
nosed cancer may also vary in practice. Thus, future studies are needed to assess the 
interrelatedness and joint effects of the lag both in diagnostic testing and receipt of 
treatment on the outcomes of stool-based CRC screening.
To conclude, using modeling we found that deferring diagnostic evaluation may 
lead to substantial increases in mortality in FIT positive patients. Although the dif-
ferences between an almost immediate evaluation and an evaluation at up to three 
months of a positive FIT are small, longer delays in follow-up of up to 12 months 
may result in more substantial losses, over time, in the overall benefits of screening.
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modeling effects of time to follow-up
Longer time intervals to diagnostic follow-up of a positive fecal colorectal cancer 
screening test may lead to more cancers progressing to more advanced-stage, and 
thereby higher risk of colorectal cancer death. For example, if the simulated Patient 
A introduced in chapter 2 would receive his/her colonoscopy examination at a later 
point indicated by the red arrow, cancer would progress further to less treatable 
stage II (Life history 3, supplementary Figure 9.1). As a result of this, cancer death 
would only be deferred, no longer prevented. Hence, for this example patient, the 
model suggests that longer time to diagnostic follow-up results in a decrease in 
life-years saved and fewer cancer-related deaths prevented. With random variation in 
the occurrence and progression of adenoma and cancer progression rates, the effects 
of time to diagnostic testing vary across different simulated patients.
statistical power analysis
For this study, we approximated the required case-control study size for statistical 
demonstration of the simulated effect of time from a positive FIT result to diagnostic 
colonoscopy on advanced-stage cancer incidence (stage II-IV) and cancer-related 
mortality, using bootstrap analysis.310 We assumed 10 years of average patient follow-
up time, and a uniform distribution for time intervals of 0 to 12 months. Patients 
were grouped according to time to follow-up of 0-3 months, 3-6 months, 6-9 and 
9-12. The associated risk differences were assessed using generalized linear model-
ing. The assumed power and significance thresholds were 80% and 5%, respectively.
Statistical demonstration of the relative differences in advanced-stage cancer inci-
dence rates (+2.7% per additional month to colonoscopy in 50-80 year-old patients) 
was estimated to require 3000 cases with advanced-stage cancer and a preceding 
positive FIT, and a similar number of random FIT positive patients matched in terms 
of post-colonoscopy follow-up. Demonstrating the estimated mortality rate differ-
ence (+2.3%) also required 3000 cases of deceased colorectal cancer patients with a 
history of positive FIT, and 3000 controls or random FIT positive patients.
With follow-up intervals of more than 12 months included, the power of case-
control studies improved. Assuming follow-up intervals were uniformly distributed 
from 0 to 24 months, the required number of cases and controls to statistically 
demonstrate the effect of time to colonoscopy on incidence and mortality would 
decrease to approximately 1000.
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Supplementary Table 9.1 Test performance assumptions in MISCAN.a
Performance characteristic, %
[range evaluated in sensitivity analyses]
Colorectal cancer screening test
Colono-scopy FIT
(OC Sensor, cutoff
>20	µg/g)
gFOBT
(HemoccultII)
sDNA
(Cologuard)
Sensitivity per lesion
Adenomas	≤	5	mm	b 75 [+/-15] 0.0 0.0 0.0
Adenomas 6 - 9 mm b 85 [+/-10] 4.9 [+/-5] 1.3 22.0
Adenomas	≥	10	mm	b 95 [+/-5] 16.2 [+/-5] 6.5 28.4
Stage I-IV cancer long before the 
occurrence of clinical symptomsc
95 [+/-5] 64[+/-15] 18.2 86.4
Stage I-IV cancer shortly before the 
occurrence of clinical symptomsc
95 [+/-5] 89[+/-10] 50.8 96.7
Specificity	d 100 95[+/-2.5] 97.5 90
Completeness colonoscopy e 98 - - -
Complication rate colonoscopy
with polypectomy, age 50-100y 0.4-8.5 - - -
fatal complications 0.0033 - - -
without polypectomy f - - - -
Abbreviations: FIT = fecal immunochemical test; gFOBT = guaiac fecal occult blood test; sDNA = 
multi-target stool DNA test.
a For references see Supplementary Table 9.2.
b The adenoma sensitivity estimates and uncertainty range for FIT (and sDNA) were obtained by 
calibrating our model outcomes to the estimated per-person sensitivities from Imperiale et al.161 The 
per-person sensitivity of FIT for adenomas, advanced adenomas, and cancer was 7.6, 23.8, 73.8, 
respectively. Colonoscopy sensitivity estimates were derived from a systematic review,163 and uncer-
tainty	was	assumed	to	be	larger	for	small	adenomas	to	reflect	adenoma	detection	rate	variation.263
c We assumed that fecal occult blood testing is more sensitive in cancers towards the end of the oc-
cult invasive period (close, time-wise, to becoming symptomatic): for preclinical cancers which will 
become symptomatic within the same stage, assumed test sensitivity was higher. This assumption 
showed good concordance with guaiac fecal occult blood test trial results.190
d The probability of a false positive result was random in the base-case analysis, and independent of 
person	or	lesion.	We	assumed	perfect	specificity	for	colonoscopy	including	pathological	examination	
of detected lesions. We included costs for pathological examination of non-adenomatous lesions 
(e.g. hyperplastic -) in 15% of exams not detecting adenomas.
e This is the proportion of colonoscopies visualizing the maximum point of reach of the endoscope, 
i.e. the cecum.
f Colonoscopy without polypectomy was not associated with a higher risk of complications. The 
risk of complications for polypectomy increased exponentially with age. Complications include seri-
ous GI events such perforation and gastrointestinal bleeding requiring blood transfusions; other GI 
events such as paralytic ileus, nausea, vomiting and dehydration, abdominal pain; and cardiovas-
cular events such as myocardial infarction or angina, arrhythmias, congestive heart failure, cardiac 
or respiratory arrest, or syncope, hypotension, or shock. The fatal perforation rate was derived from 
estimates of the incidence of perforation and case-fatality for perforation.271 272
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Supplementary Table 9.2 Key assumptions in MISCAN-Colon.
Parameter Value Reference
Demography
All-cause mortality United States lifetables CDC 2010
Natural history
Adenoma onset Nonhomogeneous Poisson process:
Exponential(µλ)	time	to	event,
µ=260-18y	for	age	25-80y,
µ=18-170y	for	age	80-100y,
λ=Gamma(1;2)	risk	factor
181,182,185 et al.
Adenoma progression 117
State transitions 0-89% adenomas progressive for age 0-100y
30% size 6-9mm progress to cancer
70%	size	6-9mm	first	become	10+mm
State duration, y (total) Exponential(130)
Preclinical cancer progression 157,188,189
Stage transitions a 0-31% stage I become clinical for age 0-100y
18-58% stage II become clinical for age 0-100y
58-49% stage III become clinical for age 0-100y
Stage durations, y (average) Exponential(2.5)
Colorectal cancer incidence
(without exposure to screening)
See Figure 2.3-4 SEER	1975-1979
5y Colorectal cancer survival b 58-71% stage I, depending on location
58-62% stage II, depending on location
33% stage III
6% stage IV
SEER	2000-2010
Screen test performance
Sensitivity FIT, colonoscopy See Supplementary Table 9.1 161,163,262,311
Specificity	FIT,	colonoscopy 161,262,269,270,311
Completeness colonoscopy 286,287
Complication rate colonoscopy 271,272
Costs, US $ *
FIT 26 152
Colonoscopy
without polypectomy 890
with polypectomy 1099
Complications 6051 277
Per life-year with cancer care, stage I-IV † 278
Initial 34,116-69,978
Continuing 2718-10,177
Terminal, cancer death 58,531-80,555
Terminal, other-cause death 18,063-45,939
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Supplementary Table 9.2 Legend Key assumptions in MISCAN-Colon.
Abbreviations: FIT = Fecal Immunochemical Test; CDC = United States Centers for Disease Control 
and	Prevention;	SEER	=	Surveillance	Epidemiology	and	End	Results	program.
a There is additional variation in cancer stage transitions according to bowel location.
b These cancer survival rates are adjusted for competing risks.
c Screen- and treatment costs include patient time costs (opportunity costs of spending time on 
screening or being treated for a complication or colorectal cancer), but not cost of traveling, lost pro-
ductivity, and unrelated health care or non-health care costs in added years-of-life. Patient time was 
valued at May 2014 median Unites States wage ($17.09 per hour), and assumed to be zero for FIT, 
8 hours for colonoscopy, and 16 hours for complications. Cost estimates for life-years with cancer 
care by Yabroff et al. already included patient time.278
d Care for colorectal cancer was divided in three clinically relevant phases: the initial, continuing, and 
terminal	care	phase.	The	initial	care	phase	was	defined	as	the	first	12	months	after	diagnosis;	the	
terminal	care	phase	was	defined	as	the	final	12	months	of	life;	the	continuing	care	phase	was	defined	
as all months in between. In the terminal care phase, we distinguished between cancer patients dy-
ing from the disease and cancer patients dying from another cause. For patients surviving less than 
24	months,	the	final	12	months	were	allocated	to	the	terminal	care	phase	and	the	remaining	months	
were allocated to the initial care phase.
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aBstract
BACKGROUND: The U.S. Preventive Services Task Force recommends against rou-
tine screening for colorectal cancer (CRC) in adequately screened persons older than 
75 years but does not address the appropriateness of screening in elderly persons 
without previous screening.
OBJECTIVE: To determine at what ages CRC screening should be considered in 
unscreened elderly persons and to determine which test is indicated at each age.
DESIGN: Microsimulation modeling study.
DATA SOURCES: Observational and experimental studies.
TARGET POPULATION – TIME HORIZON – PERSPECTIVE: Unscreened persons 
aged 76 to 90 years with no, moderate, and severe comorbid conditions. Lifetime 
horizon. Societal perspective.
INTERVENTION: One-time colonoscopy, sigmoidoscopy, or fecal immunochemical 
test (FIT) screening.
Outcome Measures: Quality-adjusted life-years gained, costs, and costs per quality-
adjusted life-year gained.
RESULTS OF BASE-CASE ANALYSIS: In unscreened elderly persons with no comor-
bid conditions, CRC screening was cost-effective up to age 86 years. Screening with 
colonoscopy was indicated up to age 83 years, sigmoidoscopy was indicated at age 
84 years, and FIT was indicated at ages 85 and 86 years. In unscreened persons 
with moderate comorbid conditions, screening was cost-effective up to age 83 years 
(colonoscopy indicated up to age 80 years, sigmoidoscopy at age 81 years, and FIT 
at ages 82 and 83 years). In unscreened persons with severe comorbid conditions, 
screening was cost-effective up to age 80 years (colonoscopy indicated up to age 77 
years, sigmoidoscopy at age 78 years, and FIT at ages 79 and 80 years).
RESULTS OF SENSITIVITY ANALYSIS: Results were most sensitive to assuming a 
lower willingness to pay per quality-adjusted life-year gained.
LIMITATION: Only persons at average risk for CRC were considered.
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CONCLUSION: In unscreened elderly persons CRC screening should be considered 
well beyond age 75. A colonoscopy is indicated at most ages.
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introDuction
In its most recent recommendation statement on colorectal cancer (CRC) screening, 
the U.S. Preventive Services Task Force (USPSTF) recommends screening using fecal 
occult blood testing, sigmoidoscopy, or colonoscopy, starting at age 50 years and 
continuing up to age 75 years.246 The USPSTF recommends against routine screening 
in persons older than 75 years with an adequate screening history.246 This latter 
recommendation is warranted by an analysis showing that the benefits of continuing 
screening from age 50 to 85 years instead of 75 years do not justify the additional 
colonoscopies required.204 Although the USPSTF did not address the appropriateness 
of screening in inadequately screened elderly persons, this recommendation has led 
many members of the medical community to believe that no one older than 75 years 
should be screened for CRC.312,313 However, because unscreened elderly persons are 
at greater risk for CRC than adequately screened elderly persons, screening them is 
likely to be effective and cost-effective up to a more advanced age. If so, the lack of 
more specific recommendations on the age to stop screening may result in an un-
founded denial of access to screening in elderly persons who were never screened 
for CRC—a group representing 23% of all U.S. persons older than 75 years.89
Many other elderly persons continue to be screened up to their late 80s or early 
90s.63 However, at these ages, screening is not likely to be cost-effective, even in 
those without previous screening. First, the high risk for death of competing disease 
at advanced age tends to offset the benefits of screening.314,315 Second, the risks for 
screening-induced harms (colonoscopy-related complications and overdiagnosis and 
overtreatment of CRC) increase with increasing age.271
The objective of this study was to determine up to what age CRC screening should 
be considered in elderly persons without previous screening and to determine 
which screening test—a colonoscopy, sigmoidoscopy, or fecal immunochemical test 
(FIT)—is indicated at what age. We performed separate analyses for elderly persons 
with no, moderate, and severe comorbid conditions because the effectiveness and 
cost-effectiveness of screening depend heavily on a person’s life expectancy.
metHoDs
We used Microsimulation Screening Analysis–Colon (MISCAN-Colon) to quantify the 
effectiveness and costs of screening (Chapter 2).
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Populations simulated
For each age between 76 and 90 years, we simulated a cohort of 10 million el-
derly persons without previous screening with no, moderate, and severe comorbid 
conditions (a total of 45 cohorts). Compared with cohorts of adequately screened 
elderly persons, the risk for CRC in these cohorts was substantially greater: CRC and 
adenomas were prevalent in 0.3% and 14.1%, respectively, of simulated persons 
aged 80 years with negative screening colonoscopies at ages 50, 60, and 70 years; 
these lesions were prevalent in 2.6% and 44.9%, respectively, of simulated patients 
aged 80 years without previous screening.
We used comorbid condition level–specific life tables to simulate elderly persons 
with no, moderate, and severe comorbid conditions (27). Persons are classified as 
having moderate comorbid conditions if they have an ulcer, rheumatologic disease, 
peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease and in 
case of a history of acute myocardial infarction; as having severe comorbid condi-
tions if they have chronic obstructive pulmonary disease, congestive heart failure, 
moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and 
chronic hepatitis, or AIDS; and as having no comorbid conditions if none of these 
conditions are present.
screening strategies
We simulated 1-time colonoscopy, 1-time sigmoidoscopy, and 1-time FIT screening 
within each cohort. Test characteristics and complication rates for each screening test 
are given in supplementary table 10.1. Patients with an adenoma or CRC detected 
during sigmoidoscopy or with a positive FIT result were referred for a diagnostic 
colonoscopy. Persons with adenomas detected and removed during a screening or 
diagnostic colonoscopy were assumed to have colonoscopy surveillance accord-
ing to the current guidelines.139 We assumed that surveillance continued until the 
diagnosis of CRC or death. Adherence to screening and diagnostic and surveillance 
colonoscopies was assumed to be 100%.
We restricted ourselves to 1-time colonoscopy and 1-time sigmoidoscopy screening 
because performing more screening colonoscopies or sigmoidoscopies is unlikely 
to be cost-effective at older age. We explored the effect of FIT screening during 2 
consecutive years in a sensitivity analysis.
utility losses associated with crc screening
We assumed a utility loss (that is, a loss of quality of life) equal to 2 full days of life 
per colonoscopy (0.0055 quality-adjusted life-years [QALYs]), 1 day of life per sigmoid-
oscopy (0.0027 QALYs), and 2 weeks of life per complication (0.0384 QALYs) (table 
10.1).278,316,317 We also assigned a utility loss to each life-year (LY) with CRC care.316
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Table 10.1 Utility Losses and Costs Associated With CRC Screening
Variable Initial Care Continuing Care Terminal Care,
CRC Death
Terminal Care,
Other-Cause Death
Utility loss, QALYa
Per FIT 0
Per sigmoidoscopy
Without biopsy 0.0027
With biopsy 0.0027
Per colonoscopy
Without polypectomy/biopsy 0.0055
With polypectomy/biopsy 0.0055
Per complication of colonoscopy 0.038
Per LY with CRC care b c
Stage I CRC 0.12 0.05 0.70 0.05
Stage II CRC 0.18 0.05 0.70 0.05
Stage III CRC 0.24 0.24 0.70 0.24
Stage IV CRC 0.70 0.70 0.70 0.70
Costs, d
Per FIT 42
Per sigmoidoscopy
Without biopsy 299
With biopsy 557
Per colonoscopy
Without polypectomy/biopsy 887
With polypectomy/biopsy 1096
Per complication of colonoscopy 6045
Per LY with CRC care b
Stage I CRC 36 683 3050 63 809 19 176
Stage II CRC 49 234 2870 63 555 17 279
Stage III CRC 59 759 4021 67 041 21 457
Stage IV CRC 77 790 12 178 88 368 49 866
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The assignment of utility losses to LYs with CRC care works 2 ways: On the 1 
hand, screening prevents cancer by the detection and removal of adenomas, thereby 
reducing LYs with CRC care and hence resulting in a gain of quality of life. On the 
other hand, screening results in overdiagnosis and overtreatment of cancer, resulting 
in LYs with CRC care in persons who would never have been diagnosed with CRC 
without screening and hence a loss of quality of life. The net effect on quality 
of life depends on the balance between cancer cases prevented and cancer cases 
overdiagnosed and can be either positive or negative.
costs associated with crc screening
The cost-effectiveness analyses were conducted from a societal perspective. The 
costs of colonoscopy, sigmoidoscopy, and FIT were based on 2007 Medicare pay-
ment rates and copayments (table 10.1).152,317 The costs of complications were 
obtained from a cost analysis of cases of unexpected hospital use after endoscopy in 
2007.277 We added patient time costs to both. The costs of LYs with CRC care were 
obtained from an analysis of SEER–Medicare linked data and included copayments 
and patient time costs.278 We adjusted all costs to reflect the 2013 level using the U.S. 
consumer price index.318 The assignment of costs to LYs with CRC care also works 2 
ways: On the 1 hand, screening prevents cancer, reducing the costs of CRC care. On 
← Table 10.1 Legend Utility Losses and Costs Associated With CRC Screening
Abbreviations: CRC = colorectal cancer; FIT = fecal immunochemical test; LY = life-year; QALY = 
quality-adjusted life-year.
a The loss of quality of life associated with a particular event.
b Care for CRC was divided in 3 clinically relevant phases: the initial, continuing, and terminal care 
phase.	The	initial	care	phase	was	defined	as	the	first	12	mo	after	diagnosis;	the	terminal	care	phase	
was	defined	as	the	final	12	mo	of	life;	the	continuing	care	phase	was	defined	as	all	months	in	be-
tween. In the terminal care phase, we distinguished between patients with CRC who were dying of 
CRC	and	those	dying	of	another	cause.	For	patients	surviving	less	than	24	mo,	the	final	12	mo	were	
allocated to the terminal care phase and the remaining months were allocated to the initial care 
phase.
c Utility losses for LYs with initial care were derived from a study by Ness et al.316 For LYs with con-
tinuing care for stage I and II CRC, we assumed a utility loss of 0.05 QALYs; for LYs with continuing 
care for stage III and IV CRC, we assumed the corresponding utility losses for LYs with initial care. 
For LYs with terminal care for CRC, we assumed the utility loss for LYs with initial care for stage IV 
CRC. For LYs with terminal care for another cause, we assumed the corresponding utility losses for 
LYs with continuing care.
d Costs are presented in 2013 U.S. dollars and include copayments and patient time costs (i.e., the 
opportunity costs of spending time on screening or being treated for a complication or CRC) but do 
not	 include	travel	costs,	costs	of	 lost	productivity,	and	unrelated	health	care	and	non–health	care	
costs in added years of life. We assumed that the value of patient time was equal to the median wage 
rate in 2012: $16.71/h.317 We assumed that FITs, sigmoidoscopies, colonoscopies, and complica-
tions used up 1, 4, 8, and 16 h of patient time, respectively. Patient time costs were already included 
in the estimates for the costs of LYs with CRC care obtained from a study by Yabroff et al.278
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the other hand, screening results in overtreatment of cancer, increasing these costs. 
The net effect can be either a reduction or an increase in costs.
outcomes
For each cohort, we quantified the effectiveness (that is, the number of CRC cases 
prevented, CRC deaths prevented, LYs gained, and QALYs gained) and costs of 
1-time colonoscopy, sigmoidoscopy, and FIT screening, applying the conventional 
3% annual discount rate for both.
analyses
We first determined the cost-effectiveness of each screening strategy compared with 
no screening for all cohorts. For each comorbidity level, we determined the upper 
age at which each screening strategy was cost-effective compared with no screening, 
assuming a willingness to pay per QALY gained of $100 000.
We subsequently performed an analysis to determine the optimal screening strategy 
for each cohort (that is, the most effective, still cost-effective screening strategy). To 
do so, we first excluded all dominated screening strategies (that is, those that were 
more costly and less effective than combinations of other strategies). We determined 
the incremental cost-effectiveness ratio for all remaining strategies (the so-called 
efficient strategies): the additional costs per additional QALY gained compared with 
the next-less-effective and costly strategy. From the efficient strategies, we selected 
the optimal strategy, again assuming a willingness to pay per QALY gained of $100 
000.
sensitivity analyses
We repeated our analyses, assuming one half and twice the base-case utility losses 
for colonoscopy, sigmoidoscopy, and complications; a utility loss of 0.12, 0.18, 0.24, 
and 0.70 QALYs for each LY with continuing care for stage I, II, III, and IV CRC, 
respectively; 25% higher and 25% lower costs for colonoscopy, sigmoidoscopy, and 
FIT; 25% higher and 25% lower costs for CRC care; twice the base-case miss rates 
for adenomas and CRC for both sigmoidoscopy and colonoscopy; no surveillance in 
patients with adenomas; a 25% higher and a 25% lower risk for CRC in all cohorts; 
and a willingness to pay per QALY gained of $50 000. Further, we explored the effect 
of FIT screening during 2 consecutive years.
This study did not include patient-specific information and was exempt from 
institutional review board review.
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role of the Funding source
The study was supported by the National Cancer Institute. The funding source had 
no role in the study’s design, conduct, and reporting.
results
effectiveness
The effectiveness of CRC screening in unscreened elderly persons declined with 
increasing age (table 10.2, supplementary table 10.2). For example, 1-time colo-
noscopy screening prevented fewer CRC deaths (4.5 vs. 11.9 per 1000 persons) and 
resulted in fewer LYs gained (12.3 vs. 68.5 per 1000 persons) in healthy persons aged 
90 years than in healthy persons aged 76 years. Moreover, whereas colonoscopy 
screening prevented 15.4 CRC cases per 1000 persons aged 76 years, it resulted in 
overdiagnosis and hence overtreatment of 7.7 CRC cases per 1000 persons aged 
90 years. As a result, colonoscopy screening resulted in a positive overall effect on 
length and quality of life (that is, a net health benefit) in healthy persons aged 76 
years (67.2 QALYs gained per 1000 persons) but in a net harm in healthy persons 
aged 90 years (1.7 QALYs lost per 1000 persons).
One-time sigmoidoscopy and, particularly, 1-time FIT screening were generally less 
effective than 1-time colonoscopy screening (table 10.2): For example, in healthy 
persons aged 76 years, colonoscopy screening resulted in 67.2 QALYs gained per 
1000 persons, whereas sigmoidoscopy and FIT screening resulted in 53.9 and 24.2 
QALYs gained per 1000 persons, respectively. The only exceptions were seen at the 
most advanced ages, at which FIT screening was most effective—a result primarily 
explained by the 0 utility loss associated with this test. In persons with moderate 
and, particularly, severe comorbid conditions, screening was less effective than in 
persons without comorbid conditions (supplementary table 10.3).
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costs
Whereas the effectiveness of screening in unscreened elderly persons declined 
with increasing age, the net costs of screening increased substantially (table 10.3). 
Although colonoscopy screening was associated with a lifetime cost of $725 000 per 
1000 healthy persons aged 76 years, it was associated with a lifetime cost of $2 130 
000 per 1000 healthy persons aged 90 years. This increase was again explained by 
the shift from preventing to overtreating CRC with age.
Table 10.3 Costs	of	1-Time	Colonoscopy,	Sigmoidoscopy,	and	FIT	Screening	 in	Elderly	Persons	
Without Previous Screening With No Comorbid Conditions a
Screening 
Strategy
Cost (Thousands), US$
Screening 
Tests b
Diagnostic
Exams
Surveillance
Exams
Complications LYs With CRC 
Care c
Total d
1-time COL
76y|| 983 0 569 98 −925 725
80y 987 0 484 114 −483 1102
85y 987 0 350 137 230 1705
90y 986 0 239 168 737 2130
1-time FSIG
76y|| 387 309 397 64 −718 439
80y 392 331 345 75 −380 764
85y 392 330 251 89 189 1251
90y 390 323 169 106 592 1580
1-time FIT
76y e 42 80 88 14 −7 218
80y 42 87 78 17 130 355
85y 42 93 62 23 356 577
90y 42 98 46 29 541 756
Abbreviations: CRC = colorectal cancer; FIT = fecal immunochemical test.
a Results are based on comparison with no screening, with results per 1000 persons and discounted 
by	3%.	Persons	are	classified	as	having	no	comorbid	conditions	if	none	of	the	following	conditions	
are present: an ulcer, a history of acute myocardial infarction, rheumatologic disease, peripheral vas-
cular disease, diabetes, paralysis, cerebrovascular disease, chronic obstructive pulmonary disease, 
congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis 
and chronic hepatitis, or AIDS.
b At very advanced age, the costs of screening colonoscopies and sigmoidoscopies show a slight 
decline. This is explained by the small observed decrease in the prevalence of adenomas at very 
advanced	age	(11–18,	20,	21).
c Screening prevents costs by preventing LYs with CRC care and induces costs by adding LYs with 
CRC care. The net effect can be an increase in costs (positive values) or a decrease in costs (nega-
tive values).
d Discrepancies between the columns may occur due to rounding.
e More detailed results for this cohort are given in Supplementary Table 10.2.
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Besides being the most effective strategy, colonoscopy screening was also the most 
expensive (table 10.3). For example, in healthy persons aged 76 years, the costs 
of colonoscopy screening were $725 000 per 1000 persons compared with $439 000 
and $218 000 for sigmoidoscopy and FIT screening, respectively. In persons with 
moderate and, particularly, severe comorbid conditions, screening was not only less 
effective but also more costly (supplementary table 10.4).
cost-effectiveness compared with no screening
As the effectiveness of screening declined with increasing age and the costs increased 
substantially, the cost-effectiveness of screening deteriorated rapidly with age (Fig-
ure 10.1). In unscreened elderly persons without comorbid conditions, colonoscopy 
and sigmoidoscopy screening were cost-effective up to age 85 years, whereas FIT 
screening was cost-effective up to age 86 years. In elderly persons with moderate 
comorbid conditions, colonoscopy and sigmoidoscopy screening were cost-effective 
up to age 82 years, whereas FIT screening was cost-effective up to age 83 years. In 
persons with severe comorbid conditions, colonoscopy and sigmoidoscopy screen-
ing were cost-effective up to age 79 years, whereas FIT screening was cost-effective 
up to age 80 years.
incremental cost-effectiveness
We determined the optimal screening strategy for each cohort on the basis of the in-
cremental cost-effectiveness ratios of the efficient screening strategies. In unscreened 
elderly persons with no comorbid conditions, colonoscopy screening was most ef-
fective and still cost-effective up to age 83 years (supplementary table 10.5, and 
Figure 10.2), sigmoidoscopy screening was the optimal strategy at age 84 years, and 
FIT screening was the optimal strategy at ages 85 and 86 years. In elderly persons 
with moderate comorbid conditions, colonoscopy screening was the optimal strategy 
up to age 80 years, sigmoidoscopy screening was the optimal strategy at age 81 
years, and FIT screening was the optimal strategy at ages 82 and 83 years. In persons 
with severe comorbid conditions, colonoscopy screening was the optimal strategy 
up to age 77 years, followed by sigmoidoscopy screening at age 78 years and FIT 
screening at ages 79 and 80 years.
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Figure 10.1 a-c The	 Cost-Effectiveness	 of	 Once-Only	 Colonoscopy,	 Sigmoidoscopy,	 and	 FIT	
Screening	Compared	with	No	Screening	in	Elderly	Without	Prior	Screening	with	No	(A),	Moderate	
(B), and Severe Comorbidity (C) (3% discounted).a b
Should colorectal cancer screening be considered in elderly persons without previous screening? 193
← Figure 10.1 Legend
Abbreviations: QALY = quality-adjusted life-year; FIT = fecal immunochemical test.
a	Individuals	are	classified	as	having	moderate	comorbidity	if	diagnosed	with	an	ulcer,	rheumatologic	
disease, peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease and in case of 
a history of acute myocardial infarction; as having severe comorbidity if diagnosed with constructive 
obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic 
renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and as having no comorbidity if none 
of these conditions is present.
b The dashed red line indicates a threshold for the willingness to pay per QALY gained of $100,000. 
Screening strategies costing less than $100,000 per QALY gained are considered cost-effective.
c	‡‡	Signs	indicate	ages	at	which	screening	is	associated	with	a	net	health	loss,	rather	than	a	benefit	
(Table 10.2, Supplementary Table 10.3).
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sensitivity analyses
Besides comorbid condition level, the upper age at which screening was cost-effec-
tive was most sensitive to lowering the threshold for the willingness to pay per QALY 
gained to $50 000 (supplementary table 10.6). Based on this threshold, screening 
unscreened elderly persons with no, moderate, and severe comorbid conditions 
should be considered up to age 84, 80, and 77 years, respectively. The upper ages 
at which screening should be considered were robust to all other sensitivity analyses 
(supplementary table 10.6).
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Figure 10.2 a-c The	Incremental	Costs-Effectiveness	of	the	Efficient	Screening	Strategies	in	Elderly	
Without Prior Screening with No (A), Moderate (B), and Severe Comorbidity (C) (results per 1,000 
individuals; 3% discounted).a b c
Abbreviations: QALY = quality-adjusted life-year; FIT = fecal immunochemical test
a	Individuals	are	classified	as	having	moderate	comorbidity	if	diagnosed	with	an	ulcer,	rheumatologic	
disease, peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease and in case of 
a history of acute myocardial infarction; as having severe comorbidity if diagnosed with constructive 
obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic 
renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and as having no comorbidity if none 
of these conditions is present.
b In elderly without prior screening with no, moderate, and severe comorbidity, none of the screening 
strategies is cost-effective from age 87, 84, and 81 onwards, respectively (Figure 10.1).
c	For	each	age,	the	efficient	screening	strategies	are	connected	by	an	efficiency	frontier.	A	dashed	
line indicates that the incremental cost-effectiveness ratio of a screening strategy exceeds $100,000 
per QALY gained, implying that the strategy is no longer considered cost-effective.
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The tests that were indicated at specific ages differed substantially between analyses 
(supplementary table 10.6). Besides the threshold for the willingness to pay per 
QALY gained, the level of CRC risk and the utility losses associated with colonoscopy, 
sigmoidoscopy, and complications were the most important factors in this respect.
In persons aged 84 years without comorbid conditions and persons aged 78 years 
with severe comorbid conditions, sigmoidoscopy screening was not cost-effective 
compared with FIT screening during 2 consecutive years. In persons aged 85 years 
without comorbid conditions, persons aged 82 years with moderate comorbid con-
ditions, and persons aged 79 and 80 years with severe comorbid conditions, FIT 
screening during 2 consecutive years was cost-effective compared with 1-time FIT 
screening.
Discussion
Our study shows that in elderly persons without previous CRC screening, screening 
remains cost-effective well beyond age 75 years, which is the recommended age to 
discontinue screening in adequately screened persons (table 10.4). In unscreened 
elderly persons with no comorbid conditions, screening was cost-effective up to age 
86 years. Screening with colonoscopy was most effective and still cost-effective up to 
83 years, sigmoidoscopy was indicated at age 84 years, and FIT was indicated at ages 
85 and 86 years. In unscreened elderly persons with moderate comorbid conditions, 
screening was cost-effective up to age 83 years (colonoscopy indicated up to age 80 
years, sigmoidoscopy at age 81 years, and FIT at ages 82 and 83 years). In persons 
with severe comorbid conditions, screening was cost-effective up to age 80 years 
(colonoscopy indicated up to age 77 years, sigmoidoscopy at age 78 years, and FIT 
at ages 79 and 80 years).
In the special situation when an elderly person is willing to have only one type 
of screening test, the cost-effectiveness of that test compared with no screening 
becomes relevant. In such a person without comorbid conditions, colonoscopy and 
sigmoidoscopy screening can be considered up to age 85 years and FIT screening 
can be considered up to age 86 years. The ages for similar persons with moderate 
comorbid conditions are 82 years for colonoscopy and sigmoidoscopy and 83 years 
for FIT; for persons with severe comorbid conditions, the ages are 79 years for 
colonoscopy and sigmoidoscopy and 80 years for FIT.
Although the incidence of CRC increases up to very advanced ages,319 the effective-
ness of screening declines with increasing age. This decline is primarily explained 
by the increasing risk for other-cause death. with age, which reduces both the prob-
ability that screening will prevent CRC death and the number of LYs gained if death 
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is prevented. Moreover, the risks for screening-induced harms (colonoscopy-related 
complications and, more importantly, overdiagnosis and overtreatment of CRC) 
increase with age.271 At the same time, the shift from preventing to overtreating CRC 
causes the net costs of screening to increase with age. Together, these phenomena 
explain the rapid deterioration of the cost-effectiveness of screening with increasing 
age.
Table 10.4 Results	 Summary	 of	 CRC	 Screening	 Indicated	 in	 Elderly	 Persons	Without	 Previous	
Screening
Comorbid
Condition
Status a
Age Up to 
Which CRC 
Screening 
Should Be 
Considered, y
Screening Strategy Indicated, by Age
76y 77y 78y 79y 80y 81y 82y 83y 84y 85y 86y
No comorbid conditions 86 COL COL COL COL COL COL COL COL FSIG FIT FIT
Moderate comorbid conditions 83 COL COL COL COL COL FSIG FIT FIT
Severe comorbid conditions 80 COL COL FSIG FIT FIT
Abbreviations: COL = 1-time colonoscopy; CRC = colorectal cancer; FSIG = 1-time sigmoidoscopy; 
FIT = 1-time fecal immunochemical test.
a	Persons	are	classified	as	having	moderate	comorbid	conditions	if	they	have	an	ulcer,	rheumatologic	
disease, peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease and in case of 
a history of acute myocardial infarction; as having severe comorbid conditions if they have chronic 
obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic 
renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and as having no comorbid condi-
tions if none of these conditions are present.
Although colonoscopy every 10 years, sigmoidoscopy every 5 years, and FIT every 
year are almost equally effective when applied from age 50 to 75 years (1, 2), 
colonoscopy screening is more effective than sigmoidoscopy and FIT when only 
one screening examination is performed because of its greater overall sensitivity 
for adenomas and CRC. However, because colonoscopy is also more expensive 
than sigmoidoscopy and FIT and because the effectiveness of all screening tests is 
marginal at very advanced ages, screening with colonoscopy is not cost-effective 
compared with sigmoidoscopy and FIT at the most advanced ages at which screen-
ing should be considered.
Screening remains cost-effective up to a more advanced age in persons without 
comorbid conditions than in those with comorbid conditions because their more 
favorable life expectancy increases the probability that screening will prevent CRC, 
thus increasing the effectiveness of screening while simultaneously reducing the 
costs of CRC care.
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To our knowledge, our study is the first to investigate the net health benefit and 
the cost-effectiveness of CRC screening in persons older than 75 years without previ-
ous screening. An earlier study by Ko and Sonnenberg314 demonstrated that the 
effectiveness of screening for preventing CRC death declines with increasing age, 
whereas the probability of screening-related complications increases with age. Fur-
ther, a study by Lin and colleagues315 demonstrated that the number of LYs gained by 
screening declines with age, resulting in an increase in the number of colonoscopies 
required per LY gained. However, neither study considered costs or measured the 
overdiagnosis and overtreatment of cancer, which is the most important adverse 
effect of screening in elderly persons. As a result, these studies cannot easily be 
used to determine whether unscreened elderly persons should be screened. Some 
other, more recent studies have suggested that screening should be continued after 
age 75 years.312,313 However, these studies did not distinguish between adequately 
screened elderly persons and elderly persons without previous screening. Further, 
these studies based their conclusions only on CRC incidence data.
The USPSTF selected its recommended screening strategies based on the number 
of colonoscopies required per LY gained (undiscounted),204,246 but we based our 
conclusions on the costs per QALY gained (discounted at 3% per year). We did 
so for 2 reasons. First, policymakers should be able to compare the efficiency of a 
wide range of health interventions; the USPSTF outcome measure does not allow 
for this. Second, we believe that effects on both length and quality of life should 
be considered. However, the two approaches led to screening recommendations 
associated with similar numbers of colonoscopies per LY gained: Screening with 
colonoscopy as recommended by the USPSTF (that is, at ages 50, 60, and 70 years) 
required 30 to 35 colonoscopies per LY gained.204 Also, screening with colonoscopy 
in unscreened persons aged 83 years with no comorbid conditions, for example, 
required 32 colonoscopies per LY gained.
Our study has two main limitations. First, we did not perform separate analyses 
by sex and race. However, we do not expect that results from such analyses would 
have differed much from the results presented in this paper because a substantial 
part of the difference in life expectancy between men and women and between 
blacks and whites is explained by differences in the prevalence of moderate and 
severe comorbid conditions. Also, persons with the most favorable life expectancy 
(that is, white females) are at lowest risk for CRC and vice versa. Hence, the effect 
of life expectancy on the cost-effectiveness of screening is counterbalanced by the 
effect of CRC risk (at least partially).320 Second, we did not perform separate analyses 
for identifiable high-risk subgroups, such as elderly persons with a family history of 
CRC.321 In some of these subgroups, screening may be cost-effective up to a more 
advanced age.
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Our analysis highlights some future research directions. First, future research 
should determine the optimal number of FIT screenings in elderly persons who 
are relatively young and not willing to have a screening colonoscopy or sigmoidos-
copy. Second, other research should study how the benefits, burden, and harms of 
screening affect patient decisions about CRC screening. Third, studies evaluating the 
appropriate age to stop screening by comorbid condition level are also required for 
adequately screened persons.
In conclusion, our study demonstrates that in the 23% of U.S. elderly persons 
without previous screening, CRC screening should be considered well beyond age 
75 years. In unscreened elderly persons with no comorbid conditions, CRC screening 
should be considered up to age 86 years (up to age 83 years for those with moderate 
comorbid conditions and up to age 80 years for those with severe comorbid condi-
tions). Screening with colonoscopy is indicated at most ages.
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Supplementary Table 10.1 Test Characteristics of Colonoscopy, Sigmoidoscopy, and FIT
Test Characteristic Test
Colonoscopy Sigmoidoscopy FIT
Specificity,	% 90 a 92 a 98 b
Sensitivity, %
Small	adenomas	(≤5	mm) 75 c 75 c 0 b
Medium-sized	adenomas	(6–9	mm) 85 c 85 c 5 b
Large	adenomas	(≥10	mm) 95 c 95 c 26 b
CRCs that would not have been clinically 
detected in their current stage
95 c 95 c 41 b
CRCs that would have been clinically detected 
in their current stage
95 c 95 c 77 b
Reach 95% cecum 6%	splenic	flexure	d
88% sigmoid-
descending	flexure
-
Complication rate
Positive result Increases exponentially with 
age (0.002-0.048 for 76-90 y) e
0 0
Negative result 0 0 0
Mortality rate
Positive result 0.033/1000 f 0 0
Negative result 0 0 0
Abbreviations: CRC = colorectal cancer; FIT = fecal immunochemical test.
a We assumed that in 10% of all negative colonoscopy results and in 8% of all negative sigmoid-
oscopy results a non-adenomatous lesion was detected, resulting in a polypectomy or a biopsy, 
respectively.
b The sensitivity of colonoscopy and sigmoidoscopy for the detection of adenomas and CRC within 
the reach of the endoscope was obtained from a systematic review on miss rates seen in tandem 
colonoscopy studies.163
c	The	test	characteristics	of	FIT	were	fitted	to	the	positivity	rates	and	detection	rates	seen	in	the	first	
screening round of the Dutch screening trial. We assumed that the probability that a CRC bleeds and 
thus the sensitivity of FIT for CRC depends on the time until clinical diagnosis, in concordance with 
our	findings	for	guaiac	fecal	occult	blood	test.190
d The reach of sigmoidoscopy was obtained from a study by Painter et al.322
e	Age-specific	risks	for	complications	of	colonoscopy	requiring	a	hospital	admission	or	emergency	
department visit were obtained from a study by Warren et al.271
f The mortality rate associated with colonoscopies with a polypectomy was derived by multiplying the 
risk for a perforation obtained from a study by Warren et al271 by the risk for death given a perforation 
obtained from a study by Gatto et al.272
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Supplementary Table 10.2 Effects	of	1-Time	Colonoscopy	Screening	 in	Persons	Aged	76	Years	
Without Previous Screening With No Comorbid Conditions a
Effect Screening No Screening Screening	−	
No Screening 
b
Effects	on	health	care	use,	n
Colonoscopies
Screening with polypectomy/biopsy 461 0 461
Screening without polypectomy/biopsy 539 0 539
Surveillance with polypectomy/biopsy 219 0 219
Surveillance without polypectomy/biopsy 370 0 370
Complications of colonoscopy 16.2 0 16.2
LYs with initial CRC care c
Stage I 11.5 6.4 5.1
Stage II 8.0 12.4 −4.4
Stage III 5.1 7.3 −2.2
Stage IV 0.7 2.9 −2.2
LYs with continuing CRC care
Stage I 92.8 34.9 57.9
Stage II 60.0 61.6 −1.6
Stage III 33.9 30.7 3.2 d
Stage IV 1.5 5.2 −3.7
LYs with terminal care, ending in CRC death
Stage I 0.5 0.7 −0.2
Stage II 1.0 2.6 −1.6
Stage III 1.5 3.2 −1.8
Stage IV 1.1 5.8 −4.7
LYs with terminal care, ending in other-cause death
Stage I 8.3 5.1 3.2
Stage II 5.4 9.3 −4.1
Stage III 2.9 4.6 −1.7
Stage IV 0.2 1.0 −0.8
Effects	on	health
CRC cases, n 27.9 43.4 −15.5
CRC deaths, n 4.5 16.4 −11.9
LYs lost due to CRC, n 32.5 100.9 −68.4	e
Utility losses, QALYs
Screening colonoscopies 5.5 0 5.5
Surveillance colonoscopies 3.2 0 3.2
Complications of colonoscopy 0.6 0 0.6
LYs with CRC care 25.7 33.8 −8.1
Total 35.1 33.8 1.3
QALYs lost (LYs lost due to CRC + total utility loss), n 67.5 134.7 −67.2	f
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Supplementary Table 10.2 Effects	of	1-Time	Colonoscopy	Screening	in	Persons	Aged	76	Years	
Without Previous Screening With No Comorbid Conditions a (Continued)
Effect Screening No Screening Screening	−	
No Screening 
b
Effects	on	costs	(thousands),	$
Screening colonoscopy 983 0 983
Surveillance colonoscopy 569 0 569
Complications of colonoscopy 98 0 98
LYs with CRC care 2404 3329 −925
Total 4054 3329 725 g
Abbreviations: CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year.
a	Results	per	1000	persons,	discounted	at	3%	per	year.	Persons	are	classified	as	having	no	comor-
bid conditions if none of the following conditions are present: an ulcer, a history of acute myocardial 
infarction, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, cerebrovascular 
disease, constructive obstructive pulmonary disease, congestive heart failure, moderate or severe 
liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS.
b Discrepancies between columns may occur due to rounding.
c Because screening results in prevention and earlier detection of CRC, it reduces the total numbers 
of LYs with initial care for CRC, terminal care for CRC, and terminal care for other causes in patients 
with CRC; however, because screening improves the average survival of patients with CRC, it in-
creases the total number of LYs with continuing care for CRC.
d The increase in LYs with continuing care for stage III CRC is explained by the more favorable 
average survival that we model for screen-detected vs. clinically detected cancer as described in 
Chapter 2.
e The number of LYs gained by screening (Table 10.2).
f The number of QALYs gained by screening (Table 10.2).
g The costs of screening (Table 10.1).
202 Chapter 10 Should colorectal cancer screening be considered in elderly persons without previous screening? 203
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
0.
3 
E
ffe
ct
iv
en
es
s	
of
	1
-T
im
e	
C
ol
on
os
co
py
,	S
ig
m
oi
do
sc
op
y,
	a
nd
	F
IT
	S
cr
ee
ni
ng
	in
	E
ld
er
ly
	P
er
so
ns
	W
ith
ou
t	P
re
vi
ou
s	
S
cr
ee
ni
ng
	W
ith
	
M
od
er
at
e 
an
d 
S
ev
er
e 
C
om
or
bi
d 
C
on
di
tio
ns
 a
S
cr
ee
ni
ng
 S
tra
te
gy
, b
y 
C
om
or
bi
di
ty
 L
ev
el
C
R
C
 C
as
es
 
P
re
ve
nt
ed
, n
C
R
C
 D
ea
th
s 
P
re
ve
nt
ed
, n
LY
s 
G
ai
ne
d,
 
nb
E
ffe
ct
	o
n	
Q
ua
lit
y	
of
	L
ife
,	Q
A
LY
sc
Q
A
LY
s 
G
ai
ne
d,
 n
d
S
cr
ee
ni
ng
 
Te
st
s
D
ia
gn
os
tic
 
E
xa
m
s
S
ur
ve
ill
an
ce
 
E
xa
m
s
C
om
pl
ic
at
io
ns
LY
s 
W
ith
 
C
R
C
 C
ar
e 
e
M
od
er
at
e 
co
m
or
bi
di
ty
1-
tim
e 
C
O
L
76
 y
9.
0
46
.3
−5
.5
0
−2
.6
−0
.6
+3
.8
41
.4
80
 y
8.
1
35
.2
−5
.5
0
−2
.2
−0
.7
0.
0
26
.8
85
 y
5.
6
18
.9
−5
.5
0
−1
.6
−0
.8
−4
.2
6.
8
90
 y
3.
5
8.
8
−5
.5
0
−1
.1
−1
.0
−6
.1
−4
.8
1-
tim
e 
FS
IG
76
 y
7.
2
36
.9
−2
.7
−1
.6
−1
.8
−0
.4
+2
.9
33
.4
80
 y
6.
6
28
.7
−2
.7
−1
.7
−1
.6
−0
.4
−0
.1
22
.2
85
 y
4.
6
15
.4
−2
.7
−1
.7
−1
.1
−0
.5
−3
.4
5.
9
90
 y
2.
9
7.
1
−2
.7
−1
.6
−0
.7
−0
.6
−4
.9
−3
.5
1-
tim
e 
FI
T
76
 y
3.
3
17
.9
0
−0
.4
−0
.4
−0
.1
−1
.5
15
.6
80
 y
3.
4
15
.4
0
−0
.4
−0
.4
−0
.1
−2
.8
11
.7
85
 y
2.
7
9.
4
0
−0
.5
−0
.3
−0
.1
−4
.0
4.
6
90
 y
1.
9
4.
8
0
−0
.5
−0
.2
−0
.2
−4
.4
−0
.5
Se
ve
re
 c
om
or
bi
di
ty
1-
tim
e 
C
O
L
76
 y
2.
6
6.
7
32
.3
−5
.5
0
−2
.0
−0
.5
+1
.4
25
.7
80
 y
−2
.2
5.
9
23
.3
−5
.5
0
−1
.6
−0
.6
−1
.7
13
.9
85
 y
−9
.4
4.
0
12
.2
−5
.5
0
−1
.1
−0
.8
−4
.5
0.
4
90
 y
−1
4.
6
2.
6
5.
8
−5
.5
0
−0
.7
−1
.0
−5
.7
−7
.1
202 Chapter 10 Should colorectal cancer screening be considered in elderly persons without previous screening? 203
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
0.
3 
E
ffe
ct
iv
en
es
s	
of
	1
-T
im
e	
C
ol
on
os
co
py
,	S
ig
m
oi
do
sc
op
y,
	a
nd
	F
IT
	S
cr
ee
ni
ng
	in
	E
ld
er
ly
	P
er
so
ns
	W
ith
ou
t	P
re
vi
ou
s	
S
cr
ee
ni
ng
	W
ith
	
M
od
er
at
e 
an
d 
S
ev
er
e 
C
om
or
bi
d 
C
on
di
tio
ns
 a  
(c
on
tin
ue
d)
S
cr
ee
ni
ng
 S
tra
te
gy
, b
y 
C
om
or
bi
di
ty
 L
ev
el
C
R
C
 C
as
es
 
P
re
ve
nt
ed
, n
C
R
C
 D
ea
th
s 
P
re
ve
nt
ed
, n
LY
s 
G
ai
ne
d,
 
nb
E
ffe
ct
	o
n	
Q
ua
lit
y	
of
	L
ife
,	Q
A
LY
sc
Q
A
LY
s 
G
ai
ne
d,
 n
d
S
cr
ee
ni
ng
 
Te
st
s
D
ia
gn
os
tic
 
E
xa
m
s
S
ur
ve
ill
an
ce
 
E
xa
m
s
C
om
pl
ic
at
io
ns
LY
s 
W
ith
 
C
R
C
 C
ar
e 
e
1-
tim
e 
FS
IG
76
 y
2.
0
5.
3
25
.8
−2
.7
−1
.6
−1
.4
−0
.3
+1
.1
20
.8
80
 y
−1
.9
4.
8
19
.0
−2
.7
−1
.7
−1
.2
−0
.4
−1
.4
11
.6
85
 y
−7
.6
3.
3
10
.0
−2
.7
−1
.7
−0
.8
−0
.5
−3
.6
0.
6
90
 y
−1
1.
7
2.
1
4.
6
−2
.7
−1
.6
−0
.5
−0
.6
−4
.5
−5
.4
1-
tim
e 
FI
T
76
 y
−2
.2
2.
5
12
.7
0
−0
.4
−0
.3
−0
.1
−1
.8
10
.1
80
 y
−4
.2
2.
5
10
.4
0
−0
.4
−0
.3
−0
.1
−2
.9
6.
7
85
 y
−7
.1
2.
0
6.
2
0
−0
.5
−0
.2
−0
.1
−3
.7
1.
7
90
 y
−9
.5
1.
4
3.
2
0
−0
.5
−0
.1
−0
.2
−4
.0
−1
.7
A
bb
re
vi
at
io
ns
:	C
R
C
	=
	c
ol
or
ec
ta
l	c
an
ce
r;	
C
O
L	
=	
co
lo
no
sc
op
y;
	F
S
IG
	=
	fl
ex
ib
le
	s
ig
m
oi
do
sc
op
y;
	F
IT
	=
	fe
ca
l	i
m
m
un
oc
he
m
ic
al
	te
st
;	L
Y
	=
	li
fe
-y
ea
r;	
Q
A
LY
	=
	q
ua
lit
y-
ad
ju
st
ed
 li
fe
-y
ea
r.
a 	R
es
ul
ts
	a
re
	b
as
ed
	o
n	
a	
co
m
pa
ris
on
	w
ith
	n
o	
sc
re
en
in
g,
	g
iv
en
	p
er
	1
00
0	
pe
rs
on
s,
	a
nd
	d
is
co
un
te
d	
by
	3
%
	p
er
	y
ea
r.	
P
er
so
ns
	a
re
	c
la
ss
ifi
ed
	a
s	
ha
vi
ng
	m
od
er
at
e	
co
m
or
bi
d 
co
nd
iti
on
s 
if 
th
ey
 h
av
e 
an
 u
lc
er
, r
he
um
at
ol
og
ic
 d
is
ea
se
, p
er
ip
he
ra
l v
as
cu
la
r d
is
ea
se
, d
ia
be
te
s,
 p
ar
al
ys
is
, o
r c
er
eb
ro
va
sc
ul
ar
 d
is
ea
se
 a
nd
 in
 c
as
e 
of
 
a 
hi
st
or
y 
of
 a
cu
te
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n 
an
d 
as
 h
av
in
g 
se
ve
re
 c
om
or
bi
d 
co
nd
iti
on
s 
if 
th
ey
 h
av
e 
ch
ro
ni
c 
ob
st
ru
ct
iv
e 
pu
lm
on
ar
y 
di
se
as
e,
 c
on
ge
st
iv
e 
he
ar
t f
ai
lu
re
, 
m
od
er
at
e 
or
 s
ev
er
e 
liv
er
 d
is
ea
se
, c
hr
on
ic
 re
na
l f
ai
lu
re
, d
em
en
tia
, c
irr
ho
si
s 
an
d 
ch
ro
ni
c 
he
pa
tit
is
, o
r A
ID
S
. N
eg
at
iv
e 
va
lu
es
 o
cc
ur
 w
he
n 
th
e 
nu
m
be
r o
f C
R
C
 
ca
se
s 
pr
ev
en
te
d 
by
 s
cr
ee
ni
ng
 is
 e
xc
ee
de
d 
by
 th
e 
nu
m
be
r o
f C
R
C
 c
as
es
 o
ve
rd
ia
gn
os
ed
 b
y 
sc
re
en
in
g.
b  T
he
 e
ffe
ct
 o
f s
cr
ee
ni
ng
 o
n 
qu
an
tit
y 
of
 li
fe
.
c  T
he
 e
ffe
ct
 o
f t
he
 s
cr
ee
ni
ng
 te
st
, d
ia
gn
os
tic
 c
ol
on
os
co
pi
es
, s
ur
ve
ill
an
ce
 c
ol
on
os
co
pi
es
, c
om
pl
ic
at
io
ns
, a
nd
 L
Y
s 
w
ith
 C
R
C
 c
ar
e 
on
 q
ua
lit
y 
of
 li
fe
. V
al
ue
s 
ar
e 
de
riv
ed
 b
y 
m
ul
tip
ly
in
g 
nu
m
be
r(
s)
 o
f e
ve
nt
s 
w
ith
 th
e 
co
rr
es
po
nd
in
g 
ut
ili
ty
 lo
ss
(e
s)
 p
er
 e
ve
nt
 s
ta
te
d 
in
 T
ab
le
 1
0.
1.
 A
n 
ex
am
pl
e:
 W
he
n 
ap
pl
yi
ng
 th
e 
1-
tim
e 
co
lo
-
no
sc
op
y 
sc
re
en
in
g 
st
ra
te
gy
, 1
00
0 
pe
rs
on
s 
ha
ve
 a
 s
cr
ee
ni
ng
 c
ol
on
os
co
py
 in
 e
ac
h 
co
ho
rt.
 B
ec
au
se
 th
e 
ut
ili
ty
 lo
ss
 p
er
 s
cr
ee
ni
ng
 c
ol
on
os
co
py
 is
 0
.0
05
5 
Q
A
LY
s,
 
th
e 
to
ta
l u
til
ity
 lo
ss
 d
ue
 to
 s
cr
ee
ni
ng
 c
ol
on
os
co
pi
es
 is
 5
.5
 Q
A
LY
s 
in
 e
ac
h 
co
ho
rt.
d 	
Th
e	
ef
fe
ct
	o
f	s
cr
ee
ni
ng
	o
n	
qu
an
tit
y	
an
d	
qu
al
ity
	o
f	l
ife
	in
co
rp
or
at
ed
	in
	1
	m
ea
su
re
	(
i.e
.,	
th
e	
ne
t	h
ea
lth
	b
en
efi
t	o
f	s
cr
ee
ni
ng
),	
ca
lc
ul
at
ed
	b
y	
ad
di
ng
	L
Y
s	
ga
in
ed
	
an
d 
al
l e
ffe
ct
s 
on
 q
ua
lit
y 
of
 li
fe
. D
is
cr
ep
an
ci
es
 b
et
w
ee
n 
th
e 
co
lu
m
ns
 m
ay
 o
cc
ur
 d
ue
 to
 ro
un
di
ng
.
e  S
cr
ee
ni
ng
 re
su
lts
 in
 a
 g
ai
n 
of
 q
ua
lit
y 
of
 li
fe
 b
y 
pr
ev
en
tin
g 
LY
s 
w
ith
 C
R
C
 c
ar
e 
an
d 
a 
lo
ss
 o
f q
ua
lit
y 
of
 li
fe
 b
y 
ad
di
ng
 L
Y
s 
w
ith
 C
R
C
 c
ar
e.
 T
he
 n
et
 e
ffe
ct
 c
an
 b
e 
a 
ga
in
 o
f q
ua
lit
y 
of
 li
fe
 (p
os
iti
ve
 v
al
ue
s)
 o
r a
 lo
ss
 o
f q
ua
lit
y 
of
 li
fe
 (n
eg
at
iv
e 
va
lu
es
). 
A
s 
a 
re
su
lt 
of
 th
e 
sh
ift
 fr
om
 p
re
ve
nt
in
g 
to
 o
ve
rd
ia
gn
os
in
g 
C
R
C
 w
ith
 in
cr
ea
si
ng
 
ag
e,
 th
e 
ne
t e
ffe
ct
 o
n 
qu
al
ity
 o
f l
ife
 b
ec
om
es
 le
ss
 fa
vo
ra
bl
e 
w
ith
 a
ge
.
204 Chapter 10
Supplementary Table 10.4 Costs of 1-Time Colonoscopy, Sigmoidoscopy, and FIT Screening in 
Elderly	Persons	Without	Previous	Screening	With	Moderate	and	Severe	Comorbid	Conditions	a
Screening Strategy, Cost (Thousands), $
by Comorbidity Level Screening 
Tests b
Diagnostic 
Exams
Surveillance 
Exams
Compli-
cations
LYs With 
CRC Care c
Total d
Moderate comorb.
1-time COL
76 y 983 0 462 90 −434 1102
80 y 987 0 388 106 −57 1425
85 y 987 0 278 131 502 1898
90 y 986 0 185 161 838 2170
1-time FSIG
76 y 387 309 323 58 −336 742
80 y 392 331 278 69 −41 1029
85 y 392 330 199 84 409 1414
90 y 390 323 132 100 673 1618
1-time FIT
76 y 42 80 72 13 116 324
80 y 42 87 63 16 252 460
85 y 42 93 50 22 448 655
90 y 42 98 36 28 578 782
Severe comorb.
1-time COL
76 y 983 0 354 83 −91 1329
80 y 987 0 288 99 250 1625
85 y 987 0 199 123 658 1967
90 y 986 0 131 154 868 2139
1-time FSIG
76 y 387 309 248 52 −67 930
80 y 392 331 206 63 207 1200
85 y 392 330 143 77 534 1477
90 y 390 323 94 95 698 1600
1-time FIT
76 y 42 80 56 12 204 395
80 y 42 87 47 15 337 528
85 y 42 93 36 20 493 685
90 y 42 98 26 27 576 769
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Abbreviations:	CRC	=	colorectal	cancer;	COL	=	colonoscopy;	FSIG	=	flexible	sigmoidoscopy;	FIT	=	
fecal immunochemical test; LY = life-year, comorb. = comorbidity.
a Results are based on a comparison with no screening, given per 1000 persons, and discounted by 
3%	per	year.	Persons	are	classified	as	having	moderate	comorbid	conditions	if	they	have	an	ulcer,	
rheumatologic disease, peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease 
and in case of a history of acute myocardial infarction and as having severe comorbid conditions if 
they have chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver 
disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS.
b At very advanced age, the costs of screening colonoscopies and sigmoidoscopies show a slight 
decline. This is explained by the small observed decrease in the prevalence of adenomas at very 
advanced age.
c Screening prevents costs by preventing LYs with CRC care and induces costs by adding LYs with 
CRC care. The net effect can be an increase in costs (positive values) or a decrease in costs (nega-
tive values).
d Discrepancies between the columns may occur due to rounding.
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Supplementary Table 10.5 ICERs	of	the	Efficient	Screening	Strategies	in	Elderly	Persons	Without	
Previous Screening by Comorbid Condition Level a
Screening Strategy, 
by Comorbidity 
Level and Age b
QALYs 
Gained. 
Nc
Incremental 
QALYs 
Gained, d
Cost 
(Thousands), 
$c
Incremental Cost 
(Thousands), $d
ICER	
(Thousands), 
$/QALY e
Optimal 
Screening 
Strategf
No comorbidity
76 yg
FSIG 53.9 53.9 439 439 8
COL 67.2 13.3 725 285 21 X
77 yg
FSIG 50.3 50.3 503 503 10
COL 62.3 12.1 799 296 24 X
78 yg
FSIG 46.2 46.2 588 588 13
COL 57.1 10.9 898 310 28 X
79 y
FIT 20.5 20.5 313 313 15
FSIG 42.5 22.0 673 360 16
COL 52.1 9.6 998 325 34 X
80 y
FIT 19.2 19.2 355 355 18
FSIG 38.6 19.4 764 409 21
COL 46.9 8.4 1102 338 40 X
81 y
FIT 16.6 16.6 398 398 24
FSIG 32.1 15.5 878 480 31
COL 39.0 7.0 1244 366 52 X
82 y
FIT 14.8 14.8 444 444 30
FSIG 27.5 12.7 976 532 42
COL 33.3 5.8 1365 390 67 X
83 y
FIT 12.9 12.9 488 488 38
FSIG 22.8 9.9 1076 588 59
COL 27.4 4.7 1490 414 88 X
84 y
FIT 11.0 11.0 535 535 49
FSIG 18.3 7.3 1171 636 87 X
COL 22.0 3.7 1608 437 118
85 y
FIT 9.0 9.0 577 577 64 X
FSIG 14.3 5.3 1251 674 127
COL 17.1 2.7 1705 454 168
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Supplementary Table 10.5 ICERs	of	the	Efficient	Screening	Strategies	in	Elderly	Persons	Without	
Previous Screening by Comorbid Condition Level a (continued)
Screening Strategy, 
by Comorbidity 
Level and Age b
QALYs 
Gained. 
Nc
Incremental 
QALYs 
Gained, d
Cost 
(Thousands), 
$c
Incremental Cost 
(Thousands), $d
ICER	
(Thousands), 
$/QALY e
Optimal 
Screening 
Strategf
86 y
FIT 7.2 7.2 619 619 86 X
FSIG 10.7 3.4 1332 714 210
COL 12.5 1.8 1810 478 266
Moderate comorbidity
76 y
FIT 15.6 15.6 324 324 21
FSIG 33.4 17.8 742 418 23
COL 41.4 8.0 1102 361 45 X
77 y
FIT 15.0 15.0 347 347 23
FSIG 31.6 16.6 789 443 27
COL 38.9 7.4 1153 363 49 X
78 y
FIT 13.5 13.5 387 387 29
FSIG 27.3 13.8 885 497 36
COL 33.5 6.2 1262 377 61 X
79 y
FIT 12.4 12.4 426 426 34
FSIG 24.3 11.9 966 540 45
COL 29.5 5.2 1356 390 75 X
80 y
FIT 11.7 11.7 460 460 39
FSIG 22.2 10.5 1029 569 54
COL 26.8 4.6 1425 396 86 X
81 y
FIT 9.9 9.9 500 500 51
FSIG 17.8 7.9 1121 621 79 X
COL 21.5 3.7 1537 416 112
82 y
FIT 8.6 8.6 542 542 63 X
FSIG 14.7 6.1 1204 662 109
COL 17.6 2.8 1638 434 155
83 y
FIT 7.0 7.0 583 583 83 X
FSIG 11.0 4.1 1290 707 172
COL 13.0 2.0 1744 453 227
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Supplementary Table 10.5 ICERs	of	the	Efficient	Screening	Strategies	in	Elderly	Persons	Without	
Previous Screening by Comorbid Condition Level a (continued)
Screening Strategy, 
by Comorbidity 
Level and Age b
QALYs 
Gained. 
Nc
Incremental 
QALYs 
Gained, d
Cost 
(Thousands), 
$c
Incremental Cost 
(Thousands), $d
ICER	
(Thousands), 
$/QALY e
Optimal 
Screening 
Strategf
Severe comorbidity
76 y
FIT 10.1 10.1 395 395 39
FSIG 20.8 10.8 930 535 50
COL 25.7 4.8 1329 399 83 X
77 y
FIT 9.1 9.1 425 425 47
FSIG 18.2 9.1 995 571 63
COL 22.4 4.1 1400 404 99 X
78 y
FIT 8.1 8.1 460 460 57
FSIG 15.3 7.2 1071 611 85 X
COL 18.6 3.3 1483 412 125
79 y
FIT 7.4 7.4 493 493 67 X
FSIG 13.6 6.1 1134 640 105
COL 16.4 2.8 1554 420 150
80 y
FIT 6.7 6.7 528 528 79 X
FSIG 11.6 4.8 1200 672 140
COL 13.9 2.3 1625 424 184
Abbreviations:	FIT	=	fecal	immunochemical	test;	FSIG	=	flexible	sigmoidoscopy;	COL	=	colonoscopy;	
LY	=	life-year;	ICER	=	incremental	cost-effectiveness	ratio;	QALY	=	quality-adjusted	life-year.
a QALYs gained and costs per 1000 persons, discounted at 3% per year. Results are also displayed 
in Figure 10.2.	Persons	are	classified	as	having	moderate	comorbid	conditions	if	they	have	an	ulcer,	
rheumatologic disease, peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease 
and in case of a history of acute myocardial infarction; as having severe comorbid conditions if 
they have chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver 
disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and as having no 
comorbid conditions if none of these conditions are present. In elderly persons without previous 
screening with no, moderate, and severe comorbid conditions, none of the screening strategies are 
cost-effective from age 87, 84, and 81 y onwards, respectively (Figure 10.1).
b All screening strategies consist of a 1-time screening examination followed by diagnostic and sur-
veillance colonoscopies if indicated.
c Compared with no screening.
d	Compared	with	 the	next	 less	effective	and	efficient	 strategy,	which	 is	 no	 screening	 for	 the	 first	
screening strategy mentioned at each age.
e Incremental cost per incremental QALY gained.
f The most effective, still cost-effective screening strategy based on a threshold for the willingness to 
pay per QALY gained of $100 000.
g In elderly persons without previous screening with no comorbid conditions aged 76 to 78 y, FIT 
screening is dominated by a combination of sigmoidoscopy screening and no screening (Figure 
10.2).
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aBstract
IMPORTANCE: A substantial amount of endoscopic resources are devoted to surveil-
lance of patients with colorectal adenomas, while there is limited direct evidence to 
support current practice. The European Polyp Surveillance (EPoS) study is planned 
to evaluate currently recommended surveillance, but results are not expected for 
>10 years.
OBJECTIVE: To simulate lifetime colorectal cancer benefits and costs of currently 
recommended surveillance compared to less intensive surveillance or screening
DESIGN: Microsimulation screening analysis (MISCAN) model validated for surveil-
lance evaluation
SETTING: Simulated U.S. population cohort
PARTICIPANTS: 50 year-old patients with adenomas detected through colonoscopy 
or fecal immunochemical test (FIT) screening
EXPOSURES: Patients with 1-2 small tubular adenomas (low-risk adenoma, LRA) 
were simulated to receive colonoscopy after 5 or 10 years; patients with 3-10 small 
tubular or ≥1 advanced adenomas (high-risk adenoma, HRA) received colonoscopy 
after 3 or 5 years. Reference outcomes were those of continued screening with 
colonoscopy or FIT.
MAIN OUTCOMES: Estimated lifetime colorectal cancer mortality; life-years and cost 
per life-year gained, discounted at 3% per year.
RESULTS: For adenoma patients identified through colonoscopy screening, contin-
ued screening was associated with an estimated lifetime colorectal cancer mortality 
risk of 18.8 per 1000 for patients with LRA, and 31.0 per 1000 for patients with HRA. 
Low-intensity colonoscopy surveillance was associated with decreased mortality risks 
of 15.7 and 22.8 per 1000, respectively (life-years gained 6 and 30 per 1000; cost/
life-year US$ 4856 and 5752). High-intensity surveillance was associated with further 
decreased risks of 11.7 and 18.2 (life-years gained 26 and 58; incremental cost/
life-year US$ 19,754 and 9125). In adenoma patients identified through FIT, baseline 
risks with continued screening were higher, however, surveillance outcomes were 
similar.
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CONCLUSIONS: Microsimulation modeling suggests that currently recommended 
surveillance is highly effective and cost-effective in the long run compared to less 
intensive surveillance strategies. Evidence from the EPoS trial is needed to inform 
practice on more intermediate term effects, and for validation of long-term model 
projections.
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introDuction
There is wide consensus across different societies regarding the merits of screening 
of average-risk patients aged 50-75 years.114,115,246 Less clarity exists on the appro-
priate management of patients with removed adenomas. Although European and 
American guidelines largely agree on risk classifications of adenoma patients and 
recommended intervals for repeat examination,323 there are surprisingly little cancer 
outcome data to support these recommendations. Long-term follow-up data from 
the National Polyp Study suggests that colonoscopy surveillance may reduce mortal-
ity by 50% compared to mortality in the general population.193 However, concerns 
have been raised that intensive surveillance may no longer be cost-effective with 
improvements in the quality of colonoscopy.141 Some cost-effectiveness models 
have suggested that currently recommended surveillance for patients with low-risk 
adenomas may overuse resources.324,325 The European Polyp Surveillance (EPoS) trial 
is planned to study the question of appropriate surveillance of patients with resected 
adenomas, but results are not expected for more than a decade.146
To inform policy makers on the appropriate intensity of surveillance in patients 
with low-risk adenoma (LRA) and high-risk adenoma (HRA) surveillances, we used 
an established microsimulation model to estimate benefits and costs associated with 
currently recommended surveillance versus less intensive surveillance strategies.
metHoDs
The MISCAN-Colon model (chapter 2) was used to evaluate screening and sur-
veillance intervention strategies in a virtual population similar to the United States 
in terms of life expectancy and colorectal cancer risk. We defined findings of 1-2 
small (1-9mm) adenomas during screening as LRA, 3-10 small adenomas or ≥1 larger 
adenoma as HRA, and advanced adenomas as lesions >9mm in diameter, with >25% 
villous component, or with high-grade dysplasia. We did not model histological 
adenoma features, only size and multiplicity.
effectiveness of screening and surveillance
The effects of screening and surveillance for colorectal cancer follow from the mod-
el’s natural history assumptions and the test’s assumed ability to detect and remove 
precursor adenomas and cancer (see Chapter 9 for test performance assumptions). 
Modeled effects of fecal immunochemical test (FIT) and colonoscopy screening have 
been shown to be consistent with observational data.105,107 Overall estimated 20-year 
colorectal cancer mortality risk during surveillance is concordant with National Polyp 
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Study data (Figure 2.6).326 For the present study, we also compared modeled rates of 
adenoma detection in surveillance to reported rates from the literature (supplemen-
tary Figure 11.1-4, supplementary table 11.1). In addition to our default model 
for the United States, we evaluated three alternative model variants.  
The default model was consistent with observed adenoma detection rates (ADRs) 
for patients with LRA and HRA,54,327,328 and with advanced adenoma detection rates 
(A-ADRs) for patients with LRA,54,55,142,327,328 but underestimated the A-ADR for HRA 
patients.54,55,327-329 Alternative models with assumed higher adenoma miss rates or 
adenoma growth rates matched better with observed A-ADRs for HRA, but overesti-
mated A-ADRs in LRA patients. Main study outcomes (described below) are reported 
for the default model, as well as two of the alternative models (as sensitivity analyses).
risk of complications
Assumed age-specific complication risks for colonoscopy use were based on pub-
lished literature.271,272 Overall complication rates increased exponentially from 4.1 per 
1000 for age 50 years to 146.1 per 1000 for age 100 years.
screening and treatment cost assumptions
Screening, complication, and treatment costs were approximated using 2007 or 
older Medicare payment and co-payment rates (treatment cost data were from 1998-
2003),152,277,278 and included patient time valued at median US wage.279 Costs were 
updated to 2015 using the general consumer price index.279
outcomes
The main study outcomes were lifetime colorectal cancer mortality, life-years, and 
cost per life-year gained, according to baseline adenoma risk category and primary 
screening method. Life-years and costs were discounted at the conventional annual 
rate of 3%.38 We defined costs per life-years of <US $50,000 as very cost-effective, 
and ratios exceeding US $100,000 as not cost-effective. Other outcomes reported 
include cancer incidence and the endoscopy resources used for surveillance and 
screening.
analysis
We simulated 10 million men and women born Jan 1st 1965. Patients were screened 
at age 50 years with either colonoscopy or FIT as the primary test. For the main 
analysis, we included patients with adenomas detected in screening, which we 
classified as LRA or HRA according to above definitions. For each risk class, we 
evaluated a less and more intensive scenario for colonoscopy surveillance analogous 
to the strategies planned for evaluation in the EPoS study: LRA patients received 
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examination at 5 or 10 years; HRA patients were examined at 3 or 5 years. Successive 
surveillance intervals were determined based on the latest findings and – in case of 
a negative findings – findings during previous examinations (supplementary table 
11.1). Surveillance was continued up to the first of several events: age 85 years, 
diagnosis of cancer, or death. Outcomes were compared across the two scenarios 
and against a scenario in which all patients returned to screening in 10 years after 
the index examination.
sensitivity analysis
Several alternative scenarios to the base-case were evaluated for their influence 
on cost-effectiveness of surveillance: a stopping age for screening of 80 years in-
stead of 75 years; indefinite surveillance up to age 100 years; surveillance of an 
older age-cohort of 70 year olds with and without prior screening; faster assumed 
adenoma growth (no changes in cancer risk); lower assumed colonoscopy quality 
(-10% sensitivity for all lesions); higher assumed colonoscopy quality (98% sensitivity 
for all lesions, and 98% exam completeness); 50% higher endoscopy cost; and, 50% 
lower treatment cost.
results
With colonoscopy screening offered to patients of age 50 years, 2.0 million patients 
(21.9%) had detected adenomas. Of these, 1.6 million patients were classified LRA 
(17.3%), and 0.4 million (4.6%) were HRA. In FIT screening, 453 thousand patients 
(4.8%) had a positive test result at age 50, 167 thousand patients (1.8%) had adeno-
mas detected during follow-up colonoscopy, 93 thousand (1.0%) had LRA, and 74 
thousand (0.8%) had HRA.
cancer outcomes
In LRA patients identified through colonoscopy screening, continued screening was 
associated in the model with a lifetime colorectal cancer risk of 64.4 per 1000, and 
a lifetime cancer mortality risk of 18.8 per 1000 (table 11.1, Figure 11.1, Figure 
11.2). Low-intensity surveillance, decreased cancer incidence and mortality risks to 
59.1 and 15.7 per 1000, respectively, a reduction of 8% and 17% compared to no 
surveillance. High-intensity surveillance further decreased the risks to 48.5 (-25%, 
compared to no surveillance) and 11.7 per 1000 (-38%).
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Figure 11.1a-d CRC incidence among adenoma patients in a colonoscopy (left) and FIT (right) 
screening setting with surveillance.
220 Chapter 11
0
5
10
15
20
25
30
35
0 10 20 30 40 50
No surveillance
Light surveillance
Intense surveillance
LRA patients, COL screening
0
5
10
15
20
25
30
35
0 10 20 30 40 50
LRA patients, FIT screening
0
5
10
15
20
25
30
35
0 10 20 30 40 50
HRA patients, COL screening
0
5
10
15
20
25
30
35
0 10 20 30 40 50
HRA patients, FIT screening
Time from index examination (years)
C
um
ul
at
iv
e 
m
or
ta
lit
y 
pe
r 1
00
0
Figure 11.2a-d CRC mortality among adenoma patients in a colonoscopy (left) and FIT (right) 
screening setting with surveillance.
In LRA patients identified through FIT screening, lifetime cancer incidence and 
mortality risks with continued screening were higher than the estimated risks for 
colonoscopy screening, 91.8 and 24.2 per 1000, respectively (table 11.1, Figure 
11.1, Figure 11.2). Surveillance had stronger outcome effects, with similar esti-
mated risks resulting as were found for colonoscopy screening. With low-intensity 
surveillance, incidence was 73.5 (-20%) and mortality was 19.6 per 1000 (-19%); with 
high-intensity surveillance the risks were 55.4 (-40%) and 13.4 (-45%), respectively.
HRA patients identified through colonoscopy screening had an absolute lifetime 
incidence risk of 104.9 per 1000 with no surveillance, and a mortality risk of 31.0 per 
1000 (table 11.1, Figure 11.1, Figure 11.2). Light-intensity surveillance reduced 
estimated risks to 89.2 (-15%) and 22.8 (-26%) per 1000, respectively, and high-
intensity surveillance further reduced estimated risks to 75.2 (-28%) and 18.2 (-41%) 
per 1000.
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Table 11.1 Simulated effectiveness and cost of surveillance with background colonoscopy and FIT 
screening.
Risk group Outcome
COL screening FIT screening
Survellance intensity Survellance intensity
None Low High None Low High
LRA Incidence 64.4 59.1 48.5 91.8 73.5 55.4
Stage I-II 42.3 40.8 35.4 63.9 50.3 40.3
Stage III-IV 22.1 18.2 13.2 27.9 23.2 15.2
Mortality 18.8 15.7 11.7 24.2 19.6 13.4
LY gained 0 6 26 0 10 41
Colonoscopies 2737 3014 4178 1550 2593 4209
Cost (US$ mln) 5.0 5.1 5.4 5.3 5.6 6.0
Treatment 2.7 2.6 2.1 4.0 3.3 2.6
Endoscopy 2.4 2.5 3.3 1.4 2.3 3.4
ICER 0 4856 19754 0 22469 15811
HRA Incidence 104.9 89.2 75.2 132.2 88.8 76.2
Stage I-II 68.8 63.7 54.9 92.8 62.4 54.4
Stage III-IV 36.1 25.5 20.3 39.4 26.4 21.8
Mortality 31.0 22.8 18.2 34.6 22.5 18.8
LY gained 0 30 58 0 42 68
Colonoscopies 2718 3710 4895 1601 3706 4881
Cost (US$ mln) 6.8 6.9 7.2 7.0 7.1 7.4
Treatment 4.4 3.8 3.2 5.6 3.9 3.3
Endoscopy 2.4 3.1 4.0 1.4 3.1 4.1
ICER 0 5752 9125 0 2891 10791
Abbreviations: LRA = low-risk adenoma; HRA = high-risk adenoma; LY = life-year; mln = million; 
ICER	=	incremental	cost-effectiveness	ratio.
In a FIT-based screening setting, HRA patients again had higher risks than com-
parable patients in a colonoscopy screening setting, and surveillance reduced risks 
to a more comparable level to risks with surveillance in colonoscopy-detected LRA 
patients. Estimated lifetime risk of colorectal cancer was 132.2 per 1000, and lifetime 
mortality risk was 34.6 per 1000 (table 11.1, Figure 11.1, Figure 11.2). Low-
intensity surveillance reduced incidence and mortality already by a third to 88.8 
(-33%) and 22.5 per 1000 (-35%), respectively, and intensive surveillance reduced 
incidence to 76.2 per 1000 (-42%) and mortality by almost half to 18.8 per 1000 
(-46%).
The risk reductions associated with surveillance translated to a gain of 6-10 life-
years with low-intensity surveillance and 26-41 with high-intensity surveillance for 
1000 patients with LRA. For patients with HRA, benefits were larger: 30-42 for low-
intensity surveillance and 58-68 for high-intensity surveillance.
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resources
Colonoscopy screening was associated with a total number 2718-2737 colonoscopies 
per 1000 patients, compared to 1550-1601 with FIT-based screening (table 11.1). 
Low-intensity surveillance increased use of colonoscopy resources to 2593-3014 for 
1000 LRA patients and 3706-3710 per 1000 HRA patients. High-intensity surveillance 
increased colonoscopies to similar amounts for LRA (4178-4209) and HRA patients 
(4881-4895). Relative cost increases from no to intensive surveillance were smaller 
due to high averted cancer treatment costs (table 11.1). For patients with LRA, total 
cost of screening and treatment varied from US$ 5.0-5.3 million with no surveillance 
to US$ 5.4-6.0 million with high-intensity surveillance (8-13% increase). For HRA 
patients, total costs varied even less, from 6.7-6.9 with no surveillance to 7.1-7.3 with 
high-intensity surveillance (6% increase).
cost-effectiveness
Cost-effectiveness ratios were lower in general for HRA patients than LRA patients, 
and varied by primary screening method. For LRA patients, incremental cost-
effectiveness ratios for low- and high-intensity surveillance were US$ 4856-22,469 
and US$ 19,754-15,811, respectively (table 11.1, Figure 11.3). For HRA patients, 
incremental cost-effectiveness ratios for low-intensity surveillance were US$ 2891-
5752, and for high-intensity surveillance ratios varied US$ 9125-10,791.
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Figure 11.3a-d Benefits	and	costs	of	surveillance	among	adenoma	patients	in	a	colonoscopy	(left) 
and FIT (right) screening setting. a
Abbreviations: LRA = low-risk adenoma; HRA = High-risk adenoma.
a The vertical dashed lines represent cost-saving thresholds for surveillance, and the diagonal 
dashed lines represent US $ 100,000 cost per life-year thresholds relative to screening. Screening 
(bottom), low-intensity surveillance (middle), and high-intensity surveillance (top) scenarios are rep-
resented by the black diamonds.
sensitivity analysis
Low- and high-intensity surveillance remained cost-effective for scenarios evaluated 
in sensitivity analyses (table 11.2, supplementary table 11.3). Although relative 
surveillance benefits decreased if screening was extended up to older age (1-33 life-
years gained for LRA patients, and 17-56 for HRA patients), surveillance was initiated 
at an older age (14-38 for LRA, and 34-70 for HRA), large adenoma prevalence was 
increased without changes to overall cancer incidence (8-38 for LRA, and 21-51 for 
HRA), and assumed colonoscopy sensitivity was higher (5-30 for LRA, and 26-61 for 
HRA), estimated incremental cost-effectiveness ratios were nowhere higher than US$ 
67,895.
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Discussion
In regard of the  lack of evidence for long-term effectiveness and cost-effectiveness 
of currently recommended surveillance for patients with colorectal adenomas, we 
validated an established microsimulation screening analysis model to assess benefits 
and costs of various colonoscopy surveillance strategies. The results of our study 
suggest that currently recommended surveillance may be very cost-effective in the 
long term compared to less intensive surveillance or continued screening. These 
findings underscore the appropriateness of current professional guidelines in the 
United States, which recommend examination of patients with low-risk adenomas 
with colonoscopy after 5 years and of patients with high-risk adenomas after 3 years.
Table 11.2 Sensitivity	 analysis	 of	 the	 benefits	 and	 cost	 of	 surveillance	 against	 colonoscopy	
screening.a
Risk 
group analysis
Cost (US$ million) Life-years gained Cost/Life-year (US$)
Surveillance intensity
None Low High None Low High None Low High
LRA Main 5.0 5.1 5.4 0 6 26 - 4856 19754
End	age	screening	(80y) 5.2 5.1 5.4 0 1 17 - -10614 18295
End	age	surveillance	(100y) 5.0 5.1 5.6 0 6 27 - 10127 25117
Older unscreened pts (70y) 2.6 3.0 3.1 0 14 20 - 23636 30799
Older screened pts (70y) 3.1 2.8 2.8 0 31 38 - -8297 -917
Fast adenoma growth b 4.7 4.7 5.1 0 7 22 - 5030 28975
Low quality (-10% sensitivity) 5.4 5.5 5.8 0 7 30 - 5650 15806
High quality (98% sensitivity) 4.4 4.4 4.9 0 5 19 - 6181 33416
High endoscopy cost (+50%) 6.2 6.3 7.1 0 6 26 - 16581 40967
Lower treatment cost (-50%) 3.7 3.8 4.4 0 6 26 - 14153 31090
HRA Main 6.8 6.9 7.2 0 30 58 - 5752 9125
End	age	screening	(80y) 6.8 6.9 7.2 0 17 45 - 6620 9125
End	age	surveillance	(100y) 6.8 7.1 7.4 0 32 62 - 10536 9310
Older unscreened pts (70y) 3.9 4.1 4.3 0 34 49 - 4040 19542
Older screened pts (70y) 4.7 3.3 3.7 0 48 59 - -28960 38424
Fast adenoma growth b 5.6 5.8 6.2 0 21 39 - 13660 21897
Low quality (-10% sensitivity) 7.2 7.4 7.7 0 34 64 - 5379 7364
High quality (98% sensitivity) 6.1 6.2 6.6 0 26 50 - 6087 14741
High endoscopy cost (+50%) 8.0 8.5 9.2 0 30 58 - 17939 25526
Lower treatment cost (-50%) 4.6 5.0 5.6 0 30 58 - 15063 20964
Abbreviations: LRA = low-risk adenoma; HRA = high-risk adenoma; pts = patients.
a Costs and life-years presented are per 1000 patients. Results for FIT screening are in Supplemen-
tary Table 11.3.
b We assumed a longer mean duration from adenoma onset to large adenoma size, but similar over-
all adenoma dwell time.
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In our study, patients with adenomas had high estimated risks of developing 
cancer compared to the general population in the United States: 6-9% for patients 
with LRA and 10-13% for patients with HRA without surveillance, versus 4.5% for an 
average individual.330 Surveillance was estimated to decrease absolute risks by up to 
3% compared to colonoscopy screening, and by up to 5.6% compared to FIT-based 
screening. Corresponding benefits in terms of life-years gained were maximum 68 
per 1000 patients with discounting (162 without discounting), which is substantial 
in comparison with other health care interventions.29 In contrast, the increase in the 
cost of care was only modest, with no more than 13% higher costs. Averted treatment 
costs weighed more heavily on total expenditure than the additional colonoscopies, 
which explains the relative low cost-effectiveness ratios of less than US$ 25,000 per 
life-year gained, well below the often applied threshold of US $50,000 or the GDP-
linked WHO-CHOICE guideline (3xGDP).
We found that surveillance was associated with similar estimated risks for adenoma 
patients identified through FIT and colonoscopy screening. However, compared to 
FIT-based testing, surveillance benefits were relatively higher. This suggests that FIT 
screening is inadequate for patients with adenomas, and that there may be a more 
pressing need for surveillance in FIT-based screening settings than in colonoscopy 
screening settings. There were other factors which influenced cost-effectiveness of 
surveillance, including a higher screening cessation age of 80 years, higher colo-
noscopy quality, and older age. Surveillance remained cost-effective compared to 
screening (ratios <US$ 70,000) for all sensitivity analyses.
In the EPoS study design, it was assumed that less intensive surveillance is non-
inferior to more intensive surveillance in terms of the incidence reduction, with 
25% (LRA) and 35% (HRA) difference thresholds for inferiority.146 We found that 
high-intensity surveillance was associated with substantial reductions in incidence 
and mortality compared to low-intensity, although differences generally remained 
below the above thresholds. The apparent conflict in results is due to the different 
study horizons: while we evaluated lifelong effectiveness and costs of surveillance, 
EPoS will look at effectiveness over a 10 year period. More frequent testing may 
initially increase diagnosis of early-stage cancer (Figure 11.1). In clinical studies 
such as EPoS, it is important to realize that benefits may accrue over longer periods 
of time, and that small effects in the short-term may not rule out more substantial 
long-term effects. 
Our estimated relative mortality risks for LRA and HRA patients were consistent 
with data from the Norwegian cancer registry.145 In a study by Løberg and colleagues 
(reflecting a situation without screening of average-risk patients), patients with de-
tected LRA and HRA had standardized mortality ratios of 0.75 (95%CI, 0.63-0.88) and 
1.16 (95% CI, 1.02-1.31), respectively, compared to the general population. Relative 
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to previous model estimates of the background colorectal cancer mortality risk in 
the United States (2.8%, without discounting), our base-case estimates of the relative 
risk for adenoma patients were 0.68 for LRA and 1.11 for HRA with colonoscopy 
every 10 years.263 These findings suggests that surveillance normalizes cancer risk for 
adenoma patients.107
For this study, we also validated our model to published data on ADR during initial 
surveillance colonoscopy. Our model reproduced observed ADRs for both LRA and 
HRA patients (supplementary Figure 11.1). The model underestimated A-ADRs for 
HRA patients compared to observed data. Some of the difference may be explained 
by the fact that we did not explicitly model villousness or severe dysplasia. It may 
also imply that the base-case model underestimated adenoma growth rates for pa-
tients with previous HRAs. We assumed that adenoma growth rates in a person are 
random for each lesion, which may not be valid for patients who had previous HRA. 
Alternative models with lower assumed colonoscopy quality and higher assumed 
adenoma growth rates matched better with observed data for HRA patients (supple-
mentary Figure 11.2-3). Despite non-trivial differences between the base-case and 
alternative models in terms of absolute surveillance benefits, surveillance was also 
effective and cost-effective for these alternative models (table 11.2).
Our results partially contradict those from previous cost-effectiveness studies, 
which have suggested that surveillance after 5 years in patients with LRA may not 
be cost-effective.324,325 The models used for those studies were relatively more sim-
plistic, either not explicitly modeling the adenoma-carcinoma sequence or assuming 
fixed transtition rates from small to advanced adenomas and advanced adenomas 
to cancer, thereby not allowing for age dependency or person-specific risks of on-
cogenesis. Also none of the models were validated to data sources other than those 
used to inform the model. In our model, there is uncertainty regarding the adenoma 
dwelling time. Compared to other microsimulation models, the assumed adenoma 
dwell time is relatively short, which may have overstated surveillance benefits.50
There are other limitations for this study. First, our model does not explicitly 
describe adenoma histology, while surveillance guidelines also consider villousness, 
high-grade dysplasia, and serrated histology. However, observational do data suggest 
that multiplicity is the most important determinant of adenoma recurrence risk,54 and 
that some of the other high-risk features may be strongly related to adenoma size.53 
Second, our analyses assumed 100% adherence with both screening and surveil-
lance. In practice, screening adherence will  be lower than 100%, and a surveillance 
indication may dramatically improve patient adherence relative to screening. Thus, 
in practice, surveillance benefits could be even higher. Finally, there is insufficient 
data to evaluate whether 1 year follow-up in patients with adenomas >20mm in di-
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ameter or ≥5 adenomas at baseline is warranted.59,60 In general, the option of further 
personalization in surveillance guidelines deserves more attention in future studies.
To conclude, we estimated that surveillance for adenoma patients as recommended 
by the United States Multi-Society Task Force is effective and cost-effective in the 
long term compared to less intensive surveillance or screening. Our findings support 
the use of colonoscopy surveillance for settings with sufficient colonoscopy capac-
ity. Reductions in cancer-related mortality were also substantial for less intensive 
surveillance, which suggests that this could be considered as an alternative option 
for settings with a stronger aversion of or lower capacity for colonoscopy. Evidence 
from the EPoS study is needed to inform policymakers on the effects of surveillance 
in the intermediate-term, and to further refine the long-term model projections.
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Supplementary Figure 11.1a-d Simulated vs observed adenoma detection in patients with base-
line LRA and HRA; base-case U.S. model. a
Abbreviations: ADR = Adenoma Detection Rate; A-ADR = Advanced Adenoma Detection Rate.
a Grey diamonds represent model results for 18 scenarios with varying age (mean: 55, 60, 65), 
screening test (FIT, colonoscopy), and surveillance interval (1y, 3y, 5y). Black dots represent ob-
served data points from the literature. More details for these studies are provided in Supplementary 
Table 11.1.
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Supplementary Figure 11.2a-d Simulated versus observed adenoma detection in patients with 
baseline LRA and HRA; model with higher adenoma miss rates. a, b
Abbreviations: ADR = Adenoma Detection Rate; A-ADR = Advanced Adenoma Detection Rate.
a Grey diamonds represent model results for 18 scenarios with varying age (mean: 55, 60, 65), 
screening test (FIT, colonoscopy), and surveillance interval (1y, 3y, 5y). Black dots represent ob-
served data points from the literature. More details for these studies are provided in Supplementary 
Table 11.1.
b In this model, we decreased assumed colonoscopy sensitivity by 5% for all lesions.
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Supplementary Figure 11.3a-d Simulated versus observed adenoma detection in patients with 
baseline LRA and HRA; model with higher adenoma growth rates. a, b
Abbreviations: ADR = Adenoma Detection Rate; A-ADR = Advanced Adenoma Detection Rate.
a Grey diamonds represent model results for 18 scenarios with varying age (mean: 55, 60, 65), 
screening test (FIT, colonoscopy), and surveillance interval (1y, 3y, 5y). Black dots represent ob-
served data points from the literature. More details for these studies are provided in Supplementary 
Table 11.1.
b In this model, we increased growth rates of adenomas >5mm in size.
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Supplementary Figure 11.4a-d Simulated versus observed adenoma detection in patients with 
baseline LRA and HRA; model with higher adenoma miss and growth rates. a, b
Abbreviations: ADR = Adenoma Detection Rate; A-ADR = Advanced Adenoma Detection Rate.
a Grey diamonds represent model results for 18 scenarios with varying age (mean: 55, 60, 65), 
screening test (FIT, colonoscopy), and surveillance interval (1y, 3y, 5y). Black dots represent ob-
served data points from the literature. Some more details for these studies are provided in Supple-
mentary Table 11.1.
b In this model, we combined colonoscopy quality (model Supplementary Figure 11.2) with a higher 
adenoma	growth	rate	for	adenoma	≥5	mm.
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Supplementary Table 11.1 Published adenoma detection rates during surveillance.
Index
Finding
Reference Patients, N Age, 
mean
Interval, y ADR, % AADR, 
% a
Cancer %
LRA Lieberman, 2007 473 63 2,3 or 5 4.6  
Laiyemo, 2008 656 60.7 4 37.7 4.9
Pinsky, 2009 650 63 3.5 30.2 6.5
Martinez, 2009 4644 - 4 34.5 6.9 0.50
Chung, 2011 671 57.8 2,3 or 5 45.8 2.4
355 2 28.5 1.7
316 3-5.5 53.5 2.2
Martinez, 2012 1194 - 1  3.8
Gupta, 2015 2477 62.3 3-5 7.6
HRA Lieberman, 2007 249 62-64 2,3 or 5 13.7  
Laiyemo, 2008 855 61.5 4 42.1 8.7
Martinez, 2009 4523 - 4 35.3 15.5 0.80
Chung, 2011 539 59.8 2,3 57.3 12.2
516 2 36.6 10.1
Martinez, 2012 2028 - 1  11.2  
Abbreviations: ADR = Adenoma Detection Rate; AADR = Advanced Adenoma Detection Rate.
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Supplementary Table 11.2 Applied surveillance intervals. a
Index
Finding
First
Interval
First
Finding
Second
Interval
Second
Finding
Third
Finding
HRA 3 (5) HRA 3 (5) HRA 3 (5)
LRA 5 (10)
NA 5 (10)
LRA 5 (10) HRA 3 (5)
LRA 5 (10)
NA 10 (10-2S)
NA 5 (10) HRA 3 (5)
LRA 5 (10)
NA 10 (10-2S)
LRA 5 (10) HRA 3 (5) HRA 3 (5)
LRA 5 (10)
NA 5 (10)
LRA 5 (10) HRA 3 (5)
LRA 5 (10)
NA 10 (10-2S)
NA 10 (10-2S) HRA 3 (5)
LRA 5 (10)
NA 10 (10-2S)
Abbreviations: HRA = High-risk adenoma; LRA = low-risk adenoma; 10-2S= return to screening after 
10 years.
a	Intervals	showed	first	are	for	the	intense	surveillance	regimen;	intervals	for	the	light	regimen	are	
shown within parentheses
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Supplementary Table 11.3 Sensitivity	 analysis	 of	 the	 benefits	 and	 cost	 of	 surveillance	 in	 a	FIT	
screening setting.a
Risk 
group Analysis
Cost (US $ million) Life-years gained Cost/Life-year (US $)
Surveillance 
Intensity
Surveillance 
Intensity
Surveillance Intensity
None Low High None Low High None Low High
LRA Main 5.3 5.6 6.0 0 10 41 - 22469 15811
End	age	screening	(80y) 5.3 5.6 6.0 0 6 33 - 41850 18077
End	age	surveillance	(100y) 5.3 5.6 6.2 0 11 42 - 24653 19695
Older unscreened pts (70y) 3.9 4.3 4.5 0 19 30 - 23248 19277
Older screened pts (70y) 3.3 3.3 3.4 0 23 32 - 2204 16267
Fast adenoma growth b 4.6 5.1 5.7 0 8 33 - 67895 22967
Low quality (-10% sensitivity) 5.9 6.2 6.6 0 13 48 - 5379 7364
High quality (98% sensitivity) 4.4 4.5 5.1 0 9 30 - 15997 27199
High endoscopy cost (+50%) 6.0 6.7 7.7 0 10 41 - 67363 34277
Lower treatment cost (-50%) 3.3 3.9 4.7 0 10 41 - 56128 26372
HRA Main 7.0 7.1 7.4 0 42 68 - 2891 10791
End	age	screening	(80y) 6.9 7.1 7.4 0 30 56 - 6282 10791
End	age	surveillance	(100y) 7.0 7.2 7.6 0 45 73 - 6504 11254
Older unscreened pts (70y) 4.7 4.9 5.1 0 44 60 - 3239 17551
Older screened pts (70y) 4.4 4.0 4.2 0 55 70 - -8078 15154
Fast adenoma growth b 5.4 6.2 6.6 0 29 51 - 25888 18687
Low quality (-10% sensitivity) 7.4 7.6 7.8 0 44 74 - 5262 6309
High quality (98% sensitivity) 6.3 6.3 6.6 0 41 61 - -1452 17516
High endoscopy cost (+50%) 7.6 8.6 9.4 0 42 68 - 23862 28446
Lower treatment cost (-50%) 4.2 5.1 5.7 0 42 68 - 22417 23050
Abbreviations: LRA = low-risk adenoma; HRA = high-risk adenoma; pts = patients.
a Costs and life-years presented are per 1000 patients.
b We assumed a shorter mean duration from adenoma onset to large adenoma size, but similar 
overall adenoma dwell time

PART V
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Colorectal cancer screening is a rapidly developing and expanding discipline in 
preventive medicine. In this thesis, we attempted to answer some of the current 
questions regarding the public health impact of screening (Part II, Chapter 3-5), 
the importance of various modifiable factors related to the quality of screening, 
including the test used for screening (Part III, Chapter 6-9), and the potential for 
more personalized screening or surveillance (Part IV, Chapter 10-12). For most of the 
questions addressed in this thesis no direct answers were available from empirical 
data at the time of study conduct. We therefore used microsimulation modeling to 
provide an initial hint of an answer in some cases, and in other cases, more definite 
answers. All studies and study findings are briefly summarized below. Subsequently, 
strengths, limitations, and implications for future practice and research will be ad-
dressed.
stuDy summaries
Potential public health impact of screening
In Part II, we estimated the public health impact of and capacity for potential higher 
uptake of screening in the United States. First, in Chapter 3, we estimated for the 
American Cancer Society what could be the impact of increased colorectal cancer 
screening on future cancer incidence and mortality. Their request for this analysis 
derived from the 2014 National Colorectal Cancer Roundtable initiative to increase 
colorectal cancer screening rates in the United States from the 2013 level of ap-
proximately 60% to 80% by 2018. To estimate the impact we simulated colorectal 
cancer test use as observed in the past from National Health Interview Survey data, 
and compared a scenario of stable future screening uptake to a scenario in which 
screening uptake would increase to 80% by 2018. Our results suggested that, if 
the United States succeeds to screen an additional 20% of the screening-eligible 
population, this could reduce disease incidence by 22% and mortality by 33%. The 
latter converted to a total of 280,000 avertible colorectal cancer cases and 200,000 
avertable colorectal cancer deaths through 2030.
In Chapter 4, we assessed whether there actually would be sufficient colonos-
copy capacity to screen 80% of the United States population. Microsimulation was 
used to estimate colonoscopy demand within a national screening program with 
FIT or colonoscopy as the primary screening method. A national survey (Survey 
of Endoscopic Capacity [SECAP]) was conducted to estimate colonoscopy volume 
in 2012, as well as the additional available capacity. The results suggested that, 
currently, there is sufficient national capacity to screen 80% of the population using 
FIT, colonoscopy, or a mix of the two tests. Screening was estimated to require 
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5-13 million colonoscopies depending on the primary screening test, while current 
estimated colonoscopy volume is 15 million. Sensitivity analyses pointed out that 
actual observed patterns of testing from National Health Interview Survey data are 
more intensive than recommended screening, with over 20 million estimated exams 
required with 80% screening uptake. However, the total estimated colonoscopy 
capacity of approximately 25 million would be sufficient to meet this higher need.
In Chapter 5, we looked beyond the potential impact of achieving 80% colorectal 
cancer screening by 2018, at the total potential impact of screening with full screen-
ing uptake. We expressed the maximum potential impact of screening on colorectal 
cancer mortality in terms of the population attributable fraction (PAF) of risk for 
nonuse of screening. PAF was derived in two ways: first, using microsimulation 
modeling, comparing disease-related mortality in a scenario with 100% hypothetical 
screening uptake to that recently observed in Surveillance Epidemiology and End 
Results data; second, we followed the traditional approach to estimating PAFs using 
Levin’s formula, which was informed by empirical data on the relative risk reduc-
tion associated with screening use and the prevalence of screening. Our modeling 
suggested that full uptake of screening in the United States population could have 
reduced colorectal cancer mortality by 63% compared to the 2010 level. Our results 
also suggest that Levin’s formula may underestimate the PAF compared to modeling, 
with a considerably more conservative estimate of 46% resulting for the PAF. The 
difference was mainly due to incorporation by the model of lagged effects of past 
increases in screening and disparities in effects by age.
Determinants of screening effectiveness
In Part III, we estimated the potential influence of several effect determinants on out-
comes of colorectal cancer screening programs. First, in Chapter 6, we looked at the 
effect of adherence on the comparative benefits of colonoscopy versus a program of 
annually repeated stool-based testing for colorectal cancer. For this study, we used 
observed test adherence and outcome data from the National Colonoscopy Study, 
a multi-center randomized clinical trial of colonoscopy versus ≥4 rounds of annual 
high-sensitivity FOBT (Hemoccult Sensa, Beckman Coulter Inc.) in approximately 
3500 average-risk persons. Modeling was used to project out the long-term risks of 
cancer incidence and mortality associated with observed adherence, and to contrast 
these with hypothetical scenarios of no screening and 100% screening adherence. In 
the National Colonoscopy Study,  adherence was higher for colonoscopy screening 
(86%) than for sFOBT screening (50% completing all sFOBTs after 4 years, and 
80% completing ≥1), With observed study participant adherence, colonoscopy was 
estimated to be significantly more effective than sFOBT, with relative effects on 
cancer incidence of -32% versus -1% and on cancer-related mortality of -59% versus 
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-43%. Compared to screening with 100% adherence, colonoscopy with observed 
adherence resulted in a moderate loss of 14% of the total potential mortality reduc-
tion, compared to the 33% for sFOBT.
In Chapter 7, we evaluated the importance and effect of variation in colonoscopy 
quality, as measured by a physician’s adenoma detection rate (ADR). This work 
succeeded previous work by our research consortium which had already found a 
strong association between ADR and fatal interval cancer risk.124 Using a subset of 
these data consisting of only screening colonoscopies (nearly 60,000), we informed 
our microsimulation model for estimating the long-term impact of variable ADRs on 
cancer outcomes, colonoscopy volume, risk, and overall treatment and screening 
costs in a colonoscopy screening setting. We found estimated differences of 50-60% 
in lifetime incidence and mortality between the lower and upper ADR quintiles. Un-
like suggestions from literature, the estimated colonoscopy burden for surveillance 
of adenoma patients did not rise to unacceptable levels with higher ADRs (+4.6% 
per 5% point ADR increase), and the increase in risk of complications was modest 
compared to the estimated decrease in cancer risk (max +0.6/1000 complications 
vs -3.0/1000 cancer cases per 5% point ADR increase). Perhaps most importantly, 
our work suggested that higher ADRs may result in lower net costs of screening 
and treatment than lower ADRs due to averted treatments (-3.2% per 5% point ADR 
increase).
In Chapter 8, we expanded our work on the impact of varying levels of ADR to 
settings of fecal-based testing, where colonoscopy is used for follow-up of positive 
results. For various ADR quintile, we contrasted FIT screening outcomes with previ-
ously simulated colonoscopy screening outcomes. Our results suggested that both 
colonoscopy and FIT are sensitive to variable ADR. However, FIT screening may be 
affected less by suboptimal levels of ADR: in the lowest ADR quintile, the estimated 
relative risk of colorectal cancer mortality with FIT vs colonoscopy was 1.22 (95%CI, 
0.92-1.75), while in the lowest ADR quintile the relative risk was significantly less 
than one 0.85 (95%CI, 0.82-0.93). The relative stability of FIT outcomes was due to 
our assumptions that FIT primarily detects advanced adenomas,161 and that colonos-
copy providers primarily miss smaller adenomas.163
In Chapter 9, we looked at the understudied question to the effect of longer time 
to diagnostic colonoscopy in persons with a positive colorectal cancer screening 
result. Since no appropriate data were available to inform our model on the effect of 
time to diagnostic follow-up, we used modeling alone to estimate the risk associated 
with longer time to follow-up. The effect of delayed diagnostic testing applies only 
to screening tests other than primary colonoscopy, and we focused specifically on 
the increasingly popular FIT (gFOBT and sDNA evaluated as sensitivity analyses). In 
our analysis, we compared health outcomes and cost for a program of annual FIT 
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between ages 50 and 75 years with follow-up of positive results after various time 
intervals of up to 12 months. Our results suggested that increasing time to diagnostic 
testing may result in proportional increases in cancer incidence and, particularly, 
mortality, and may decrease the overall benefits of screening in life-years gained by 
almost 10%. Screening cost was affected much less by time to follow-up.
Personalizing screening and surveillance
In Part IV, we evaluated the cost-effectiveness of taking into account more than just 
age for recommendations of screening. First, in Chapter 10, the central study question 
was whether and up to what age to screen previously unscreened elderly people 
over age 75 years. For this study in specific, we used microsimulation modeling 
with life-tables stratified by people’s comorbidity status. Persons were classified as 
either having no comorbidities, moderate comorbidities, or severe comorbidities. We 
evaluated the merits of several tests, including colonoscopy, flexible sigmoidoscopy, 
and FIT up to age 90 years. The results of our study suggested that screening is often 
warranted well beyond age 75 years. With some variation in cost-effectiveness for 
the different types of evaluated screening tests (less invasive testing generally being 
cost-effective up to older ages than more invasive testing), screening was indicated 
up to age 83-86 years in persons without comorbidities, up to age 80-83 years in 
persons with moderate comorbidities, and up to age 77-80 in persons with severe 
comorbidities with a cost-effectiveness threshold of US$ 100,000.
Finally, in Chapter 11, we evaluated the appropriate intensity of surveillance in 
patients with removed colorectal adenomas using modeling. We distinguished pa-
tients with low-risk (1-2 small tubular) and high-risk (3-10 small tubular, 1 or more 
larger) adenomas. Evaluated surveillance strategies were based on the European 
Polyp Surveillance (EPoS) study design:146 patients with low-risk adenomas received 
colonoscopy at 5 or 10 years, and patients with high-risk adenoma at 3 or 5 years. 
Outcomes were compared to those of screening as recommended for average-risk 
patients with colonoscopy every 10 years or annual FIT. For this study specifically, 
we validated our model to published data on adenoma detection rates (any and ad-
vanced only) during  surveillance examinations. The results of our study suggested 
that currently recommended, intensive surveillance is effective and cost-effective 
compared to less intensive surveillance or regular screening. In the base-case analy-
sis, we found stable differences in mortality compared to no surveillance of relatively 
38-46%, and incremental costs per life-year gained were generally below US $25,000.
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metHoDoloGical consiDerations
The practical implications of this thesis are as multi-faceted as its scope. As for any 
research project, the implications of our work are defined to large extent by its 
strengths and limitations. In the following paragraphs, we highlight some of the main 
strengths and limitations.331
uncertainty of the estimated health impact of colorectal cancer screening
There were several factors which contributed to quality and reliability of our work 
for the American Cancer Society in Chapter 3, and the related study in Chapter 5. 
The Microsimulation Screening Analysis model is a well-established tool to assess 
the benefits of screening. Its predictions for the public health impact of colorectal 
cancer screening in the United States were derived from and underpinned by ro-
bust evidence from randomized controlled screening trials. It has been validated to 
multiple different studies,190,192,263 and used for two consecutive decision analyses for 
the United States Preventive Services Task Force.204,259 Our current analysis closely 
replicated the age and sex composition of the United States population and colorec-
tal cancer test utilization. The analysis factored in demographic trends. Patterns of 
test utilization were based on observed data from National Health Interview Surveys, 
which is considered the principal source to assess the use of preventive health care 
services in the United States.331
Besides these strengths, there are also some notable limitations and uncertain-
ties. The National Health Interview Survey data did not provide great detail about 
the different types of stool-based tests used for screening, while data suggest that 
performance varies by brand.262,311 We assumed that people mainly used the common 
gFOBT (Hemoccult II, Beckman Coulter Inc.), and the increasingly popular FIT (OC 
Sensor, Eiken Chemical Inc.) after 2000 (only Chapter 3), which is a simplification 
of more complex reality. The data also did not allow us to tease out exactly which 
proportion of colorectal exams was performed for screening purposes, diagnostic 
purposes, and surveillance. A German study has suggested that health effects for 
diagnostic exams may be smaller than those for screening.167 However, the size of 
the difference (91% vs 72-85% reduction) suggests that misrepresentation of the 
use of colonoscopy for symptoms may only have moderate impact on estimated 
test benefits. An underestimation of the use of exams for symptoms could have 
overstated effects of testing.
No trials have assessed the effect of colonoscopy on proximal disease. Although 
many observational studies have reported substantial effects,165-167,332,333 some studies 
have reported no effect of colonoscopy for the proximal end of the colon.244,334,335 
We assumed no difference in the effect of colonoscopy proximal and distal to the 
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splenic flexure, apart from some effect of potential incompleteness of exams (i.e. 
not reaching the end of the colon in some persons). Analogous to colonoscopy, 
the current generation of stool-based tests (sFOBT, FIT, and multi-target stool DNA 
tests) have not been evaluated in any randomized controlled trials to this date. 
Cancer outcomes data are scant, generally, for stool-based tests, although some 
initial observational data have been published recently.105,106 Our model predictions 
for colonoscopy and FIT efficacy are in line with currently available observational 
data for the effects of screening.105,107 Although this suggest that the results of our 
model may be realistic, the evidence is relatively weak compared to evidence from 
randomized clinical trials.
We did not assess in Chapter 3 and 5 the population-level effect of screening on 
life-years gained (or QALY), which is more uncertain than the effect of screening 
on cancer-related mortality. Except for the UK Flexible Sigmoidoscopy Study Ran-
domized controlled trials,117 no trials have found significant reductions in all-cause 
mortality. Several studies reported even higher mortality in the screening group 
than the intervention group (not statistically significant).120,162,188,189,265 The difficulty of 
observing all-cause mortality effects stems from the small proportion of total deaths 
attributable to colorectal cancer, which we mentioned to be only 1.3% in 2012 in 
our introductory chapter. The risk of colorectal adenomas and cancer may be as-
sociated with higher risk of other conditions, for example cardiovascular diseases,336 
which could mean that the effect on life-years may be smaller than we estimated for 
incidence and mortality. However, the fact that there are few very strong risk factors 
for colorectal cancer, suggests that this relation may be relatively weak.
Finally, we could not assess whether currently unscreened people have average-
risk for colorectal cancer or competing causes of death. While higher risk for cancer 
would suggest that we have underestimated the potential public health impact of 
increased screening in the United States, higher competing risks or poorer overall 
health status would imply a lower benefit in terms of life-years. Since currently 
unscreened people are relatively less educated, insured, and are more often from 
ethnic minorities,82,222 it is possible that our assumption has somewhat underesti-
mated colorectal cancer benefits. Recent observational data suggest that the inverse 
association between screening uptake and other cause mortality may be relatively 
weak.337
scratching the surface of the need versus capacity question
In contrast to the studies presented in Chapter 3 and 5, Chapter 4 on screening 
capacity in the United States was less prone to most of the limitations discussed 
above. Health outcomes were not considered. Correct classification of test indication 
was less important for our study since we evaluated hypothetical scenarios for future 
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screening, and as a sensitivity analysis, extrapolated test use patterns as observed in 
National Health Interview Survey data. As an indicator of the study’s face-validity, 
both the survey and model estimates for colonoscopy volume in 2012 were similar 
to indirect estimates derived by combining estimates of population screening rates 
and population size338
A limitation of this work was that the Survey for Endoscopic Capacity in the United 
States did not allow for a very detailed assessment of colonoscopy volume and 
capacity by geographical sub-regions (beyond North, South, East, West). Capacity 
constraints are effective at the regional or even local level, given there is limited 
possibility for traveling to receive preventive services. Even if survey data were 
sufficiently detailed to look at regional or even local availability of services, it would 
have been unwieldy for the model to capture this level of detail. Local health systems 
should ultimately assess whether capacity is sufficient , and take potential measures 
for expansion where needed.
Other limitations of the study include a suboptimal response rate of approximately 
two third, and uncertainty regarding the physicians’ estimates of potential available 
colonoscopy capacity on top of current estimated volume. Survey respondents were 
asked to estimate the number of additional colonoscopies that they could perform 
without additional resources. It is unknown whether these estimates reflect what 
could be done without changes to current practice or reflect a shifting of resources 
away from other procedures. Survey questions indicated that the main limiting fac-
tors to increasing capacity are resources (physicians, nurses, equipment).
effectiveness indicators or modifiers
In the third section of this thesis, we studied more select population subgroups for 
the effectiveness of fecal versus endoscopic screening methods under various spe-
cific modifiable conditions. The same limitations as we discussed above for model 
predictions of population benefits of screening in general, apply to this section.
A key distinctive factor and strength for at least two of these studies, however, 
was the fact that we could use high-quality data to partially inform the studies and 
effect estimates. In stool-based testing persistent adherence is critical for favorable 
long-term benefits.83,84,86,87,339 As discussed before in Chapter 1, long-term adherence 
and associated effects are unknown for sFOBT as well as FIT. The data we used from 
the National Colonoscopy Study (NCS) comprised adherence and outcome data for 
sFOBT across up to seven rounds of testing. This is the longest follow-up recorded in 
a trial for any of the current stool-based tests, after major trials from the nineties have 
studied less effective gFOBT tests. NCS was a multi-center randomized clinical trial 
comparing adherence and performance of colonoscopy versus sFOBT, safeguarding 
comparability of participants and services across both study arms. In our model, 
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NCS adherence and positivity data were closely replicated to assess corresponding 
long-term effects, and short-term predictions for advanced adenoma detection rates 
and cancer incidence could be validated against observed data. Given the similarity 
of our model to the model used to inform recent United States Preventive Services 
Task Force recommendations,259 another strength of this study was we that we could 
immediately compare our predictions to those for the task force, to quantify the loss 
in colorectal cancer mortality benefits attributable to suboptimal adherence.
A limitation of this study was that the NCS was underpowered to statistically 
compare primary outcomes such as incidence and mortality. There were relatively 
few observations for study rounds 6-7, which mainly reflect data from only one study 
center. Finally, NCS generalizability may be limited to the extent that test other stool-
test brands perform differently, participant navigation is not available in practice in 
some settings, and in the sense that persons included in the study gave consent a 
priori to be randomized to colonoscopy versus sFOBT. The latter means that the 
study cohort consists of persons who are in principal willing to undergo screening, 
which may be a very select group in some settings. The scope of the modeling analy-
ses was limited to benefits, instead of also including harms and cost-effectiveness.
Similar to the adherence study of Chapter 6, the two studies on the impact of varia-
tion in adenoma detection of Chapter 7-8 also used high-quality data to populate 
the model. The dataset that was utilized is still the largest published to this date 
on the relationship between this principal quality indicator for colonoscopy and 
cancer outcomes. The complete dataset has been used to justify updating clinical 
quality guidelines in the United States (Kaiser Permanente Northern and Southern 
California).124,131 We used a subset of nearly 60,000 screening-only exams from the 
total database, to look specifically at the relation between ADRs and interval cancer 
risk after screening colonoscopy. This allowed for an immediate comparison be-
tween the data and our model, which is particularly apt for simulating average-risk 
screening populations. The model closely matched data for four out of five ADR 
categories, which increased the likelihood that our assumptions represent actual 
practice variation.
Despite the relatively large dataset and number of cancers, there remains some 
uncertainty regarding the validity of ADR as a quality indicator. As the proportion of 
a physician’s colonoscopies detecting one or more adenomas, ADR is an imperfect 
proxy for adequate management of all clinically relevant lesions. Although it was 
inversely related with interval cancer risk, confidence intervals for cancer incidence 
were still relatively wide, and no individual inter-quintile differences were statisti-
cally significant at a 95% confidence level. However, the broader empirical study 
by Corley and colleagues reported similar inverse relationships between ADR and 
outcomes that were statistically significant. 
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The ADR-outcome relationship was also studied only for pools of physicians ac-
cording to ADR category. The precision of the quality indicator at the individual 
level could not be assessed, given cancer incidence is too low (~50 per 100,000 
years). Being a product of both adenoma prevalence and the physician’s ability 
to detect adenomas, it is unclear from what number of exams ADR differences 
truly reflect physician rather than case-mix differences: with a low number of 5-10 
exams to measure ADR, differences will surely reflect mostly differences between 
examined individuals; even with 100 exams there is likely still substantial adenoma 
prevalence variation from the one to the next sample of persons (standard error ~5% 
point).325 In our study, the number of included colonoscopy exams per physician 
varied substantially (median 375, range 77-1262), but it was not powered to assess 
the ADR-outcome relationship for physicians with a small included exam base.
Another general limitation of studies on ADRs and cancer outcomes is that the 
effect of improving ADRs has not been established. ADR was intended as a quality 
indicator for colonoscopy.132 In some settings, however, it is treated more like a 
sufficient quality measure, being linked directly to physician payment modifiers to 
stimulate higher ADRs and better quality of care.340 It is unclear whether such policy 
may induce gaming. Physicians may no longer adequately examine patients once 
the first polyp is removed, or may not adequately clear polyp margins, if ADR is 
the only intra-procedure quality metric used to assess colonoscopist performance. 
In this case, the estimated causal association between ADR and outcomes in our 
study would break down. Thus, an exclusive focus of managers and health care 
systems on ADRs for colonoscopy quality assessment may lead to a deterioration of 
colonoscopy quality and health outcomes rather than improvement.
Finally, we estimated costs of screening and treatment for the ADR study using 
Medicare payment and copayment rates from 2007 or earlier. These approximations 
may not  reflect true costs, with payment rates from private insurers for screening 
tests known to be higher than those for Medicare enrollees.341 Rates may also be 
outdated. Cancer treatment costs may have risen rapidly with the use of expansive 
new chemotherapeutic agents. We updated costs using the general consumer price 
index which may not reflect these increases in treatment costs. Our sensitivity analy-
ses did suggest that colonoscopy cost assumptions were not critical for our overall 
conclusions.
The final chapter of Part III, Chapter 9, was different from the preceding chapters 
in the sense that no data were available to directly inform the model on the relation-
ship between the outcome determinant and outcomes itself. The effect of time to 
diagnostic colonoscopy after positive fecal colorectal cancer tests is an understudied 
subject. It is known already for years that the interval to colonoscopy may vary sub-
stantially across screening participants.342,343 Delays in the Veterans Affairs health care 
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system have aroused wide media attention in recent years.344 Remarkably, apart from 
two small and underpowered empirical studies, no previous studies investigated the 
effect of delayed follow-up after positive stool-test results. Despite uncertainty on 
how sojourn time is distributed across cancer patients, our model showed that even 
with extreme assumptions (+50% average duration compared to base) there may be 
a clinically relevant effect of time to colonoscopy. By model parameter variation, 
we were further able to reveal that the positive predictive value of stool-based 
tests may be a crucial effect modifier. High-specificity tests such as low-sensitivity 
gFOBT, or less frequently repeated testing may greatly increase the risk of longer 
time to follow-up. Without modeling, it would have been difficult to establish these 
relationships.
A limitation of the study on time to diagnostic follow-up after positive fecal 
colorectal cancer test results is that the model assumed very regular (exponential) 
patterns for potential occurrence of cancer between a positive stool test result and 
follow-up. The exponential model for cancer progression basically assumes that 
cancer incidence and progression rates are constant over time. This may not repre-
sent real life. Although we varied the estimated mean duration in each cancer stage 
(sojourn times), we did not assess whether an altogether different time distribution 
would lead to different results. Empirical study is therefore needed to complement 
our work.
Bounded personalization
In Part IV of this thesis we studied two variations on the subject of personalized 
screening. The potential value of personalized medicine in general, and screening 
in particular, is substantial in theory. In practice, it is limited by availability of data 
to assess cancer and other-cause risk differences for a large amount of potential risk 
factors. We focused in this section on two questions, namely: under what comorbid 
conditions and up to what age elderly people should receive screening, if they did 
not receive any previous screening; and, what intensity of surveillance is appropri-
ate for patients with classified low- or high-risk adenoma. Comorbidity classes and 
adenoma classes were determined previously by other studies. Available data were 
confined to those classes, which constrained the scope of these studies.
A key strength of the study on the potential benefits of screening in elderly 
unscreened persons is that it addressed a very practical and timely question for 
physicians in the United States. As we mentioned in the introduction to this thesis, 
screening is organized in an opportunistic fashion in the United States.345 A large 
proportion of elderly people in the United States have never received any screening. 
With neither published data on the effect of screening for this population subgroup 
nor clear guidelines,246 primary care practitioners were left to their own good judg-
General discussion 249
ment in deciding what to recommend for these persons. Synthesizing knowledge 
of the natural history of colorectal cancer, screening test performance, and life 
expectancy according to comorbidity classes,346 our study was the first to show that 
screening may be effective and cost-effective for previously unscreened people well 
beyond age 75 years.
Methodologically, the same strengths and limitations for the model apply to this 
study as above for other studies. We assumed no relationship between adenoma or 
cancer risk and comorbidity status. In elderly persons, this relationship is potentially 
more important for outcomes than for 50-75 year-old persons, because of higher 
other-cause mortality risk. Our assumption of independency may have overestimated 
screening benefits.
There were other limitations. First, the applied comorbidity classes were relatively 
broad in dividing persons into just three separate categories and factoring in only 
the most common medical conditions. Alternative co-morbidity scores may be more 
common in practice, such as the Charlson comorbidity index. There were also no 
empirical data available at the time of study conduct regarding the effect of screen-
ing in elderly unscreened persons. In recent years, one case-control study of 623 
cases did suggest that screening may have very significant effects among elderly 
in general, but these findings need to be replicated by others.347 Further, a blank 
screening history was the only risk factor considered for elderly persons, while there 
are many other known risk factors for colorectal cancer, including irregular screen-
ing exposure. Although the present study did not cover these alternative risk factors, 
the question to personalized stopping ages was addressed more comprehensively 
by the first author in a follow-up study.348 Finally, we did not assess preferences and 
utilities from a personalized perspective, which would be methodologically more 
challenging.
A strength of our work on the benefit and cost-effectiveness of colonoscopy sur-
veillance in patients with colorectal adenoma (Chapter 11), is that we validated our 
model to the best available data as identified by expert panels on adenoma risk dur-
ing the initial surveillance period.139 In itself, these data are difficult to interpret and 
do not provide clear-cut directions for optimal surveillance strategies. As mentioned 
above, previous studies have assessed the cost-effectiveness of adenoma surveil-
lance using similar data sources, but none externally validated their model.324,325,349 
Our model matched well with the published adenoma detection rates during initial 
surveillance examination for most patients, except in detection of advanced adeno-
mas for patients with high-risk adenomas at baseline. In sensitivity analyses, we 
evaluated alternative model variants to compensate for this suboptimal fit. Overall, 
there was a great consistency across evaluated models in suggesting low- and high-
intensity surveillance to be both effective and cost-effective.
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A limitation of the empirical work used to inform our study is the limited study 
sizes. Most studies reported small numbers of observed cancers. Therefore, carcino-
genic risk for new-onset adenomas after adenoma removal is not clear. Our assumed 
conversion rates were based on standard assumptions regarding natural history, 
informed by large randomized controlled screening trials. As the base-case model 
validation suggested, the assumptions may not hold for patients with a history of 
high-risk adenomas.  
A limitation of our study is that we only considered adenoma size and multiplicity 
to assess recurrence risk. We could not separately evaluate risk and recommenda-
tions for patients classified as high-risk for adenomas with high-grade dysplasia, 
(tubulo-)villous histology, or serrated features. Adenomas over 20mm in diameter 
could also not be studied separately, due to our model configuration. NCI pooling 
studies suggest that there may be a risk difference for high-risk patients with only tu-
bular adenomas versus adenoma with alternative histology.54 Evidence also suggests, 
however, that there is a strong correlation between size and presence of high-grade 
dysplasia, which may limit the loss of information by incorporating size alone.53
Practical imPlications
Promote informed screening participation
The main conclusion from our work for the American Cancer Society can only be 
that the public health benefit of increased colorectal cancer screening, or screening 
in general, is potentially very substantial. We estimated that screening may reduce 
colorectal cancer-related deaths in the United States by 30-60% if screening uptake 
is increased to 80-100% (a 50-100% reduction in nonuse of screening). We believe 
these findings warrant further promotion of screening in the United States, and 
support the initiative to increase colorectal cancer screening rates to 80% by 2018. 
The US National Colorectal Cancer Roundtable media campaign has already quoted 
our findings.350
The implications stretch beyond the United States situation. Our results suggest 
that screening may have substantial benefits elsewhere, although an important dis-
tinction to make is that in most screening programs worldwide, stool-based tests 
are the prevailing screening modality, while in the United States, colonoscopy is 
the dominant screening test. As we showed in Chapter 6, the effects of stool-based 
testing may be lower compared to the effects of a completed colonoscopy given that 
long-term adherence with fecal tests is well below 100%.
There is a balance of benefits and harms in screening that we paid less attention 
to in our work presented in Chapters 3-5. We believe that to provide people with 
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sound information regarding benefits as well as harms is critically important. A 
common argument against screening is that it medicalizes healthy people. Inherently 
in screening there is balance of a small minority who benefits compared to a large 
majority in whom screening has no effect at all. Even in relatively effective colorectal 
cancer screening programs, to prevent one cancer-related death, at least 50 people 
may have to undergo colonoscopy examinations without any mortality benefit. In 
an era of patient-centered care, it is essential that people are made aware of this 
balance. Thus, initiatives such as the 80% by 2018 campaign should by no means 
forgo individuals’ preferences and impede on people’s autonomy by providing 
information that is one-sided.351 Physicians in the United States who benefit from 
selling preventive services may have to be disincentivized. In other countries, with 
organized screening programs which take screening promotion from the hands of 
care providers, policy makers should be aware that high screening participation by 
poorly informed people does not necessarily define a successful program.
implement quality monitoring and assurance programs
The main implication from our work in Part III of this thesis, is that quality assurance 
is essential for optimizing colorectal cancer screening outcomes. We estimated that 
up to 33% of screening benefits may be lost due to suboptimal adherence in a ran-
domized clinical trial setting (in persons who provide consent to undergo screening), 
that long-term colorectal cancer outcomes may differ up to 60% between lower and 
higher colonoscopy quality settings (for an up to 32% difference in screening benefit 
compared to no screening), and that up to 10% of fecal testing benefits may be lost if 
follow-up of positive test results is delayed by 12 months. Although the relationship 
between these factors and participant outcomes should come as no surprise, the 
strength of the association has not been previously quantified. The magnitude of 
the effects support the American Gastroenterological Association guidelines which 
identified programmatic screening adherence and quality as the key program perfor-
mance indicators.114,352
In practice, programs differ in terms of their performance. Adherence to screening 
is highly variable across different screening programs,5 similar to quality of colo-
noscopy,353 and diagnostic follow-up of positive results.354 Some settings may be 
faced with low participant adherence while in other settings colonoscopy quality is 
falling short. Quality monitoring is therefore the first critical step to effective quality 
management. Once program performance is assessed, tailored interventions can be 
tested and implemented to target potential program deficiencies. For each of the 
above program aspects, there already exist interventions that have been evaluated in 
the literature, such as the use of navigators,355,356 telephone reminders,357 electronic 
reminders,238 process flow maps,343 and endoscopist training programs.295
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measure adenoma detection rates, but use with care
Our findings of a strong inverse association between ADR and long-term health 
outcomes support recent recommendations to use ADR as a primary intra-procedure 
quality indicator for colonoscopy.131 The true novelty of our work was in suggesting 
an inverse relationship also with net costs of care. Total estimated costs of screening 
and treatment were lower for patients from physicians with high ADRs than for 
physicians with low ADRs. This implies that initiatives to measure and improve 
colonoscopy quality may be highly cost-effective. In the United States, this may 
also contribute to achieving the Institute for Healthcare Improvement’s triple aim 
to improve the health of population, while reducing per-capita cost of care. For 
other countries, the cost implications could be an important side-aim for improving 
colonoscopy quality through appropriate quality assurance programs.
It is important to note that our work does not directly support the use of payment 
modifiers or any other incentives for increasing ADRs. It is not clear what the ef-
fect of such policies is. Although the evidence for the validity of ADR as a quality 
indicator is quite strong, ADR has previously mentioned limitations as a quality 
measure. The effect of ADR-related interventions on primary health outcomes (can-
cer, mortality) should ideally be established by other studies before these are widely 
applied.295,358 Further, the use of complementary quality indicators like the number 
of detected adenomas per colonoscopy and withdrawal time should be considered 
for more rigorous quality assessment, to the extent that these are not already used. 
Finally, professional societies should consider setting minimum sample sizes for ADR 
assessment and/or recommending potential adjustments for case-mix differences.359
colonoscopy is the most efficacious screening test, but may not be 
acceptable to all
Our findings from Part III single out colonoscopy as the most effective colorectal 
cancer screening test for people willing to undergo the test. In Chapter 8, high-
quality colonoscopy was more efficacious than fecal testing for both incidence and 
mortality reductions. Even in settings with lower colonoscopy quality, a colonoscopy 
would likely outperform fecal testing due to the suboptimal long-term adherence 
(Chapter 6). As we demonstrated in Chapter 9, there may be additional factors 
affecting long-term outcomes of fecal testing. Thus, when exclusively considering 
the long-term effectiveness of each strategy and assuming that people are willing to 
undergo screening colonoscopy, this should be the preferred strategy for screening. 
This reflects the standpoint of the American College of Gastroenterology and United 
States Multi-Society Task Force guidelines.102,115
Literature suggests that many people may not be willing to undergo screening 
colonoscopy,85,86 or may at least prefer non-invasive tests a priori over colonos-
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copy.360 Thus, offering colonoscopy as the sole option for screening, may have 
negative effects on overall population adherence. Conversely, adding FIT as an 
adjuvant test to colonoscopy may dramatically increase screening rates, as observed 
in California.95 While some professional societies have suggested to offer persons an 
informed choice of practically all available tests for screening, the evidence for the 
success of such strategies is contentious.351 The best way to exploit both the high 
potential effects of colonoscopy and the high acceptability of fecal tests may be to 
offer tests sequentially or in rank order from more to less effective, however, this is 
still to be investigated.
There are other criteria than effectiveness to consider when deciding which test 
strategy is most suitable for screening (chapter 1). It will be important to evalu-
ate the harms and cost-effectiveness of colonoscopy screening compared to sFOBT 
screening with actual adherence. There may also be practical factors that put con-
straints on the feasibility of offering colonoscopy for all, such as limited capacity or 
budgetary restrictions. In the Netherlands there currently is insufficient colonoscopy 
capacity for nation-wide colonoscopy screening. Past modeling studies have sug-
gested that FIT screening is optimal in this case.361 Finally, available evidence for a 
favorable benefits/harms ratio for colonoscopy may be valued differently by policy 
makers from various settings. While American expert groups have endorsed colo-
noscopy screening for years, European experts have been reluctant to take a similar 
standpoint in regard of the limited availability of experimental data on the benefits 
and harms of colonoscopy.113 This reflects a principal standpoint on the quality of 
evidence, the debate of which is beyond the scope of this work.
Personalize stopping ages based on screening history and comorbidity 
status
The decision analysis on screening in elderly unscreened people addressed a very 
specific question and has practical implications. We found that screening may be 
considered for previously unscreened older persons depending on whether a person 
is in good health. Although United States Preventive Services guidelines have already 
suggested this in 2008,362 the value of our work is in taking a model to classify 
people’s overall health status and specifying corresponding screening cessation 
ages. Especially in settings where screening is organized in an opportunistic fashion 
the findings from our study are informative. Even in organized screening settings, 
however, policymakers could consider to offer screening beyond the usual stopping 
age of 75 years in people who have not been screened regularly before age 75 years.
More indirect, our work further suggests that a person’s screening history is highly 
predictive of colorectal cancer risk and screening benefit. In the decision analysis 
for the United States Preventive Services Task Force,259 our model partners showed 
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that screening persons beyond 75 years had no favorable benefit-to-harms ratio 
if persons were already screened for 25-30 years. However, we found that with 
no prior screening, the balance may be quite different. This suggests that future 
analyses and guidelines for more individualized screening should certainly consider 
past screening adherence as a predictor of screening benefit. Recent guideline rec-
ommendations also state this more explicitly.103
surveillance should be based on adequately measured adenoma 
characteristics
Our work in Chapter 11 also has some implications for surveillance practice. Our 
results suggest that currently recommended surveillance in the United States for 
patients with low- and high-risk adenomas is effective and cost-effective compared 
to less intensive surveillance.139 Previous suggestions that higher colonoscopy quality 
may lead to overuse of resources are not supported by our results, although inter-
mediate-term results as assessed in the European Polyp Surveillance study may be 
different.141 Whether more intensive surveillance for patients with very large polyps, 
or more than 5 small or 3 large adenomas is also cost-effective, as recommended in 
Europe, remains unclear. These strategies were not evaluated by us, and thus, cannot 
be dismissed as inappropriate based on our findings.
An indirect implication of our work is that assessment of adenoma size and multi-
plicity is requisite. In practice, polyps are often removed in piece-meal fashion, and 
many settings collect all detected polyps by organ section in a single jar for pathology 
review. This does not allow for accurate assessment of adenoma multiplicity. Size 
measurement is often foregone based on the argument that it is difficult to measure 
accurately. Opportunistically, however, inaccurate measurement is to be preferred 
over no measurement at all as the best of two imperfect options; even imprecise 
size estimates may allow for appropriate management of many more patients than 
no measurement at all.
Future researcH
Important research is being conducted to compare the benefits of the most common 
screening methods and surveillance strategies. Our suggestions for future research 
span several related subjects, including the cost-effectiveness of colonoscopy versus 
fecal testing with observed adherence, the impact of screening on life-years gained, 
development of more sensitive non-invasive screening tests, the effect of improved 
colonoscopy quality scores, and the potential for further personalization of screening 
and surveillance. Each of these research directions is briefly discussed below.
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cost-effectiveness of colonoscopy versus fecal colorectal cancer testing
To complement our work presented in Chapter 6, more research is needed on the 
benefit-to-harms ratio and cost-effectiveness of colonoscopy versus sFOBT with ac-
tual observed participant adherence rates. Follow-up studies could also look at the 
break-even point for adherence with colonoscopy screening at which this strategy 
would become equivalent to sFOBT screening in terms of health benefits. Explor-
atory analyses with the NCS data suggest that the break-even point for colonoscopy 
adherence may be between 50-60%. Finally, discrete choice experiments could be 
conducted to evaluate how offering screening tests in rank order from most to 
least effective, i.e. offering colonoscopy as the preferred test, and offering alterna-
tives only if colonoscopy is rejected, influences people’s behavior. Outcomes of this 
research could be combined with outcomes of effectiveness and cost-effectiveness 
research to estimate the ultimate impact of rank-ordered choice offers on primary 
screening outcomes.
all-cause mortality impact of screening
In future years, researchers should try to ascertain more accurate estimates of the 
all-cause mortality impact of colorectal cancer screening. The impact of screening 
on life-years gained has not been established to this date, while the assumed high 
impact of screening is one of the main drivers for its cost-effectiveness. Several new 
screening trials are underway in the United States and Europe.86,121 Although none 
of these studies are powered on their own to find significant all-cause mortality 
effects, future meta-analyses should provide more clarity on the matter. If no effect 
on all-cause mortality is found, it may be illuminating to compare mortality rates for 
several competing causes of death for screened and unscreened subjects to identify 
how the benefit in terms of averted colorectal cancer deaths is offset. The ultimate 
implication of a lower than currently assumed all-cause mortality impact, is that cost-
effectiveness models should downward adjust the assumed survival of patients with 
screen-detected adenomas and cancers, and possibly increase the assumed health 
care costs associated with the life-years gained.
adenoma detection rate and other quality indicators
Future observational studies should assess whether improving ADRs improves 
patient’s health. As we suggested in the last paragraph, stimulating higher ADRs 
may not actually improve quality, due to potential for gaming. The preferred study 
design for this may be a retrospective cohort study, because physicians would not be 
influenced by an awareness of being studied with respect to exam quality. If such a 
study would not find a substantial effect of ADR improvement on health outcomes, 
then follow-up research should be considered for developing composite quality 
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measures which integrate multiple distinct quality indicators, assessing minimum 
individual sample sizes for more precise quality measurement, and adjusting for 
case-mix characteristics. Pooled analyses with sufficient outcome points may be 
required to determine sample size thresholds for adequate quality measurement.
test technology and genetics
Ongoing research is also needed for the development of more effective and specific 
non-invasive screening tests. In the last paragraph, we suggested that getting people 
to do colonoscopy may result in superior outcomes to annual fecal testing, due to 
difficulty in assuring persistent high adherence with the latter form of testing. For 
more sensitive and specific non-invasive forms of testing, this argument may not 
hold. These tests could reduce harms and the frequency of required testing, and 
thereby take away some of the current negative sentiments towards screening.
Breakthroughs in genetic research may be required for substantial forward leaps in 
test technology. While the genetic component of colorectal cancer is believed to be 
12-35%,363,364 most of the heritability is still unexplained.365 Genome-wide association 
studies have discovered many genetic risk factors associated with colorectal cancer, 
but these explain only a fraction of the estimated heritability in colorectal cancer. 
Another promising area of research seems to be related to the human microbiome. 
Recent studies have found associations with colorectal cancer, but future studies 
should look closer at interactions with host factors.48
replication of the impact of time to diagnostic testing
Our study on the effect of time to diagnostic follow-up of positive fecal tests sug-
gested that there are clinically significant consequences of longer time to follow-up 
on colorectal cancer mortality. Empirical studies are needed to replicate these model 
predictions. Our work has already invoked a large-scale study by our research part-
ners at Kaiser Permanente California.366 Initial findings from the study as presented 
at a conference last year suggest that effect of colonoscopy timing is less linear than 
we assumed. However, the study confirmed our findings that delays of 6 months or 
more may have substantial effects on cancer incidence and advanced-stage cancer 
incidence.
uncertainties in management of adenoma patients
The European Polyp Surveillance trial will provide essential evidence for the benefit 
of recommended surveillance in the mid-long term. This evidence will also be im-
portant for validation of long-term model projections. To further inform management 
of adenoma patients, future studies should aim to assess the potential for further 
personalization based on adenoma characteristics. Benefits of 1 year surveillance 
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intervals for patients with over 5 small adenomas, 3 or more large adenomas, and 
1 very large adenoma are unclear, while already recommended by some European 
expert groups. Large observational studies may be needed to compare recurrent or 
residual adenoma findings for various surveillance intervals in these relatively small 
patient subgroups.
individualized screening
In general, individualized screening is a central area for future study. Our work in 
Part IV looked at just two specific factors predictive of cancer risk (screening and 
adenoma history). In reality, there are many other risk factors for colorectal cancer 
and overall life expectancy. Future modeling studies should look at both start ages, 
stopping ages, and intervals for screening and surveillance, taking into consideration 
all significant risk factors, including but not limited to classical risk factors such as 
red meat consumption, alcohol, smoking and the use of aspirin. Information may 
be derived from quantitative stool-test results measuring (hemo)globin levels on 
a continuous scale, and, as we identified in this thesis, adenoma detection rates. 
With technological advancements there will likely also be increasing amounts of 
personal data including genetic and behavioral data available, at decreasing cost. 
Future research should assess the potential for both efficiency and effectiveness 
gains from more personalized screening strategies and guidelines. Initial studies by 
our group indicate that there likely is great potential.348,367
There are practical issues around personalized screening which deserve further 
attention in future research. First, personalized medicine is complex. Implementa-
tion of personalized guidelines may be problematic without technical tools to assist 
health care practitioners. Hence, if scientists and policy makers agree on the value 
of more personalized screening, researchers should also look for ways to implement 
them. A potential way for decision scientists to help effectuate personalized screen-
ing is to provide health care providers or screening organizations with a generic 
matrix containing starting ages, stopping ages and intervals for screening according 
to classes of relative disease risk and overall health status. Standardized risk tools 
could be used to allocate people on this matrix given specific personal risk charac-
teristics. The matrix would then spell out the appropriate corresponding test strategy.
Second, there may be measurement problems related to personal risk assessment. 
Many risk factors are not independent. A person’s risk may therefore only be esti-
mable using regression models incorporating a multitude of factors, to control for 
dependency and interactions. However, with many included variables, there is a 
risk of statistical overfitting (number of parameters > number of observations). With 
real-time data collection via smart applications, people’s risk status may change 
continuously. It may neither be feasible nor desirable to process all this information 
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in future screening models. Therefore, algorithms may have to be developed to 
select the most important person-level factors for informing individualized screening.
Finally, closer risk profiling or monitoring for prevention purposes may be 
too time-consuming for doctors and too intrusive for screening subjects. Before 
implementation should be considered, research is needed to estimate population 
adherence with personalized screening regimens. Researchers should evaluate how 
adherent people experience being faced with periodic health status updates and 
corresponding recommended screening strategies.
Future modeling
We want to underscore the anticipated persistent importance of modeling analyses 
in a changing landscape of screening. With expected shifts towards more individu-
alized screening, potential improvements in cancer therapy (e.g. immunotherapy, 
cas9 gene-editing),368,369 new available test technologies, likely changes in costs of 
screening and treatment, and ever tighter health care budgets, decision analyses will 
remain critical. Modeling should be informed by empirical data to the extent possible 
to improve the accuracy of predictions. Multi-disciplinary collaborations of modelers 
and health care practitioners remain vital to focus modeling on relevant questions 
for actual practice.
Important areas for improvement of the MISCAN-colon model include a stronger 
evidence-basis for the benefit of screening in terms of life-years gained, a stronger 
evidence basis for the effect of colonoscopy on proximal disease (in the right part 
of the colon), an update of the natural history model for other-than-traditional path-
ways to cancer and the molecular characteristics of lesions, and finally, as identified 
in Chapter 11, the potential inclusion of a person-specific factor for the rate of 
adenoma progression.
conclusions
A remarkable achievement of the last century for public health has been the possibil-
ity to diagnose cancers in an early, more treatable stage. Colorectal cancer screening 
is potentially one the most effective secondary prevention methods, and ever since 
trials have unanimously proven the effectiveness of both fecal and invasive testing 
for the disease, colorectal cancer screening has been widely promoted. However, 
there are still notable uncertainties related to colorectal screening, some of which 
have been addressed in this thesis. Potential population-level effects of screening 
have not yet been assessed for many countries, the comparative programmatic per-
formance of current stool-based tests versus colonoscopy are unknown, as are the 
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most effective ways to improve screening program performance, including the most 
powerful parameters for further personalization.
In Part II of this thesis, we estimated that screening has the potential to reduce 
colorectal cancer mortality in the United States by up to 60%. In Part III, we identified 
several important modifiable determinants of screening effectiveness in program-
matic participant adherence, colonoscopy quality as reflected in adenoma detection 
rates, and time to follow-up of positive stool-based colorectal cancer test results. 
We also found, for persons prepared to undergo colonoscopy and fecal testing, 
that fecal testing with observed longitudinal adherence may be less effective than 
colonoscopy. Finally, in Part IV we found that screening may often be warranted 
beyond age 75 years in people who have not been previously screened, and that 
surveillance with 3-5 year intervals is cost-effective for adenoma patients.
In the general discussion of Part V, we made several recommendations. First, we 
expressed our support for promotion of screening as a highly effective public health 
intervention, on the condition that potential participants are informed properly on 
the balance of benefits and harms. We further recommended that quality assur-
ance programs are implemented in screening practice, where the first important aim 
should be to measure a variety of relevant quality indicators, including screening 
adherence rates, time to follow-up in patients with positive stool test results, and 
ADRs. ADRs should be used with caution as the exclusive (intra-procedure) colonos-
copy quality metric for quality improvement due to uncertainty regarding potential 
adverse effects. We further recommended that screening is considered beyond age 
75 years if patients were not previously screened, and that 3-5 yearly colonoscopy 
surveillance is continued to be offered to patients with high- and low-risk adenomas, 
respectively. For implementation of effective surveillance policies, we recommended 
that physicians always attempt to assess adenoma size and multiplicity.
More research is still needed to assess whether offering colonoscopy as the pre-
ferred test for screening, and offering stool-based testing only if colonoscopy is 
denied, is an effective and cost-effective strategy to exploit both the high potential 
effects of colonoscopy and high acceptability of fecal testing. We further proposed as 
key areas for future research, the all-cause mortality effects of screening, the health 
impact of policies to stimulate higher ADRs, the search for novel DNA markers and 
improved non-invasive screening tests, and finally, the broad area of personaliza-
tion in screening. The potential for effectiveness and efficiency gains through more 
personalized screening seems very substantial.
Many critical studies are ongoing at this point, that will shape the future of colorec-
tal cancer screening. If advances in treatment will not already dramatically improve 
disease survival rates, developments in risk profiling may contribute to more ef-
fective, non-invasive strategies of screening that will further reduce the burden of 
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disease. We are optimistic that as the understanding of colorectal cancer causes and 
natural history further develops, the prospects for future colorectal cancer patients 
will also continue to improve.
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oPtimizinG outcomes oF colorectal cancer screeninG
Colorectal cancer is a leading cause of death in the Netherlands and many other 
countries. Globally, on average one in 77 people die from the disease; in Europe, 
this proportion is even one in 37. Screening is an established means for reducing 
colorectal cancer mortality, and is implemented in an increasing number of countries 
around the world.
In this thesis, a number of studies were presented with the overarching aim to 
advance the knowledge on what defines optimal screening programs. Screening op-
timization is understood here as the maximization of program effects on population 
health, the minimization of adverse side-effects, and the containment of screening 
costs. Parameters considered for optimization included the test used for screen-
ing (endoscopic or stool-based tests), screening adherence rates, the time from a 
positive stool-based test result to follow-up examination with colonoscopy, the 
quality of colonoscopy, appropriate stopping ages for screening, and the intensity 
of screening. Besides a general introduction and discussion part, this thesis consists 
of nine studies presented over three parts. All presented studies were the product of 
international collaborations, and used advanced modeling techniques for the evalu-
ation and optimization of screening.
Part I contains, in addition to a background chapter on screening and public 
health, a description of the Microsimulation Screening Analysis (MISCAN) model as 
developed by the Department of Public Health, Erasmus MC, Rotterdam, Nether-
lands. As was described, the model uses publicly available data on the prevalence 
of benign precursor polyps (adenomas) and the incidence and survival of colorectal 
cancer to simulate the natural history of the disease. The effects of screening are 
simulated based on the best available experimental data. The model has been 
validated multiple times, and is being used, amongst others, for the planning and 
monitoring of the national colorectal cancer screening program in the Netherlands.
Part II contains the results from independent collaborations with the U.S. Centers 
for Disease Control and Prevention and the American Cancer Society. The central 
question for this part was two-fold: first, what benefits may be expected from an 
increased screening participation in the United States, and second, whether sufficient 
capacity exists for higher screening uptake. In Chapter 3, MISCAN was used to esti-
mate the potential public health impact of achieving an 80% uptake of screening in 
the target population by 2018. It was estimated that achieving this aim may prevent 
277,000 new colorectal cancer cases and 203,000 disease-related deaths through 
2030. In 2030 alone, this would be a 22% reduction in incidence and a 33% reduction 
in mortality. The findings from this study were used to inform the National Colorectal 
Cancer Roundtable campaign to increase screening uptake in the United States to 
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80% by 2018 (for example, see The New York Times of Oct 31, 2015) In Chapter 4, 
the predicted required colonoscopy capacity for achieving this aim was compared 
to the estimated available capacity in 2012. This study combined model predictions 
and survey data to find that there would be sufficient colonoscopy capacity for a 
hypothetical organized nation-wide screening program with primary colonoscopy or 
stool-based testing. With continuation of current test utilization patterns as estimated 
from National Health Interview Survey data, there would be less margin in 2012 
capacity, but the expected colonoscopy demand would still remain within capac-
ity limits. In Chapter 5, the proportion of colorectal cancer deaths attributable to 
nonuse of colorectal cancer screening was estimated for the United States, as part 
of a special issue of Annals of Epidemiology devoted to population attributable risk. 
MISCAN suggested that approximately 60% of deaths could have been prevented 
with full uptake of screening by the screening eligible population.
In Part III, the central aim was to estimate the impact of variation in several 
performance indicators of screening programs on program outcomes. In Chapter 6, 
previously unpublished data was used to compare the effectiveness of two important 
test modalities: colonoscopy screening versus annual sensitive fecal occult blood 
testing (sFOBT). The National Colonoscopy Study randomized approximately 3500 persons 
after their informed consent to compare adherence for colonoscopy and sFOBT 
over time. With the observed adherence, which was higher for colonoscopy (86%) 
than sFOBT (80% completing at least one test), the MISCAN model estimated that 
colonoscopy resulted in a substantially greater mortality reduction than sFOBT (59% 
versus 43%). In Chapter 7, another set of data was used to study the effects of 
variation in a physician-related performance indicator, the adenoma detection rate 
(ADR). The ADR is the proportion of a provider’s screening colonoscopies detecting 
one or more adenomas. Kaiser Permanente Northern California collected detailed 
patient and physician-level information for almost 60,000 colonoscopies performed 
between 1998 and 2010, including post-colonoscopy cancer incidence. This informa-
tion was used in MISCAN to estimate the variation in the sensitivity of colonoscopy 
for adenomas and cancer underlying the ADR variation. These estimates were used 
subsequently to estimate variation in long-term effects and cost of screening with 
colonoscopy. The results, which have been published in a 2015 issue of the Journal of  
the American Association, show that for every 5% point increase in ADR, colorectal can-
cer mortality decreased 13%, while adverse side-effects increased 10% due to more 
frequent referral for colonoscopy surveillance. The estimated net costs of screening 
and treatment were estimated to even decrease by 3% per 5% point ADR increase. 
In a follow-up study in Chapter 8, the influence of ADR on effects of screening 
with fecal immunochemical testing (FIT) was investigated. FIT screening requires 
colonoscopy for follow-up examination of positive test results and for colonoscopy 
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surveillance in adenoma patients. Although MISCAN suggested a substantial impact 
of ADR variation on health outcomes of FIT, the association was weaker for FIT than 
estimated for primary colonoscopy screening. In Chapter 9, another quality aspect 
was investigated in a more exploratory study on the consequences of increasing 
time from a positive FIT result to follow-up examination with colonoscopy. From 
the literature it is known that many people, particularly in settings with no orga-
nized screening programs, do not receive a diagnostic exam within 6 months from 
a positive fecal colorectal cancer test result. MISCAN estimated that longer times to 
follow-up of up to 12 months may increase the risk of cancer, and decrease overall 
screening benefits in terms of life-years gained by almost 10%.
The final research part, Part IV, focused on cost-effectiveness of screening in un-
screened elderly people (75+ years) on the one hand, and cost-effectiveness of more 
frequent colonoscopy check-ups of patients with removed adenomas (surveillance) 
on the other hand. In Chapter 10, the cost-effectiveness of a single screening with 
colonoscopy, flexible sigmoidoscopy, or FIT was evaluated for unscreened elderly 
people with respect to their overall health status. MISCAN suggested that in people 
with poor overall health (severe comorbidities) screening may be warranted through 
age 80 years with a cost-effectiveness threshold of US$ 100,000 per quality-adjusted 
life-year gained. For healthy persons (no comorbidities), this was even up to age 
86 years. In Chapter 11, finally, MISCAN was used to simulate competing strategies 
from a planned randomized clinical trial on colonoscopy surveillance in adenoma 
patients, the European Polyp Surveillance (EPoS) study. The EPoS study is designed to 
separately evaluate more versus less intensive surveillance in patients with low-risk 
adenomas (1-2 ‘tubular’ adenomas up to 5mm in diameter) or high-risk adenomas 
(3-10 adenomas of any size and histology, or 1-10 adenomas ≥1cm). Modeling sug-
gested that more intensive surveillance with 3-5 year intervals is cost-effective in the 
long-term compared to less intensive surveillance with 5-10 yearly colonoscopy or 
screening as recommended for average-risk individuals. Costs per life-year gained 
were generally less than US $25,000.
In the general discussion of Part V, several recommendations were made for future 
practice. First, it was recommended that screening is promoted as a very effec-
tive public health intervention under the condition that potential participants are 
adequately informed on both potential benefits and harms. It was further recom-
mended that quality assurance programs are implemented in all screening settings, 
where the first important aim should be to measure a variety of relevant quality 
indicators. As we showed in this thesis, these included screening adherence rates, 
time factors (time to diagnostic follow-up), and indicators of colonoscopy quality. 
ADRs should be used in awareness of potential adverse effects of an exclusive focus 
on ADR as the primary colonoscopy quality metric. Finally, it was recommended 
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that screening is considered beyond age 75 years in patients who were not previ-
ously screened, and that 3-5 yearly colonoscopy surveillance is offered to patients 
with high- and low-risk adenomas, respectively. For effective surveillance policies 
it is deemed important  that physicians assess adenoma size and multiplicity as 
accurately as possible.
More research was recommended to assess whether offering colonoscopy as the 
preferred method for screening followed by stool-based testing in case of refusal 
is an effective and cost-effective strategy to exploit the advantages of both screen-
ing methods. Other recommended areas for future research included the all-cause 
mortality effects of screening, the health impact of policies to stimulate higher ADRs, 
the search for novel DNA markers and development of improved non-invasive 
screening tests, and finally, the broad area of personalization in screening. Promising 
results from studies conducted within our department suggest that the effectiveness 
and efficiency gains from more personalized (or risk-stratified) screening may be 
substantial.
Colorectal cancer screening is a rapidly developing sub-discipline of public health. 
Innovations in screening and treatment will likely continue to change the screening 
landscape toward future years. This thesis ended on the optimistic note that with 
expected progress in the understanding of the etiology of colorectal cancer, the 
prognosis for future colorectal cancer patients will likely also improve.


Appendix B
Brief summary (Dutch)

Brief summary (Dutch) 299
Het oPtimaliseren Van De uitKomsten Van 
DarmKanKerscreeninG
Darmkanker is een belangrijke doodsoorzaak in Nederland en veel andere landen. 
Wereldwijd sterft gemiddeld ongeveer een op de 77 mensen aan de gevolgen van 
darmkanker; in Europa is dit zelfs een op de 37 mensen. Screening is een bewezen 
effectief middel ter voorkoming van darmkankersterfte en wordt daarom wereldwijd 
in steeds meer landen geïmplementeerd.
In dit proefschrift is een aantal studies gepresenteerd waarin is getracht een bij-
drage te leveren aan het optimaliseren van screeningsprogramma’s voor darmkanker. 
Optimalisatie is hierbij opgevat als het maximaliseren van de beoogde gezondheids-
effecten, het minimaliseren van schadelijke neveneffecten, en het beperken van 
programmakosten. Onderzochte parameters voor optimalisatie zijn, de gebruikte 
screeningstest (inwendig of ontlastingsonderzoek), het deelnamepercentage aan 
screening, de tijd tussen een positieve ontlastingstest en inwendig vervolgonderzoek 
met ‘coloscopie’, de kwaliteit van het inwendig onderzoek, de stopleeftijd voor 
screening, en de intensiteit van screening. Naast een algemene inleiding en discus-
sie bestaat dit proefschrift uit negen studies gepresenteerd over drie delen. Alle 
hier gepresenteerde studies zijn het resultaat van internationale samenwerkingen, 
en zijn uitgevoerd met behulp van een geavanceerd model voor de evaluatie en 
optimalisatie van darmkankerscreening.
In het eerste deel van dit proefschrift is naast een algemene inleiding op 
darmkankerscreening en volksgezondheid in het algemeen, het Microsimulatie-
Screening-Analyse (MISCAN) model beschreven zoals ontwikkeld door de afdeling 
Maatschappelijke Gezondheidszorg, Erasmus MC, Rotterdam. Toegelicht is dat het 
model gegevens gebruikt over de prevalentie van goedaardige poliepen (adenomen) 
en de incidentie en overlevingskansen van darmkanker, om zo een inschatting te 
kunnen maken van het natuurlijk beloop van de ziekte. De effecten van screening 
hierop zijn gemodelleerd naar de bevindingen van de meest toonaangevende (ge-
randomiseerde) studies op dit gebied. Het model is meervoudig gevalideerd, en 
wordt onder andere gebruikt voor de planning en monitoring van het landelijke 
bevolkingsonderzoek naar darmkanker in Nederland.
Het tweede deel van dit proefschrift beschrijft de resultaten van samenwerking met 
respectievelijk de U.S. Centers for Disease Control and Prevention en de American Cancer Society. 
De centrale vraag voor dit gedeelte was tweeledig: allereerst is gekeken naar de 
potentiële baten voor de volksgezondheid van een hogere deelname aan screening 
in de Verenigde Staten, en ten tweede, naar de beschikbare capaciteit voor een 
dergelijke hogere deelname. In Hoofdstuk 3 is met MISCAN een schatting gedaan 
van de mogelijke maatschappelijke gezondheidseffecten van het behalen van een 
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deelname van 80% in de doelpopulatie voor screening in de Verenigde Staten per 
2018. Naar schatting kunnen met het behalen van dit doel, tot 2030, afgerond 277,000 
nieuwe gevallen van darmkanker worden voorkomen en 203,000 sterfgevallen aan 
darmkanker. In 2030 zou dit een geschatte reductie van 22% betekenen in het aan-
tal nieuwe gevallen van darmkanker en een 33% reductie in het geschatte aantal 
sterfgevallen. Met de bevindingen van dit onderzoek is een nationale campagne 
in de Verenigde Staten geïnformeerd die 80% deelname per 2018 tot speerpunt 
heeft (zie bijvoorbeeld de New York Times van 31 Oktober 2015). In hoofdstuk 4 is in 
vervolg hierop de verwachte benodigde coloscopiecapaciteit voor het behalen van 
dezelfde doelstelling afgezet tegen de geschatte aanwezige capaciteit anno 2012. Dit 
combinatieonderzoek van modelschattingen en enquêtegegevens suggereert dat er 
ruimschoots voldoende capaciteit is voor een hypothetisch, georganiseerd, nationaal 
screeningsprogramma in de Verenigde Staten met coloscopie of ontlastingstesten. 
Met huidige realistische gebruikspatronen van screening is er minder marge in 
de capaciteit anno 2012, maar blijft de geschatte vraag toch binnen bereik van de 
geschatte capaciteit. In Hoofdstuk 5 is ten slotte, in het kader van een speciale 
editie van het tijdschrift Annals of  Epidemiology over populatie attributief risico, gekeken 
naar het aandeel van darmkankersterfte in de Verenigde Staten dat voorkomen had 
kunnen worden met een 100% deelname aan screening. MISCAN suggereert dat met 
100% deelname afgerond 60% van de sterfgevallen aan darmkanker voorkomen had 
kunnen worden.
In het derde deel van dit proefschrift stond de vraag centraal naar de impact van 
variatie in een aantal belangrijke prestatie-indicatoren van screeningsprogrammas 
op de uitkomsten van screening. In hoofdstuk 6 zijn met behulp van niet eerder 
gepubliceerde data de effecten vergeleken van coloscopie screening versus jaarlijks 
sensitief fecaal occult bloed testen (sFOBT). De National Colonoscopy Study heeft ruim 
3500 bereidwillige personen gerandomiseerd ter vergelijking van de deelname aan 
coloscopie en sFOBT over tijd. Met de waargenomen deelname, die hoger was 
voor coloscopie (86%) dan voor sFOBT (80% deed ten minste één sFOBT), resul-
teert coloscopiescreening volgens MISCAN in een substantieel grotere reductie in 
darmkankersterfte dan sFOBT (59% versus 43%). In hoofdstuk 7 is met behulp van 
nieuwe empirische data onderzoek gedaan naar de effecten van variatie in een 
artsgebonden prestatie-indicator, de adenoom detectieratio (ADR). De ADR is het 
percentage van screeningscolonospieën waarbij een arts een of meer adenomen 
vindt. Kaiser Permanente Northern California heeft voor dit onderzoek van bijna 60,000 
coloscopieën verschillende persoonsgebonden en artsgebonden gegevens verza-
meld, inclusief gegevens met betrekking tot kankerdiagnoses na coloscopie. Op 
basis van deze gegevens is met MISCAN een schatting gemaakt van de variatie in 
sensitiviteit van coloscopie voor adenomen en kanker die ten grondslag ligt aan de 
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variatie in ADR. Deze variatie in sensitiviteit is vervolgens vertaald naar lange-termijn 
uitkomsten en kosten van screening met coloscopie. De resultaten, die in 2015 zijn 
gepubliceerd in the Journal of  the American Medical Association, laten zien dat voor elke 5% 
punt toename in ADR, de effecten van screening op darmkankersterfte met circa 
13% afnemen, terwijl de schadelijke neveneffecten door een hogere verwijzing voor 
surveillance van adenoompatiënten met circa 10% toenemen. De geschatte netto 
kosten van behandeling en screening namen zelfs af met 3%. In Hoofdstuk 8 is 
vervolgens ook gekeken naar de invloed van ADR op de effecten van screening met 
fecaal immunochemische tests (FIT). Bij FIT screening wordt coloscopie gebruikt 
voor het diagnostisch onderzoek bij een positief testresultaat en voor surveillance in 
patiënten met adenomen. Hoewel MISCAN ook hier een sterk verband met lange-
termijn effecten liet zien, was dit verband zwakker dan bij primaire screening met 
coloscopie. In Hoofdstuk 9 is ten slotte een derde kwaliteitsaspect van screening 
belicht in een exploratief onderzoek naar het effect van tijd tussen een positief 
FIT resultaat en het inwendig vervolgonderzoek met coloscopie. Uit de literatuur is 
bekend dat veel mensen, zeker in settingen zonder georganiseerde screening, pas 6 
of meer maanden na een positieve testuitslag een coloscopie krijgen. MISCAN schat 
dat bij een toenemend interval tussen positieve FIT en diagnostische coloscopie van 
tot 12 maanden, de effecten van screening in termen van gewonnen levensjaren tot 
bijna 10% kunnen afnemen.
In het vierde deel, stond de vraag centraal naar, enerzijds, de kosteneffectiviteit van 
screening voor niet eerder gescreende ouderen (75+), en anderzijds, de kosteneffec-
tiviteit van extra darmonderzoeken in patiënten met verwijderde adenomen (surveil-
lance). In Hoofdstuk 10 is rekening houden met de algehele gezondheidsstatus van 
de patiënt geschat tot welke leeftijd screening met respectievelijk coloscopie, sigmo-
idoscopie, of FIT kosteneffectief kan zijn. MISCAN suggereert dat zelfs in personen 
met een slechte gezondheidstoestand screening tot 80 jarige leeftijd kosteneffectief 
kan zijn bij een grens van US $100,000, terwijl dat in gezonde ouderen wel tot leeftijd 
86 het geval kan zijn. In Hoofdstuk 11, ten slotte, zijn met behulp van MISCAN twee 
strategieën gesimuleerd uit een geplande gerandomiseerde studie, de European 
Polyp Surveillance (EPoS) study.  De EPoS studie zal meer met minder intensieve 
surveillancestrategieën  vergelijken voor patiënten met laag-risico adenomen (1-2 
‘tubulaire’ adenomen tot 5mm in diameter) en patiënten met hoog-risico adenomen 
(3-10 adenomen van willekeurige grootte en histologie, of 1-10 adenomen ≥1cm). 
Ons onderzoek suggereert dat intensievere surveillance met 3-5 jarige intervallen 
zeer kosteneffectief is op de lange termijn vergeleken met minder intensieve surveil-
lance, of vergeleken met screening  zoals aanbevolen voor mensen zonder verhoogd 
risico op darmkanker.
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Uit de algemene discussie en samenvatting in deel 5 is een aantal kernaanbeve-
lingen naar voren gekomen. In de eerste plaats, is aanbevolen screening actief te 
(blijven) promoten als een zeer effectieve maatregel ter bevordering van de volksge-
zondheid, op voorwaarde dat patiënten goed geïnformeerd worden over zowel de 
voor- als nadelen. Verder adviseren wij dat kwaliteitsbewaking vast onderdeel moet 
zijn van alle screeningsprogramma’s, met als eerste doel om de kwaliteit te meten 
zoals die tot uitdrukking komt in verscheidene indicatoren, zoals deelnamepercen-
tages, tijdsfactoren, en indicatoren voor kwaliteit van coloscopie. ADRs moeten met 
terughoudendheid gebruikt worden als voornaamste kwaliteitsmaat voor coloscopie 
totdat meer duidelijk bestaat over het effect van programma’s om de ADR te verho-
gen. Verder is geadviseerd dat screening overwogen wordt voor mensen ouder dan 
75 jaar wanneer iemand niet eerder gescreend is, en dat 3-5 jaarlijkse surveillance 
met coloscopie wordt aangeboden aan patiënten met hoog- en laag-risico adenomen. 
Voor een effectief surveillanceprogramma is het van belang dat artsen de grootte en 
het aantal van adenomen zo goed mogelijk meten.
Toekomstig onderzoek moet uitwijzen of het aanbieden van coloscopie als 
voorkeursoptie voor screening en het reserveren van ontlastingstesten voor niet-
deelnemers een effectieve en kosteneffectieve strategie is om de voordelen van 
beide tests te benutten. Verder is onderzoek nodig naar het effect van darmkan-
kerscreening op de totale sterfte in de populatie, naar het effect van strategieën ter 
verbetering van ADRs, ter verkenning van nieuwe DNA markers en ontwikkeling 
van verbeterde ontlastingstesten, en ten slotte, op het gebied van personalisering (of 
risico-stratificering) in screening.
Darmkankerscreening is sterk in ontwikkeling. Innovaties op het gebied van 
screening en behandeling zullen de praktijk van darmkankerscreening naar verwach-
ting sterk blijven veranderen in komende jaren. Met de verwachte vooruitgang in 
het begrip van de oorzaken van darmkanker, zal ook de prognose voor toekomstige 
patiënten naar verwachting steeds verder verbeteren.
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